

Box SE9-A

12-04-00

11/28/00

11/28/00 U.S. PTO

DIVISION - CONTINUATION - CONTINUATION-IN-PART
APPLICATION TRANSMITTAL FORM

Attorney Docket No.: A-579C

Anticipated Classification Of This Application:
Class SubclassPrior Application:
Examiner

Art Unit

To the Assistant Commissioner for Patents:

This is a request for filing a ☐ continuation ☐ divisional ☒ continuation-in-part application, under 37 CFR 1.53(b), of pending prior international application Serial No. PCT/US00/01871 filed on January 27, 20 00, of Yoshinaga et al. for NOVEL POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE

For CONTINUATION or DIVISIONAL APPLNs only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 1b, below, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

1. ☒ Transmitted herewith are:
☒ 115 pages of specification, 7 pages of claim(s) and 1 page of abstract, totaling 123 pages.
☒ 35 sheet(s) of drawings.
☒ 4 pages of **Unsigned** Oath or Declaration by the applicant(s):
☒ a. Newly executed (original or copy)
☐ b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional applns. only)
☒ 28 pages of Sequence Listing; computer readable format of sequence listing; sequence statement.
2. ☒ The filing fee is calculated below:

For	Number Filed		Number Extra		Rate		Fee
Total Claims	94	- 20 =	74	x	\$18.00	=	\$1,332.00
Independent Claims	9	- 3 =	6	x	\$80.00	=	480.00
Multiple Dependent Claims	1			+	\$270.00	=	270.00
Basic Fee					\$710.00	=	710.00
Total Filing Fee							\$2,792.00

3. ☒ Please charge Deposit Account No. 01-0519, in the name of Amgen Inc., in the amount of \$2,792.00. An original and one copy are enclosed.
4. ☒ Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.
5. ☒ The Commissioner is hereby authorized to charge any additional filing fees which may be required by the accompanying application, any additional fees which may be required during pendency of this application as required by 37 CFR 1.16 or 1.17, or credit any overpayment to Deposit Account No. 01-0519 throughout the prosecution of this application.
6. ☐ Cancel in this application original claims _____ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number. EL360691010USDate of Deposit: November 28, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20531

Lynne Buchsbaum
Printed Name

Lynne Buchsbaum
Signature

7. ☒ Preliminarily, please amend the specification by inserting before the first line the following:

--This application is a ☒ continuation-in-part ☐ division of international application Serial No. PCT/US00/01871, filed January 27, 2000, which is a continuation-in-part of application Serial No. 09/264,527, filed March 8, 1999, which is a continuation of application Serial No. 09/244,448, filed February 3, 1999, which are hereby incorporated by reference.--

8. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)

8a. ☐ New formal drawings are enclosed.

9. ☒ Priority of application Serial No. PCT/US00/01871 filed on January 27, 2000 in PCT (country) is claimed under 35 USC 119.

9a. ☐ The certified copy has been filed in prior application Serial No. _____ filed _____

10. ☒ The prior application is assigned of record to Amgen Inc.

11. ☐ A preliminary amendment is enclosed.

12. ☐ Also enclosed _____

13. ☐ Other: _____

14. ☒ The power of attorney in the prior application is to:
Ron K. Levy, Registration No. 31,539; Steven M. Odre, Registration No. 29,094; and
Robert B. Winter, Registration No. 34,458


a. ☐ The power appears in the original papers in the prior application.

b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

c. ☒ Address all future communications to
Robert B. Winter
 at the address below.

Signator: ☐ Assignee of complete interest

☒ Attorney or agent of record


 Robert B. Winter
 Attorney/Agent for Applicant(s)
 Registration No. 34,458
 Phone: (805) 447-2425
 Date: November 28, 2000

Please send all future correspondence to:

U. S. Patent Operations/RBW
 Dept. 4300, M/S 27-4-A
 AMGEN, INC.
 One Amgen Center Drive
 Thousand Oaks, California 91320-1799

NOVEL POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE

This application is a continuation-in-part of international application Serial No. PCT/US00/01871, filed January 27, 2000, which is a continuation-in-part of application Serial No. 09/264,527, filed March 8, 1999, which is a continuation-in-part of application Serial No. 09/244,448, filed February 3, 1999, which are hereby incorporated by reference.

Field of the Invention

The present invention relates to polypeptides that are involved in T-lymphocyte activation. Specifically, the invention relates to T-lymphocyte costimulatory polypeptides, the nucleic acids encoding the polypeptides, expression vectors and host cells for production of the polypeptides, and compositions and methods for the treatment of diseases related to immunosuppression and immune activation.

Background of the invention

For the generation of a proper T-lymphocyte (T-cell) immune response, two signals must be provided to the T-cell by antigen presenting cells (APC). First, antigen must be presented to the T-cell receptor (TCR) via a major histocompatibility complex (MHC), in an event that determines specificity. Second, an antigen-independent, costimulatory signal must be delivered by engagement of members of the B7 family on the APC with the CD28 protein on T-cells. A productive immune response leads to proliferation, differentiation, clonal expansion, and effect or function. In the absence of the second, costimulatory signal, T-cells undergo a state of long-lasting antigen-specific unresponsiveness, termed anergy.

T-cells initiate the immune response, mediate antigen-specific effector functions, and regulate the activity of other leukocytes by secreting cytokines. The T-cell receptor (TCR) distinguishes the T-cell from other lymphocytes and can bind antigen only when it is presented by the APC within the context of a MHC. The functional activity of a particular T-cell can be correlated with the expression of membrane antigens, such as CD4 and CD8. For instance, CD4+ T-cells generally function as T helper cells (T_H) and are MHC class II restricted, whereas CD8+ cells generally function as cytotoxic T-cells (T_C) and are MHC class I restricted.

Potent T-cell costimulatory polypeptides which has been previously identified include polypeptides termed B7.1 (Freeman et al. J. Immunology 143, 2714-2722 (1989), Freeman et al. Jour. Expt. Med. 174, 625-31 (1991)) and B7.2 (Freeman et al. Science 262, 909-911 (1993), and Freeman et al. Jour. Expt. Med. 178, 2185-2192 (1993)), (or CD80 and CD86, respectively). These polypeptides are either inducibly or constitutively expressed on various APCs and are membrane-bound ligands for CD28 and CTLA-4, respectively, on T-cells. CD28 (Aruffo and Seed Proc. Natl. Acad. Sci. 84, 8573-8577 (1987) and Gross et al. J. Immun. 144, 3201-3210 (1990)) is expressed on resting T-cells and mediates a positive costimulatory signal. CTLA-4 (Brunet et al. Nature 328, 267-270 (1987) and Dariavach et al. Eur. Jour. Immun. 18, 1901-1905 (1988)) expression is induced upon T-cell activation and negatively regulates the CD28 signal, due to its higher binding affinity for B7.1 and B7.2. Mice without the CTLA-4 gene exhibit dramatically high levels of T-cells, since the switch off mechanism for the proliferation signal is impaired in the absence of

5

10

20

30

Summary of the Invention

35

unique costimulatory pathway which appears to be distinct from the pathway consisting of previously described proteins CD28, CTLA-4, B7.1, and B7.2. The polypeptides are referred to as CD28 related protein-1, or CRP1, and B7 related protein-1, or B7RP1.

The invention provides for nucleic acid molecules encoding CRP1 and B7RP1 polypeptides and related polypeptides. An isolated nucleic acid molecule of the invention comprises a nucleotide sequence selected from the group consisting of:

- a) the nucleotide sequence as set forth in Figure 1A (SEQ ID NO:1);
- b) the nucleotide sequence encoding the polypeptide from residues 1-200 or from residues 21-200 as set forth in Figure 1A (SEQ ID NO:1);
- c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in Figure 1A (SEQ ID NO: 1);
- d) a naturally occurring allelic variant or alternate splice variant of any of (a), (b) or (c);
- e) a nucleotide sequence complementary to any of (a), (b) or (c);
- f) a nucleotide sequence of (b), (c) or (d) encoding a polypeptide fragment of at least about 25, 50, 75, 100, or greater than 100 amino acid residues;
- g) a nucleotide sequence of (a), (b) or (c) comprising a fragment of at least about 10, 15, 20, 25, 50, 75, 100, or greater than 100 nucleotides; and
- h) a nucleotide sequence which hybridizes under stringent conditions to any of (a)-(g).

Also provided by the invention is an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

a) the nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO:11) or Figure 12A (SEQ ID NO: 16);

b) the nucleotide sequence encoding the polypeptide as set forth in Figure 2A (SEQ ID NO: 6) from residues 1-322 or from residues 47-322 or as set forth in Figure 3A (SEQ ID NO:11) from residues 1-288 or from residues 19-288, 20-288, 21-288, 22-288, 24-288, or 28-288; or as set forth in Figure 12A from residues 1-302 or from residues 19-302, 20-302, 21-302, 22-302, 24-302 or 28-302;

c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11) or Figure 12A (SEQ ID NO: 16);

d) a naturally occurring allelic variant or alternate splice variant of any of (a), (b) or (c);

e) a nucleotide sequence complementary to any of (a), (b) or (c);

f) a nucleotide sequence of (b), (c) or (d) encoding a polypeptide fragment of at least about 25, 50, 75, 100, or greater than 100 amino acid residues;

g) a nucleotide sequence of (a), (b) or (c) comprising a fragment of at least about 10, 15, 20, 25, 50, 75, 100, or greater than 100 nucleotides; and

h) a nucleotide sequence which hybridizes under stringent conditions to any of (a)-(g).

The subject matter of the invention also relates to CRP1 and B7RP1 polypeptides and related polypeptides. The invention provides for an isolated polypeptide comprising the amino acid sequence selected from the group consisting of:

a) the amino acid sequence as set forth in Figure 1A (SEQ ID NO:2);

b) the mature amino acid sequence as set forth in Figure 1A (SEQ ID NO:2) comprising a mature amino terminus at residue 21;

c) a fragment of the amino acid sequence set forth in Figure 1A (SEQ ID NO: 2) comprising at least about 25, 50, 75, 100, or greater than 100 amino acid residues;

d) an ortholog of (a), (b) or (c); and

e) an allelic variant or alternative splice
10 variant of (a), (b) or (d).

Also in accordance with the invention is an isolated polypeptide comprising the amino acid sequence selected from the group consisting of:

15 a) the amino acid sequence as set forth in
Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO:12) or
Figure 12A (SEQ ID NO: 17);

b) the mature amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) comprising a mature amino terminus at residues 47 or Figure 3A (SEQ ID NO:12) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24 or 28 or Figure 12A (SEQ ID NO: 17) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24, or 28;

25 c) a fragment of the amino acid sequence set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12) or Figure 12A (SEQ ID NO: 17) comprising at least about 25, 50, 75, 100, or greater than 100 amino acid residues;

30 d) an ortholog of (a), (b) or (c); and
 e) an allelic variant or alternative splice
variant of (a), (b), (c) or (d).

Also encompassed by the invention are
35 expression vectors and host cells for production of the
polypeptides, antibodies which bind to CRP1 and B7RP1

an immune disorder which may be mediated directly or indirectly by T-cells. The animal is preferably a mammal and more preferably a human. The invention also provides for a method of identifying a test molecule which binds to a CRP1 or B7RP1 polypeptide comprising contacting the polypeptide with a test compound and determining the extent of binding of the polypeptide to the test compound. The method may be used to identify agonists and antagonists of CRP1 and/or B7RP1 polypeptide.

Antagonists of CRP1 and/or B7RP1 polypeptides may be used as immunosuppressive agents for many indications, including autoimmune disorders (such as rheumatoid arthritis, psoriasis, multiple sclerosis, diabetes, and systemic lupus erythematosus), toxic shock syndrome, bone marrow and organ transplantation, inflammatory bowel disease, allosensitization due to blood transfusions, and the treatment of graft vs. host disease. In addition, antagonists may be used as inhibitory agents for T-cell dependent B-cell mediated indications including asthma and allergy, and antibody mediated autoimmunity. Agonists of the CRP1 and/or B7RP1 polypeptides may be useful in, but not restricted to, T-cell activation for tumor surveillance and removal.

An antagonist of the invention includes an antibody, or fragment thereof, which is reactive with or binds to B7RP1 or to an extracellular domain of B7RP1 wherein the antibody reduces or eliminates the binding to B7RP1 to CRP1. In one embodiment, the antibody binds selectively to human B7RP1 or to an extracellular domain thereof. The antibody or fragment thereof which is an antagonist inhibits partially or completely the immune costimulatory activity of B7RP1. In a preferred embodiment, the antibody is a monoclonal

antibody and may be murine, human, chimeric or humanized.

The invention further provides for a method of regulating the interaction of B7RP1 with CRP1 comprising administering to an animal a selective binding agent of CRP1 or a selective binding agent of B7RP1 or both. In one embodiment, the selective binding agent is an antibody which binds to B7RP1 and reduces or eliminates the binding to B7RP1 to CRP1. The invention also provides a method of regulating immune costimulation mediated by B7RP1 comprising administering to an animal a selective binding agent of B7RP1. The selective binding agent is preferably an antibody which binds to B7RP1 and partially or completely inhibits immune costimulation mediated by B7RP1.

The invention also provides for a method of regulating T-cell activation or proliferation in an animal comprising administering to the animal a nucleic acid molecule encoding a CRP1 or B7RP1 polypeptide. For example, a nucleic acid molecule encoding a B7RP1 polypeptide may be used in gene therapy to enhance T-cell activation in response to various tumors.

Also encompassed by the invention is a transgenic non-human mammal comprising a nucleic acid molecule encoding a CRP1 or B7RP1 polypeptide. The CRP1 or B7RP1 nucleic acids are introduced into the mammal in a manner that allows expression and increased circulation levels of CRP1 or B7RP1 polypeptides. The transgenic non-human mammal is preferably a rodent, and more preferably a mouse or a rat.

A method for stimulating or enhancing an immune response comprising administering B7RP1 or CRP1, or a B7RP1 agonist or CRP1 agonist is also provided. Optionally, an immune response may be stimulated or enhanced by further administering one or more other

immune stimulating molecules, such as a CD28 agonist, a CTLA4 antagonist, or molecules such as B7.1 and/or B7.2.

Also provided by the invention is a method of regulating IgE production comprising administering B7RP1 or CRP1, or a combination thereof, a B7RP1 agonist or a CRP1 agonist, or a combination thereof, or a B7RP1 antagonist or a CRP1 antagonist, or a combination thereof. For example, administration of B7RP1 or a combination of B7RP1 and a CRP1 agonist would increase IgE production and would be useful for stimulating an insufficient IgE-mediated immune response. Administration of a B7RP1 antagonist or a CRP1 antagonist, or a combination thereof, would decrease IgE production and would be useful for inhibiting an exaggerated or inappropriate IgE-mediated immune response. In one embodiment, IgE production is partially or completely inhibited by administration of a B7RP1 antagonist, or a CRP1 antagonist, or a combination thereof. In another embodiment, the invention provides for a method of preventing and/or treating an IgE-mediated disorder comprising administering a B7RP1 antagonist, or a CRP1 antagonist, or a combination thereof. IgE-mediated disorders include those characterized by excessive IgE production, such as asthma, allergic disorders, hypersensitivity and sinus inflammation.

Description of Figures

Figure 1. A) DNA and amino acid sequence murine CRP1 (mCRP1). Predicted signal sequence of CRP1 is underlined at the amino-terminus and the experimentally determined pro-peptide cleavage site is indicated by an asterisk. Predicted transmembrane sequence is underlined toward the carboxy-terminus. B)

Amino acid alignment of murine CRP1 protein sequence (mCRP1) with murine CD28 (mCD28).

Figure 2. A) DNA and amino acid sequence of murine B7RP1 (mB7RP1). Predicted signal sequence of B7RP1 is underlined at the amino-terminus and the experimentally determined pro-peptide cleavage site is indicated by an asterisk. Predicted transmembrane sequence is underlined toward the carboxy-terminus. B) Amino acid alignment of B7RP1 protein sequence (mB7RP1) with murine CD80 (mCD80).

Figure 3. A) Structure and sequence of the protein coding region of the putative human B7RP1 (hB7RP1). Predicted signal sequence of hB7RP1 is underlined at the amino-terminus. Predicted signal peptide cleavage sites are marked by asterisks. Predicted transmembrane sequence is underlined toward the carboxy-terminus. B) Amino acid alignment of the putative mature hB7RP1 protein with the mature murine B7RP1 (mB7RP1) protein.

Figure 4. A) Expression of soluble CRP1-Fc fusion protein from 293T-cells transfected with the pcDNA3/CRP1-Fc. Normalized volumes of cell lysate or conditioned medium were loaded and separated on a 10% PAGE gel as indicated. Western analysis of cell lysate and cell media supernatant for expression of cell-associated (cell lysate) and secreted (media) Fc fusion proteins. Primary antibody was Goat-anti human Fc antibody (Pierce Chemical Company, Rockford, IL.). B) Expression of soluble B7RP1-Fc fusion protein from 293T-cells transfected with the pcDNA3/ B7RP1-Fc. 20 μ l of normalized cell lysate or media supernatant were loaded and separated on a 10% PAGE gel. Western analysis was conducted as in (A).

Figure 5. Interaction of CRP1-Fc and B7RP1-Fc fusion proteins with membrane-bound proteins expressed in COS-7 cells. COS-7 cells transiently transfected with pcDNA3/CRP1, pcDNA3/B7RP1, or pcDNA3 vector alone. CHO D-cells were transfected with pSDR α /hCD28 and stably expressed human CD28 (hCD28). Cells expressing membrane-bound CRP1, B7RP1, or hCD28, are represented in rows as indicated at the left side of the panel. Fc fusion proteins were incubated with the plate-bound cells in columns as indicated at the top of the panel. After incubation, cells were washed, and bound Fc fusion proteins were detected using an anti-human Fc antibody and ACAS (Adherent Cell Analysis and Sorting; ACAS Ultima, Meridian Instruments, Inc., Okemos, MI) analysis.

Figure 6. FACS (Fluorescence-Activated Cell Sorter) analysis of expression of the receptor for B7RP1 (putatively, CRP1) on activated CD4+ and CD8+ T-cells. Mouse splenocytes were activated with PMA and ionomycin for 12 hours. B7RP1-Fc fusion protein, control Fc protein (Mock-Fc), or PBS (no stain), were incubated with the cells, washed, and subsequently incubated with goat-anti-human Fc-FITC conjugated antibody (GaHuFc-FITC) as indicated at the bottom of each panel. Cell marker antibodies (for T-cell markers CD4 and CD8) PE conjugated, or isotype control antibody (rat isotype) PE conjugated, or PBS (no stain), were added as indicated at the left side of each individual panel.

Figure 7. FACS (Fluorescence-Activated Cell Sorter) analysis of the expression of B7RP1 on B-cells. Fluorocytometric analysis of the expression of the

ligand for CRP1 (presumably, B7RP1) on mouse splenocytes. CRP1-Fc fusion protein, control Fc protein (Mock-Fc), or PBS (no stain), were incubated with the cells, washed, and subsequently incubated with goat-anti-human Fc-FITC conjugated antibody (GaHuFc-FITC) as indicated at the bottom of each panel. PE conjugated cell marker antibody to CD45R (CD45R is a B-cell marker) or isotype control antibody (rat isotype), or PBS (no stain), were added as indicated at the left side of each individual panel.

Figure 8. FACS analysis of the expression of mCRP1 ligand on peritoneal macrophages. Peritoneal cells were first distinguished in subsets on the ground of their light scattering properties (panel A). Macrophages were identified in region 5 (R5) because of their ability to strongly scatter light forward (FSC) and sideways (SSC) and because of their positive staining for the F4/80 antigen, a marker for macrophages (panel B). Macrophages in region 6 (R6) were singled out on the basis of their less intense staining for the F4/80 antigen and found to be stained by the CRP1-Fc fusion protein (presumably because of their expression of B7RP1).

Figure 9. Inhibition of T-cell proliferation using a B7RP1-Fc fusion protein. T-cells from mouse splenocytes were activated by increasing concentrations of Concanavalin A (Con A) as indicated at the bottom of the graph. mCRP1-Fc, mB7RP1, and mB7.2-Fc fusion proteins were added to enriched T-cells from splenocytes in the absence (no adds) or presence of Con A. 200,000 cells were used in the T-cell proliferation assays in a 96-well plate. Cells were incubated with media (no adds) or Fc fusion proteins as indicated in the graph legend. After 42 hr, cells were pulsed with

H-thymidine for 6 hr, then harvested and incorporated radioactivity determined. Average CPM and standard deviation from triplicate samples are represented.

- 5 Figure 10. A) Normal mesenteric lymph node from control Mouse #10 showing the cortex, paracortex and medulla of the node. Hematoxylin-eosin (H&E) stain, 40x magnification. B) Markedly enlarged mesenteric lymph node from WX11 Mouse #40 with prominent
- 10 follicular hyperplasia (FH), expansion of paracortex and medullary cord hyperplasia (MH). H&E, 40x. C) Close-up of the medullary cords (MC) and sinuses (MS) from the mesenteric lymph node of control Mouse #10. Note the small medullary cords composed of mostly small
- 15 lymphocytes adjacent to medullary sinuses with fleshy macrophages. H&E, 400x. D. Close-up of the medullary cords (MC) and sinuses (MS) from the mesenteric lymph node of WX11 Mouse #40. Note the markedly thickened medullary cords composed of large numbers of plasma
- 20 cells with occasional Russell body cells (arrow). H&E, 400x. E) Normal spleen from control Mouse #10 showing red pulp and white pulp areas with periarteriolar lymphoid sheaths (PALS), 100x. *Inset*: close-up of the marginal zone surrounding the white pulp with small
- 25 lymphocytes, macrophages and occasional plasma cells, 400x. F) Spleen from WX11 Mouse #6 with enlarged white pulp areas, including PALS and follicles (arrow), 100x. *Inset*: close-up of the marginal zone with numerous plasma cells and occasional Russell bodies, 400x. G)
- 30 Ileum with Peyer's patch from control Mouse #25 with the interfollicular zone (arrow) flanked by two secondary follicles, 40x. H) Ileum with Peyer's patch from WX11 Mouse#32 with markedly enlarged follicles with prominent germinal centers and interfollicular
- 35 tissue (arrow), 40x.

Figure 11. A) Normal mesenteric lymph node from control Mouse #5 showing the cortex, paracortex and medulla of the node. Hematoxylin-eosin (H&E) stain, 40x magnification. B) Markedly enlarged mesenteric lymph node from WX11 Mouse #33 with prominent follicular hyperplasia (*top*: rows of secondary follicles in the outer cortex), expansion of the paracortex (*center*) and medullary cord hyperplasia (*bottom*). H&E, 40x. C) Immunohistochemical staining of the mesenteric lymph node from control Mouse #10 with anti-B220 antibody (B cell marker). Note the intensely (brown) staining cortical area and thin medullary cords. Immunostaining performed using the avidin-biotin complex (ABC) immunoperoxidase method (DAB chromogen, hematoxylin counterstain), 40x. D) Immunohistochemical staining of the mesenteric lymph node from WX11 Mouse #33 with anti-B220 antibody. Note the intensely staining cortical follicles and medullary cords (although the mature plasma cells in the cords are negative for B220), 40x. E) Immunohistochemical staining of the lymph node from control Mouse #10 with anti-CD3 antibody (T-cell marker). Note the immunostaining of the paracortical zone of the node, 40x. F) Immunohistochemical staining of the lymph node from WX11 Mouse #33 with anti-CD3 antibody. Note the enlarged, intensely staining paracortical areas of the node, 40x.

Figure 12. A) Structure and sequence of the protein coding region of human B7RP1 (hB7RP1). Predicted signal sequence of hB7RP1 is underlined at the amino-terminus. Predicted signal peptide cleavage sites are marked by asterisks. Predicted transmembrane sequence is underlined toward the carboxy-terminus. B) Amino acid alignment of the putative mature hB7RP1 protein with the mature murine B7RP1 (mB7RP1) protein.

Figure 13. A) Structure and sequence of the protein coding region of human CRP1 (hCRP1). Predicted signal sequence of hCRP1 is underlined at the amino-terminus. Predicted signal peptide cleavage sites are marked by asterisks. Predicted transmembrane sequence is underlined toward the carboxy-terminus. B) Amino acid alignment of the hCRP1 protein with the murine CRP1 (mB7RP1) protein.

Figure 14. CRP1 is on resting memory T-cells. Resting splenocytes from 6-7 month old mice were double-stained using B7RP1-Fc labeled by an FITC-conjugated anti-human Fc antibody and a PE-conjugated antibody to either CD44(Fig 14A), CD45RB(Fig 14B), or CD69(Fig 14C).

Figure 15. T-cell co-stimulation by B7RP1-Fc fusion protein. A) T-cell proliferation induced by different quantities of B7RP1-Fc (closed squares), B7.2-Fc (closed circles), or OPG-Fc fusion protein control (open squares) in conjunction with anti-CD3 antibody. Fusion proteins were used at various concentrations to coat 96 well plates pre-coated with anti-human Fc FAb₂ (12.5 µg/ml) and anti-CD3 antibody (0.9 µg/ml). B7RP1-Fc and B7.2-Fc co-stimulate T-cells in a dose-dependent fashion up to 0.3 µg/ml, at which the maximal effect is achieved. B) T-cell proliferation induced by B7RP1-Fc (closed squares), B7.2-Fc (closed circles), non-fused Fc (open squares), or no Fc (open circles) in conjunction an anti-CD3 antibody (0.85 µg/ml) and in the presence of various concentrations of a rabbit anti-B7RP1-Fc polyclonal antibody. Fc fusion proteins were used at a concentration of 0.3 µg/ml and were bound to the plates as above. The anti-B7RP1-Fc antibody was raised to

purified B7RP1-Fc by subcutaneous injections of antigen emulsified in adjuvant, and then was affinity purified. The antibodies were incubated for 30 min with the Fc fusion proteins before the addition of the cells. The anti-B7RP1-Fc antibody specifically inhibits the T-cell proliferation induced by B7RP1-Fc in a dose-dependent fashion.

Figure 16. Effect of CRP1-Fc and B7RP1-Fc proteins on the incidence (A) and severity (B) of collagen induced arthritis in mice. Collagen induced arthritis susceptible B10.RIII mice were immunized at the base of the tail with 10 µg porcine collagen type II in CFA. Mice received 100 µg of fusion protein twice per week. Fc fusion proteins and control PBS treatment are indicated in the figure legend.

Figure 17. Proximal Colon in B7RP1-Fc Transgenic Mice. (A) Normal proximal colon from control Mouse#53F (female) showing the gut wall with mucosa, submucosa, muscularis and serosa. Hematoxylin-eosin (H&E) stain, 40x magnification. (B) Diffusely thickened proximal colon from B7RP1-Fc transgenic Mouse#111F with prominent glandular hypertrophy, fissuring ulceration and transmural inflammation. H&E, 40x. (C) Lower power view of proximal colon (as in panel B) from B7RP1-Fc transgenic Mouse#111F with multifocal fissuring ulceration and transmural inflammation. H&E, 20x. (D) Close-up of the fissuring ulcer and hypertrophic colonic glands from B7RP1-Fc transgenic Mouse#111F (shown in panels B and C above). Note the lumen with mucopurulent exudate. H&E, 100x. (E) Close-up of granulomatous inflammation in the submucosa of B7RP1-Fc transgenic Mouse#112F with a multinucleated giant cell surrounded by macrophages,

lymphocytes and fewer neutrophils. H&E, 400x. (F)
Close-up of granulomatous inflammation in the mucosa of
B7RP1-Fc transgenic mouse #112F with epithelioid
macrophages mixed with lymphocytes, plasma cells and
fewer neutrophils subjacent to mucosal glands. H&E,
400x.

Figure 18. Distal Colon in B7RP1-Fc
Transgenic Mice. (A) Normal distal colon from control
Mouse#53F (female) showing the layers of the gut wall
with mucosa, submucosa, muscularis and serosa.
Hematoxylin-eosin (H&E) stain, 40x magnification. (B)
Diffusely thickened distal colon from B7RP1-Fc
transgenic Mouse#111F (female) with prominent glandular
hypertrophy and hyperplasia and scattered crypt
abscesses. H&E, 40x. (C) Diffusely thickened distal
colon from B7RP1-Fc transgenic Mouse#55M (male) with
prominent glandular hypertrophy and hyperplasia. H&E,
40x. (D) Diffusely thickened distal colon from B7RP1-
Fc transgenic Mouse#112F (female) with hypertrophic
colonic glands, focal lymphoid aggregates and many
crypt abscesses. H&E, 40x. (E) Immunohistochemical
staining of the distal colon from B7RP1-Fc transgenic
Mouse#112F with anti-CD3 antibody (T-cell marker). Note
the immunostaining of the superficial mucosa and
colonic lymphoid patch. H&E, 40x. (F) Close-up of the
colonic mucosa of B7RP1-Fc transgenic Mouse#112F with a
crypt abscess (arrow) and lymphoid aggregate composed
of B220+ B cells (inset). H&E, 100x.

30

Figure 19. Small Intestine in B7RP1-Fc
Transgenic Mice. (A) Normal duodenum from control
Mouse#53F (female) showing the lumen, villi and crypts
of the mucosa and underlying submucosa, muscularis and
serosa. Hematoxylin-eosin (H&E) stain, 40x
magnification. (B) Diffusely thickened duodenum from

35

B7RP1-Fc transgenic Mouse#51F (female) with prominent crypt hypertrophy and hyperplasia and mild lymphoplasmacytic infiltrate in the lamina propria. H&E, 40x. (C) Normal jejunum from control mouse #53F

5 (female) showing the normal length of the villi and crypts in the jejunal mucosa. H&E, 40x magnification. (D) Markedly thickened jejunal mucosa from B7RP1-Fc transgenic Mouse#51F (female) with locally extensive crypt hypertrophy and hyperplasia. H&E, 40x. (E)
10 Normal ileum from control Mouse#53F (female) showing the normal length of the villi and crypts in the ileal mucosa. H&E, 40x magnification. (F) Mild atrophy of ileal mucosa from B7RP1-Fc transgenic Mouse#231M (male) with focal loss and blunting of villi. H&E, 40x.

15

Figure 20. The B7RP1-Fc fusion protein inhibits tumor growth in mice. Meth A sarcoma cells were implanted intradermally in the abdomen of Balb/C mice. On days 7, 10, 14, and 17, after implantation,
20 the mice were treated with vehicle (dark diamonds) or murine B7RP1-Fc (gray triangles, Example 7). Tumor volume was measured, as described in Example 20, on the indicated days after implantation. The tumor growth was monitored up to day 28. Each group had eight mice.

25

Figure 21. T-cell co-stimulation by human B7RP1-Fc. Anti-CD3 and human B7RP1 Fc were used to coat 96 well plates, and 1×10^5 T-cells/well (>98% CD3+) were cultured and harvested as described in
30 Example 21. A) Co-stimulation induced by anti-CD3 only (closed circles), 0.5 $\mu\text{g/ml}$ B7RP1 Fc (closed triangles), 0.5 $\mu\text{g/ml}$ OPG-Fc (open circles), and 5 $\mu\text{g/ml}$ anti-CD28 (open triangles) at different concentrations of anti-CD3 primary stimulation. Data
35 show that B7RP1-Fc co-stimulated anti-CD3 primed T-

cells to similar levels as co-stimulation using anti-CD28 antibodies. Data shown are mean [³H]TdR incorporated +/- SD in triplicate wells from one representative experiment of several experiments generated with T-cells isolated from three normal donors. B) Dose-dependent inhibition of B7RP1-Fc co-stimulation by CRP1-Fc. T-cells were cultured in wells coated with both anti-CD3 at 0.3 µg/ml and 0.5 µg/ml B7RP1-Fc. Serially diluted concentrations of CRP1-Fc (closed circles) or OPG-Fc (open circles) were preincubated with the B7RP1-Fc for 30 min prior to the addition of T-cells. Data show that CRP1-Fc inhibits B7RP1 induced co-stimulation in a dose-dependent manner. Percent inhibition is plotted against CRP1-Fc or OPG-Fc protein concentration. Data shown are mean [³H]TdR incorporated +/- SD of three experiments done in triplicate wells and are representative of experiments generated with two normal donors. C) Co-stimulation by CHO human B7RP1 cells. T-cells were purified from peripheral blood and were cultured with various concentrations of anti-CD3 in the presence of anti-CD3 alone (closed circles), 1 x 10⁴ CHO vector control cells (open circles) or 1 x 10⁴ CHO B7RP1 cells (closed triangles), as described in Example 22. The data show that membrane-bound B7RP1 co-stimulated T-cell growth to a level similar to that observed using B7RP1-Fc fusion proteins. Data shown are the mean +/- SD of triplicate cultures and are representative of results generated with two normal donors. D) Cytokine production. T-cells were cultured as described in (Figure 21A) and supernatants were collected at 48 (black bars) and 72 (gray bar) hrs. Data show that the amount of IL-2 produced by B7RP1-Fc co-stimulated cells (top graph) was similar to that produced by cells stimulated by anti-CD3 and control Fc,

but significantly less than that produced by anti-CD28 co-stimulated cells. Data also show that B7RP1-Fc co-stimulation enhanced IL-10 (middle graph) and IFN-gamma (bottom graph) production.

5

Figure 22 shows IgE levels in control and B7RP1 transgenic mice.

Figure 23 shows the combined effects of B7RP1-Fc and B7.2-Fc on chronic hypersensitivity. Mice were challenged with oxazolone as described in Example 24. B7RP1-Fc, B7.2-Fc, B7RP1-Fc+B7.2-Fc, and Fc were given at high (2 or 1+1 mg/Kg, A) and low (0.4 or 0.2+0.2 mg/Kg, B) dose around the time of challenge. A, Compared to Fc, B7RP1-Fc B7.2-Fc, and B7RP1-Fc+B7.2-Fc increased Δ ET from day 3 ($p < 0.001$). B7RP1-Fc and B7RP1-Fc+B7.2-Fc increased Δ ET more than B7.2-Fc from day 4 ($p < 0.001$). B7RP1-Fc+B7.2-Fc increased Δ ET more than B7RP1-Fc from day 4 ($p < 0.001$). B, Compared to Fc, B7RP1-Fc and B7RP1-Fc+B7.2-Fc increased Δ ET from day 4 ($p < 0.001$). B7RP1-Fc and B7RP1-Fc+B7.2-Fc increased Δ ET more than B7.2-Fc ($p < 0.001$).

Detailed Description of the Invention

The invention provides for novel polypeptides referred to herein as CRP1 and B7RP1, which comprise a receptor-ligand pair that is involved in T-cell activation. cDNAs encoding the polypeptides were identified from a library prepared from mouse intestinal intraepithelial cells and screened on the basis of homology to the CD28 and CTLA-4 polypeptides (for CRP1) or B7.1 and B7.2 polypeptides (for B7RP1).

CD28 related protein-1, or CRP1, is predicted to be a type I transmembrane protein with a signal

sequence and extracellular domain at the amino-terminus, a transmembrane domain, and a carboxy terminal intracellular domain (Figure 1). The full-length CRP1 protein is 180 amino acids in its mature
5 form. The predicted leader sequence spans about amino acid residues 1-20 (relative to the initiating methionine) and the extracellular domain of the mature protein encompasses about residues 21-145 (Example 1). The predicted transmembrane domain spans about residues
10 146-163 and the intracellular domain encompasses about residues 164-200. The amino terminal extracellular domain is similar to an Ig loop with conserved putative intra- and inter-molecular bonding cysteines. Furthermore, a "MYPPPY" motif, which is previously
15 known to be important for B7.1 and B7.2 binding to CD28 and CTLA-4, is also partially conserved.

CD28 and CTLA-4 are weakly homologous as exemplified by the 26% amino acid identity between murine CD28 and CTLA-4. There is 19% amino acid
20 identity of CRP1 with murine CD28 and 14% identity of CRP1 with murine CTLA-4. However, critical cysteine residues are conserved between murine CD28, CTLA-4 and CRP1 at residues 42, 63, 83, 109, and 137 (relative to the initiating methionine in the CRP1 protein, See
25 Figure 1A). The approximate mature protein lengths and locations of the transmembrane region relative to the carboxy terminus are also similar in CRP1, CD28, and CTLA-4.

Human CRP1 is a transmembrane protein having
30 the nucleotide and amino acid sequence as shown in Figure 13A. The predicted leader sequence spans about residues 1-19 or about residues 1-20. The predicted mature amino terminus is at residues 20 or 21. Preferably, the mature amino terminus is at position
35 21. The extracellular domain spans from any of the predicted mature amino termini to about amino acid

B7 related protein-1, or B7RP1, is predicted to be a type I transmembrane protein with a signal sequence and extracellular domain at the amino-terminus, a transmembrane domain, and a carboxy terminal intracellular domain (Figure 2A). The full-length B7RP1 protein is 276 amino acids in its mature form. The predicted leader sequence spans about amino acid residues 1-46 (relative to the initiating methionine) and the extracellular domain of the mature protein encompasses residues 47-279 (Example 3). The predicted transmembrane domain spans residues 280-298 and the intracellular domain encompasses residues 299-322. Similar to B7.1 and B7.2, the extracellular domain of B7RP1 comprises two Ig loops.

Human B7RP1 is also a transmembrane protein with conserved cysteine residue in the extracellular domain which are necessary for Ig loop structures. The predicted leader sequence encompasses about residues 1-

Human B7RP1 is also a transmembrane protein with conserved cysteine residue in the extracellular domain which are necessary for Ig loop structures. The predicted leader sequence encompasses about residues 1-

extracellular domain spans from any of the mature amino termini to about amino acid residue 259. The predicted transmembrane domain spans about residues 259-274. The intracellular domain encompasses residues 275-302. The full-length human B7RP1 nucleotide and amino acid sequence is shown in Figure 12A. Human B7RP1 is about 43% identical to the murine protein.

CRP1 and B7RP1 bind each other, but CRP1 does not detectably bind to the B7RP1 related protein B7.2; and B7RP1 does not exhibit detectable binding to CRP1-related CD28 or CTLA-4 (Example 8). B7RP1 was shown to regulate T-cell proliferation, presumably through the interaction of B7RP1 with CRP1 receptors (Example 11). Thus, CRP1 and B7RP1 represent a novel pathway for regulating T-cell proliferation and activation.

The interaction of B7RP1 with CRP1 can be regulated in such a manner that immune costimulation and T-cell proliferation and activation can be increased or decreased. By way of example, anti-B7RP1 monoclonal and polyclonal antibodies raised against murine B7RP1 blocked the B7RP1/CRP1 interaction and also blocked T-cell proliferation induced by a B7RP1-Fc fusion protein (see Example 17). A human CRP1-Fc fusion protein blocked human T-cell proliferation induced by human B7RP1-Fc (Example 21). In addition, addition of a CRP1-Fc fusion protein delayed the onset of arthritic symptoms in a mouse model of rheumatoid arthritis (see Example 18). B7RP1/CRP1 co-stimulation can also be increased by addition of B7RP1-Fc fusion protein or other activators of this pathway (Example 20).

[illegible]

10 The term "allelic variant" refers to one of
several possible naturally occurring alternate forms of
a gene occupying a given locus on a chromosome of an
organism.

The term "high stringency conditions" refers to those conditions which: (1) employ low ionic strength and high temperature for washing, for example, 0.1 X SSC (0.015 M NaCl/0.0015 M sodium citrate) 0.1% NaDodSO₄ (SDS) at 50°C, or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1%. Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 5 X SSC (750 mM NaCl, 75 mM sodium citrate) at 42°C. Another example of high stringency conditions is 50% formamide, 5 x SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS.

The term "moderate stringency conditions" refers to those conditions which include the use of a

washing solution and hybridization conditions (e.g., temperature and ionic strength) less stringent than described above. An example of moderately stringent conditions are conditions such as overnight incubation
5 at 37°C in a solution comprising: 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 µl/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled
10 artisan will recognize how to adjust the temperature, ionic strength and other parameters as necessary to accommodate factors such as probe length and the like.

Recombinant DNA technology methods are set forth in Sambrook *et al.* (*Molecular Cloning: A
15 Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)) and/or Ausubel *et al.*, eds., (*Current Protocols in Molecular Biology*, Green Publishers Inc. and Wiley and Sons, NY (1994)) which are hereby incorporated by reference in their entirety.

20 The invention provides for isolated nucleic acid molecules encoding CRP1 and B7RP1 polypeptides. Also provided for are nucleic acid molecules which are fragments, allelic variants, splice variants, or are
25 complementary in sequence to molecules encoding CRP1 and B7RP1 polypeptides. Nucleic acid molecules which are at least about 70% identical to molecules encoding CRP1 or B7RP1 or which hybridize to molecules encoding CRP1 or B7RP1 under moderate or high stringency
30 conditions are also encompassed. The nucleic acid molecules may be cDNA, genomic DNA, RNA or a partially or totally synthetic nucleic acid molecule. In preferred embodiments, nucleic acid molecules of the invention are at least about 75%, 80%, 85%, 90% or 95%

identical to nucleic acid molecules encoding CRP1 or B7RP1.

A gene or cDNA encoding a CRP1 or B7RP1 polypeptide or fragment thereof may be obtained, for example, by hybridization screening or PCR amplification of a genomic or cDNA library. Probes or primers useful for screening the library can be generated based on sequence information for other known genes or gene fragments from the same or a related family of genes, for example, conserved motifs found in CRP1 or B7RP1 related polypeptides such as a conserved array of cysteine residues. In addition, where a gene encoding a CRP1 or B7RP1 polypeptide has been identified from one species, all or a portion of that gene may be used as a probe to identify homologous genes from other species. The probes or primers may be used to screen cDNA libraries from various tissue sources believed to express the CRP1 or B7RP1 gene.

Where oligonucleotide probes are used to screen cDNA or genomic libraries, one of the following two high stringency solutions may be used. The first of these is 6 X SSC with 0.05% sodium pyrophosphate at 35°C-62°C, with the temperature depending on the length of the oligonucleotide probe. For example, 14 base pair probes are washed at 35-40°C, 17 base pair probes are washed at 45-50°C, 20 base pair probes are washed at 52-57°C, and 23 base pair probes are washed at 57-63°C. The temperature can be increased 2-3°C where the background non-specific binding appears high. A second high stringency solution utilizes tetramethylammonium chloride (TMAC) for washing oligonucleotide probes. One stringent washing solution is 3 M TMAC, 50 mM Tris-HCl, pH 8.0, and 0.2% SDS. The washing temperature using this solution is a function of the length of the probe. For example, a 17 base pair probe is washed at about 45-50°C.

Another means to prepare a gene encoding a CRP1 or B7RP1 polypeptide or fragment thereof is to employ chemical synthesis using methods well known to the skilled artisan such as those described by Engels et al. (Agnew. Chem. Intl. Ed., 28:716-734 (1989)). These methods include, *inter alia*, the phosphotriester, phosphoramidite, and H-phosphonate methods for nucleic acid synthesis. A preferred method for such chemical synthesis is polymer-supported synthesis using standard phosphoramidite chemistry. Typically, DNA encoding a CRP1 or B7RP1 polypeptide will be several hundred nucleotides in length. Nucleic acids larger than about 100 nucleotides can be synthesized as several fragments using these methods. The fragments can then be ligated together to form a full length CRP1 or B7RP1 polypeptide. Usually, the DNA fragment encoding the amino terminus of the polypeptide will have an ATG, which encodes a methionine residue. This methionine may or may not be present on the mature form of a CRP1 or B7RP1 polypeptide, depending on whether the polypeptide produced in the host cell is designed to be secreted from that cell.

CRP1 or B7RP1 nucleic acid molecules, fragments, and/or derivatives that do not themselves encode polypeptides that are biologically active may nonetheless be useful as hybridization probes in diagnostic assays to test, either qualitatively or quantitatively, for the presence of CRP1 or B7RP1 DNA or corresponding RNA in mammalian tissue or bodily fluid samples.

In some cases, it may be desirable to prepare nucleic acid and/or amino acid variants of naturally occurring CRP1 or B7RP1 polypeptides. Nucleic acid variants may be produced using site directed mutagenesis, PCR amplification, or other appropriate methods, where the primer(s) have the desired point

5

10

15

35

[illegible]

selected to be functional in the particular host cell employed (i.e., the vector is compatible with the host cell machinery such that amplification of the gene and/or expression of the gene can occur). The gene, cDNA or fragment thereof encoding the CRP1 or B7RP1 polypeptide may be amplified/expressed in prokaryotic, yeast, insect (baculovirus systems) and/or eukaryotic host cells. Selection of the host cell will depend in part on whether the CRP1 or B7RP1 polypeptide or fragment thereof is to be glycosylated and/or phosphorylated. If so, yeast, insect, or mammalian host cells are preferable.

Typically, expression vectors used in any of the host cells will contain sequences for plasmid maintenance and cloning and expression of inserted nucleotide sequences. Such sequences, referred to collectively as "flanking sequences", will include a promoter and other regulatory elements such as an enhancer(s), an origin of replication element, a transcriptional termination element, a complete intron sequence containing a donor and acceptor splice site, a signal peptide sequence, a ribosome binding site element, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. Each of these elements is discussed below. Optionally, the vector may contain a "tag" sequence, i.e., an oligonucleotide molecule located at the 5' or 3' end of a CRP1 or B7RP1 polypeptide coding sequence; the oligonucleotide molecule encodes polyHis (such as hexaHis), or other "tag" such as FLAG, HA (hemagglutinin Influenza virus) or myc for which commercially available antibodies exist. This tag is typically fused to the polypeptide upon expression of the polypeptide, and can serve as means for affinity purification of a CRP1 or B7RP1 polypeptide from the

host cell. Affinity purification can be accomplished, for example, by column chromatography using antibodies against the tag as an affinity matrix. Optionally, the tag can subsequently be removed from a purified CRP1 or B7RP1 polypeptide by various means such as using certain peptidases.

The human immunoglobulin hinge and Fc region may be fused at either the N-terminus or C-terminus of a CRP1 or B7RP1 polypeptide by one skilled in the art. The subsequent Fc-fusion protein can be purified by use of a Protein A affinity column. An immunoglobulin Fc region is known to exhibit a long pharmacokinetic half-life *in vivo* and proteins fused to an Fc region have been found to exhibit a substantially greater half-life *in vivo* compared to the unfused counterpart. Also, fusion to the Fc region allows for dimerization and/or multimerization of the molecule that may be useful for the bioactivity of some molecules.

The flanking sequence may be homologous (*i.e.*, from the same species and/or strain as the host cell), heterologous (*i.e.*, from a species other than the host cell species or strain), hybrid (*i.e.*, a combination of flanking sequences from more than one source), synthetic, or it may be the native CRP1 or B7RP1 nucleic acid flanking sequences. As such, the source of the flanking sequence may be any unicellular prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequence is functional in, and can be activated by, the host cell machinery.

The flanking sequences useful in the vectors of this invention may be obtained by any of several methods well known in the art. Typically, flanking sequences useful herein other than CRP1 or B7RP1 nucleic acid flanking sequence will have been previously identified by mapping and/or by restriction

[illegible]

Where the flanking sequence is not known, a fragment of DNA containing a flanking sequence may be isolated from a larger piece of DNA that may contain, for example, a coding sequence or even another gene or genes. Isolation may be accomplished by restriction endonuclease digestion using one or more carefully selected enzymes to isolate the proper DNA fragment. After digestion, the desired fragment may be isolated by agarose gel purification, Qiagen® column or other methods known to the skilled artisan. Selection of suitable enzymes to accomplish this purpose will be readily apparent to one of ordinary skill in the art.

35 The transcription termination element is
typically located 3' of the end of a CRP1 or B7RP1

polypeptide coding sequence and serves to terminate transcription of a CRP1 or B7RP1 polypeptide. Usually, the transcription termination element in prokaryotic cells is a G-C rich fragment followed by a poly T sequence. While the element is easily cloned from a library or even purchased commercially as part of a vector, it can also be readily synthesized using methods for nucleic acid synthesis such as those described above.

10 A selectable marker gene element encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium. Typical selection marker genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g.,
15 ampicillin, tetracycline, or kanamycin for prokaryotic host cells, (b) complement auxotrophic deficiencies of the cell; or (c) supply critical nutrients not available from complex media. Preferred selectable markers are the kanamycin resistance gene, the
20 ampicillin resistance gene, and the tetracycline resistance gene.

The ribosome binding element, commonly called the Shine-Dalgarno sequence (prokaryotes) or the Kozak sequence (eukaryotes), is usually necessary for
25 translational initiation of mRNA. The element is typically located 3' to the promoter and 5' to the coding sequence of the CRP1 or B7RP1 polypeptide to be synthesized. The Shine-Dalgarno sequence is varied but is typically a polypurine (i.e., having a high A-G
30 content). Many Shine-Dalgarno sequences have been identified, each of which can be readily synthesized using methods set forth above and used in a prokaryotic vector.

In those cases where it is desirable for a
35 CRP1 or B7RP1 polypeptide to be secreted from the host cell, a signal sequence may be used to direct export of

09728420 112800

the polypeptide from the host cell. A CRP1 or B7RP1 transmembrane domain is also inactivated by mutation or deletion to prevent attachment to the host membrane. Typically, the signal sequence is positioned in the coding region of a CRP1 or B7RP1 gene or cDNA, or directly at the 5' end of a CRP1 or B7RP1 gene coding region. Many signal sequences have been identified, and any of them that are functional in the selected host cell may be used in conjunction with a CRP1 or B7RP1 gene or cDNA. Therefore, the signal sequence may be homologous or heterologous to a CRP1 or B7RP1 gene or cDNA, and may be homologous or heterologous to a CRP1 or B7RP1 polypeptides gene or cDNA. Additionally, the signal sequence may be chemically synthesized using methods set forth above.

In most cases, secretion of the polypeptide from the host cell via the presence of a signal peptide will result in the removal of the amino terminal methionine from the polypeptide.

In many cases, transcription of a CRP1 or B7RP1 gene or cDNA is increased by the presence of one or more introns in the vector; this is particularly true where a CRP1 or B7RP1 polypeptide is produced in eukaryotic host cells, especially mammalian host cells. The introns used may be naturally occurring within a CRP1 or B7RP1 gene, especially where the gene used is a full length genomic sequence or a fragment thereof. Where the intron is not naturally occurring within the gene (as for most cDNAs), the intron(s) may be obtained from another source. The position of the intron with respect to the 5' flanking sequence and a CRP1 or B7RP1 gene is generally important, as the intron must be transcribed to be effective. As such, where a CRP1 or B7RP1 gene inserted into the expression vector is a cDNA molecule, the preferred position for the intron is 3' to the transcription start site, and 5' to the polyA

Preferred vectors for practicing this invention are those which are compatible with bacterial, insect, and mammalian host cells. Such vectors include, *inter alia*, pCRII, pCR3, and pCDNA3.1 (Invitrogen Company, San Diego, CA), pBSII (Stratagene Company, La Jolla, CA), pET15b (Novagen, Madison, WI), pGEX (Pharmacia Biotech, Piscataway, NJ), pEGFP-N2 (Clontech, Palo Alto, CA), pETL (BlueBacII; Invitrogen), and pFastBacDual (Gibco/BRL, Grand Island, NY).

After the vector has been constructed and a nucleic acid molecule encoding a full length or truncated CRP1 or B7RP1 polypeptide has been inserted into the proper site of the vector, the completed
30 vector may be inserted into a suitable host cell for amplification and/or polypeptide expression.

Host cells may be prokaryotic host cells (such as *E. coli*) or eukaryotic host cells (such as a yeast cell, an insect cell, or a vertebrate cell). The host cell, when cultured under appropriate conditions, can synthesize a CRP1 or B7RP1 polypeptide which can

5 polypeptide can be purified using methods such as
molecular sieve chromatography, affinity
chromatography, and the like.

Suitable cells or cell lines may be mammalian cells, such as Chinese hamster ovary cells (CHO), human embryonic kidney (HEK) 293 or 293T-cells, or 3T3 cells. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. Other suitable mammalian cell lines, are the monkey COS-1 and COS-7 cell lines, and the CV-1 cell line. Further exemplary mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, as well as primary explants, are also suitable. Candidate cells may be genotypically deficient in the selection gene, or may contain a dominantly acting selection gene. Other suitable mammalian cell lines include but are not limited to, mouse neuroblastoma N2A cells, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines.

Similarly useful as host cells are bacterial
35 cells. For example, the various strains of *E. coli*

(e.g., HB101, DH5 α , DH10, and MC1061) are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis*, *Pseudomonas spp.*, other *Bacillus spp.*, *Streptomyces spp.*, and the like may also
5 be employed in this method.

Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention.

10 Additionally, where desired, insect cell systems may be utilized in the methods of the present invention. Such systems are described for example in Kitts et al. (*Biotechniques*, 14:810-817 (1993)), Lucklow (*Curr. Opin. Biotechnol.*, 4:564-572 (1993)) and
15 Lucklow et al. (*J. Virol.*, 67:4566-4579 (1993)). Preferred insect cells are Sf-9 and Hi5 (Invitrogen, Carlsbad, CA).

"Transformation" or "transfection" of an expression vector into the selected host cell may be
20 accomplished using such methods as calcium chloride, electroporation, microinjection, lipofection or the DEAE-dextran method. The method selected will in part be a function of the type of host cell to be used. These methods and other suitable methods are well known
25 to the skilled artisan, and are set forth, for example, in Sambrook et al., *supra*.

The host cells transformed or transfected with an expression vector may be cultured using standard media well known to the skilled artisan. The
30 media will usually contain all nutrients necessary for the growth and survival of the cells. Suitable media for culturing *E. coli* cells are, for example, Luria Broth (LB) and/or Terrific Broth (TB). Suitable media for culturing eukaryotic cells are RPMI 1640, MEM,
35 DMEM, all of which may be supplemented with serum

and/or growth factors as required by the particular cell line being cultured. A suitable medium for insect cultures is Grace's medium supplemented with yeastolate, lactalbumin hydrolysate, and/or fetal calf serum as necessary.

Typically, an antibiotic or other compound useful for selective growth of the transformed cells only is added as a supplement to the media. The compound to be used will be dictated by the selectable marker element present on the plasmid with which the host cell was transformed. For example, where the selectable marker element is kanamycin resistance, the compound added to the culture medium will be kanamycin.

The amount of CRP1 or B7RP1 polypeptide produced in the host cell can be evaluated using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, HPLC separation, immunoprecipitation, and/or activity assays such as DNA binding gel shift assays.

If a CRP1 or B7RP1 polypeptide has been designed to be secreted from the host cells, the majority of polypeptide may be found in the cell culture medium. Polypeptides prepared in this way will typically not possess an amino terminal methionine, as it is removed during secretion from the cell. If, however, a CRP1 or B7RP1 polypeptide is not secreted from the host cells, it will be present in the cytoplasm and/or the nucleus (for eukaryotic host cells) or in the cytosol (for gram negative bacteria host cells) and may have an amino terminal methionine.

Purification of a CRP1 or B7RP1 polypeptide from solution can be accomplished using a variety of techniques. If the polypeptide has been synthesized such that it contains a tag such as Hexahistidine (CRP1

or B7RP1/hexaHis) or other small peptide such as FLAG (Eastman Kodak Co., New Haven, CT) or myc (Invitrogen, Carlsbad, CA) at either its carboxyl or amino terminus, it may essentially be purified in a one-step process by
5 passing the tagged polypeptide through an affinity column where the column matrix has a high affinity for the tag or for the polypeptide directly (*i.e.*, a monoclonal antibody specifically recognizing a CRP1 or B7RP1 polypeptide). For example, polyhistidine binds
10 with great affinity and specificity to nickel, thus an affinity column of nickel (such as the Qiagen® nickel columns) can be used for purification of CRP1 or B7RP1/polyHis. (See for example, Ausubel *et al.*, eds., *Current Protocols in Molecular Biology*, Section
15 10.11.8, John Wiley & Sons, New York (1993)).

Where a CRP1 or B7RP1 polypeptide is prepared without a tag attached, and no antibodies are available, other well known procedures for purification can be used. Such procedures include, without
20 limitation, ion exchange chromatography, molecular sieve chromatography, HPLC, native gel electrophoresis in combination with gel elution, and preparative isoelectric focusing ("Isoprime" machine/technique, Hoefer Scientific). In some cases, two or more of
25 these techniques may be combined to achieve increased purity.

If it is anticipated that a CRP1 or B7RP1 polypeptide will be found primarily intracellularly, the intracellular material (including inclusion
30 bodies for gram-negative bacteria) can be extracted from the host cell using any standard technique known to the skilled artisan. For example, the host cells can be lysed to release the contents of the periplasm/cytoplasm by French press, homogenization,
35 and/or sonication followed by centrifugation.

002222 024422 00

If a CRP1 or B7RP1 polypeptide has formed inclusion bodies in the cytosol, the inclusion bodies can often bind to the inner and/or outer cellular membranes and thus will be found primarily in the pellet material after centrifugation. The pellet material can then be treated at pH extremes or with chaotropic agent such as a detergent, guanidine, guanidine derivatives, urea, or urea derivatives in the presence of a reducing agent such as dithiothreitol at alkaline pH or tris carboxyethyl phosphine at acid pH to release, break apart, and solubilize the inclusion bodies. The polypeptide in its now soluble form can then be analyzed using gel electrophoresis, immunoprecipitation or the like. If it is desired to isolate a CRP1 or B7RP1 polypeptide, isolation may be accomplished using standard methods such as those set forth below and in Marston et al. (*Meth. Enz.*, 182:264-275 (1990)). In some cases, a CRP1 or B7RP1 polypeptide may not be biologically active upon isolation. Various methods for "refolding" or converting the polypeptide to its tertiary structure and generating disulfide linkages can be used to restore biological activity. Such methods include contacting the solubilized polypeptide with a solution having a pH usually above 7 and in the presence of a particular concentration of an appropriate chaotrope. In most cases the refolding/oxidation solution will also contain a reducing agent or the reducing agent and the corresponding oxidized form in a specific ratio to generate a particular redox potential allowing for disulfide shuffling to occur in the formation of the protein's cysteine bridge(s). Some of the commonly used redox couples include cysteine/cystamine, glutathione (GSH)/dithiobis GSH, cupric chloride,

dithiothreitol (DTT)/dithiane DTT, 2-mercaptoethanol (bME)/dithio-b(ME). In many instances a cosolvent is necessary to increase the efficiency of the refolding and the more common reagents used for this purpose include glycerol, polyethylene glycol of various molecular weights, and arginine.

CRP1 or B7RP1 polypeptides, fragments, and/or derivatives thereof may also be prepared by chemical synthesis methods (such as solid phase peptide synthesis) using techniques known in the art such as those set forth by Merrifield *et al.*, (*J. Am. Chem. Soc.*, 85:2149 (1963)), Houghten *et al.* (*Proc Natl Acad. Sci. USA*, 82:5132 (1985)), and Stewart and Young (*Solid Phase Peptide Synthesis*, Pierce Chemical Co., Rockford, IL (1984)). Such polypeptides may be synthesized with or without a methionine on the amino terminus. Chemically synthesized CRP1 or B7RP1 polypeptides or fragments may be oxidized using methods set forth in these references to form disulfide bridges. CRP1 or B7RP1 polypeptides or fragments are expected to have biological activity comparable to CRP1 or B7RP1 polypeptides produced recombinantly or purified from natural sources, and thus may be used interchangeably with recombinant or natural CRP1 or B7RP1 polypeptide.

Polypeptides

The term "CRP1 or B7RP1 polypeptide" refers to a polypeptide having the amino acid sequence of Figure 1A (SEQ ID NO:2), Figure 2A (SEQ ID NO:7) or Figure 3A (SEQ ID NO:12) and all related polypeptides described herein. Related polypeptides includes allelic variants, splice variants, fragments, derivatives, substitution, deletion, and insertion

variants, fusion polypeptides, and orthologs. Such related polypeptides may be mature polypeptides, *i.e.*, polypeptide lacking a signal peptide. A CRP1 or B7RP1 polypeptide may or may not have amino terminal
5 methionine, depending on the manner in which they are prepared.

The term "CRP1 or B7RP1 polypeptide fragment" refers to a peptide or polypeptide that is less than the full length amino acid sequence of a CRP1 or B7RP1
10 polypeptide as set forth in Figure 1A (SEQ ID NO:2), Figure 2A (SEQ ID NO:7) or Figure 3A (SEQ ID NO:12). Such a fragment may result from truncation at the amino terminus, truncation at the carboxy terminus, and/or a deletion internal to the polypeptide sequence. Such
15 CRP1 or B7RP1 polypeptides fragments may be prepared with or without an amino terminal methionine. In addition, CRP1 or B7RP1 polypeptides fragments may be naturally-occurring splice variants, other splice variants, and fragments resulting from naturally
20 occurring *in vivo* protease activity. Preferred CRP1 or B7RP1 polypeptide fragments include soluble forms of CRP1 or B7RP1 which lack a functional transmembrane domain and comprise part or all of the extracellular domain of either CRP1 or B7RP1.

The term "CRP1 or B7RP1 polypeptide variants" refers to CRP1 or B7RP1 polypeptides whose amino acid sequences contain one or more amino acid sequence substitutions, deletions, and/or additions as compared to the CRP1 or B7RP1 polypeptides amino acid sequences
30 set forth in Figure 1A (SEQ ID NO:2), Figure 2A (SEQ ID NO:7) or Figure 3A (SEQ ID NO:12). Such CRP1 or B7RP1 polypeptides variants can be prepared from the corresponding CRP1 and B7RP1 polypeptides nucleic acid molecule variants, which have a DNA sequence that
35 varies accordingly from the DNA sequences for CRP1 or B7RP1 polypeptides.

5

10

35

Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part 1*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48:1073 (1988).

Preferred methods to determine identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux, J., et al., *Nucleic Acids Research* 12(1):387 (1984); Genetics Computer Group, University of Wisconsin, Madison, WI), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215:403-410 (1990). The BLAST X program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (*BLAST Manual*, Altschul, S., et al. NCB NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215:403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

By way of example, using the computer algorithm GAP (Genetics Computer Group, University of Wisconsin, Madison, WI), two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the "matched span", as determined by the algorithm). A gap opening penalty (which is calculated

as 3 X the average diagonal; the "average diagonal" is the average of the diagonal of the comparison matrix being used; the "diagonal" is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix (see Dayhoff et al., in: Atlas of Protein Sequence and Structure, vol. 5, supp.3 (1978) for the PAM250 comparison matrix; see Henikoff et al., *Proc. Natl. Acad. Sci USA*, 89:10915-10919 (1992) for the BLOSUM 62 comparison matrix) is also used by the algorithm.

Preferred parameters for polypeptide sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol. Biol.* 48:443-453 (1970)

Comparison matrix: BLOSUM 62 from Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915-10919 (1992)

Gap Penalty: 12

Gap Length Penalty: 4

Threshold of Similarity: 0

The GAP program is useful with the above parameters. The aforementioned parameters are the default parameters for polypeptide comparisons (along with no penalty for end gaps) using the GAP algorithm.

Preferred parameters for nucleic acid molecule sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48:443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

5 The GAP program is also useful with the above parameters. The aforementioned parameters are the default parameters for nucleic acid molecule comparisons.

10 Other exemplary algorithms, gap opening penalties, gap extension penalties, comparison matrices, thresholds of similarity, etc. may be used by those of skill in the art, including those set forth in the Program Manual, Wisconsin Package, Version 9,
15 September, 1997. The particular choices to be made will depend on the specific comparison to be made, such as DNA to DNA, protein to protein, protein to DNA; and additionally, whether the comparison is between pairs of sequences (in which case GAP or BestFit are
20 generally preferred) or between one sequence and a large database of sequences (in which case FASTA or BLASTA are preferred).

 Polypeptides that are at least about 70 percent identical will typically have one or more amino
25 acid substitutions, deletions, and/or additions as compared to a wild type CRP1 or B7RP1 polypeptide. In preferred embodiment, polypeptides will have about 75%, 80%, 85%, 90% or 95% identity to CRP1 or B7RP1 polypeptides. Usually, the substitutions of the native
30 residue will be either alanine, or a conservative amino acid so as to have little or no effect on the overall net charge, polarity, or hydrophobicity of the polypeptide. Conservative substitutions are set forth in Table I below.

35

Table I
Conservative Amino Acid Substitutions

Basic:	arginine
	lysine
	histidine
Acidic:	glutamic acid
	aspartic acid
Uncharged Polar:	glutamine
	asparagine
	serine
	threonine
	tyrosine
	phenylalanine
	tryptophan
Non-Polar:	cysteine
	glycine
	alanine
	valine
	proline
	methionine
	leucine
	norleucine
	isoleucine

5

CRP1 or B7RP1 polypeptide derivatives are provided by the invention. In one embodiment, chemically modified CRP1 or B7RP1 polypeptide compositions in which CRP1 or B7RP1 polypeptides are
10 linked to a polymer are included within the scope of the present invention. The polymer selected is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment.
15 The polymer selected is usually modified to have a

single reactive group, such as an active ester for acylation or an aldehyde for alkylation, so that the degree of polymerization may be controlled as provided for in the present methods. The polymer
5 may be of any molecular weight, and may be branched or unbranched. Included within the scope of the invention is a mixture of polymers. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.

10 The water soluble polymer or mixture thereof may be selected from the group consisting of, for example, polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate based polymers, poly-(N-vinyl
15 pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol.

For the acylation reactions, the polymer(s)
20 selected should have a single reactive ester group. For reductive alkylation, the polymer(s) selected should have a single reactive aldehyde group. A preferred reactive aldehyde is polyethylene glycol propionaldehyde, which is water stable, or mono C1-C10
25 alkoxy or aryloxy derivatives thereof (see U.S. Patent No. 5,252,714).

Pegylation of CRP1 or B7RP1 polypeptides may be carried out by any of the pegylation reactions known in the art, as described for example in the following
30 references: *Focus on Growth Factors* 3: 4-10 (1992); EP 0 154 316; and EP 0 401 384. Preferably, the pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble
35 polymer) as described below.

Table 1. Demographic characteristics of the study population	
Age (years)	Mean (SD)
18-24	20.5 (2.5)
25-34	29.5 (4.5)
35-44	39.5 (5.5)
45-54	49.5 (6.5)
55-64	59.5 (7.5)
65-74	69.5 (8.5)
75-84	79.5 (9.5)
85-94	89.5 (10.5)
95-104	99.5 (11.5)
105-114	109.5 (12.5)
115-124	119.5 (13.5)
125-134	129.5 (14.5)
135-144	139.5 (15.5)
145-154	149.5 (16.5)
155-164	159.5 (17.5)
165-174	169.5 (18.5)
175-184	179.5 (19.5)
185-194	189.5 (20.5)
195-204	199.5 (21.5)
205-214	209.5 (22.5)
215-224	219.5 (23.5)
225-234	229.5 (24.5)
235-244	239.5 (25.5)
245-254	249.5 (26.5)
255-264	259.5 (27.5)
265-274	269.5 (28.5)
275-284	279.5 (29.5)
285-294	289.5 (30.5)
295-304	299.5 (31.5)
305-314	309.5 (32.5)
315-324	319.5 (33.5)
325-334	329.5 (34.5)
335-344	339.5 (35.5)
345-354	349.5 (36.5)
355-364	359.5 (37.5)
365-374	369.5 (38.5)
375-384	379.5 (39.5)
385-394	389.5 (40.5)
395-404	399.5 (41.5)
405-414	409.5 (42.5)
415-424	419.5 (43.5)
425-434	429.5 (44.5)
435-444	439.5 (45.5)
445-454	449.5 (46.5)
455-464	459.5 (47.5)
465-474	469.5 (48.5)
475-484	479.5 (49.5)
485-494	489.5 (50.5)
495-504	499.5 (51.5)
505-514	509.5 (52.5)
515-524	519.5 (53.5)
525-534	529.5 (54.5)
535-544	539.5 (55.5)
545-554	549.5 (56.5)
555-564	559.5 (57.5)
565-574	569.5 (58.5)
575-584	579.5 (59.5)
585-594	589.5 (60.5)
595-604	599.5 (61.5)
605-614	609.5 (62.5)
615-624	619.5 (63.5)
625-634	629.5 (64.5)
635-644	639.5 (65.5)
645-654	649.5 (66.5)
655-664	659.5 (67.5)
665-674	669.5 (68.5)
675-684	679.5 (69.5)
685-694	689.5 (70.5)
695-704	699.5 (71.5)
705-714	709.5 (72.5)
715-724	719.5 (73.5)
725-734	729.5 (74.5)
735-744	739.5 (75.5)
745-754	749.5 (76.5)
755-764	759.5 (77.5)
765-774	769.5 (78.5)
775-784	779.5 (79.5)
785-794	789.5 (80.5)
795-804	799.5 (81.5)
805-814	809.5 (82.5)
815-824	819.5 (83.5)
825-834	829.5 (84.5)
835-844	839.5 (85.5)
845-854	849.5 (86.5)
855-864	859.5 (87.5)
865-874	869.5 (88.5)
875-884	879.5 (89.5)
885-894	889.5 (90.5)
895-904	899.5 (91.5)
905-914	909.5 (92.5)
915-924	919.5 (93.5)
925-934	929.5 (94.5)
935-944	939.5 (95.5)
945-954	949.5 (96.5)
955-964	959.5 (97.5)
965-974	969.5 (98.5)
975-984	979.5 (99.5)
985-994	989.5 (100.5)
995-1004	999.5 (101.5)
1005-1014	1009.5 (102.5)
1015-1024	1019.5 (103.5)
1025-1034	1029.5 (104.5)
1035-1044	1039.5 (105.5)
1045-1054	1049.5 (106.5)
1055-1064	1059.5 (107.5)
1065-1074	1069.5 (108.5)
1075-1084	1079.5 (109.5)
1085-1094	1089.5 (110.5)
1095-1104	1099.5 (111.5)
1105-1114	1109.5 (112.5)
1115-1124	1119.5 (113.5)
1125-1134	

Generally, conditions which may be alleviated or modulated by administration of CRP1 or B7RP1 polymer conjugates include those described herein for non-
25 conjugated CRP1 or B7RP1 polypeptides. However, the conjugated disclosed herein may have additional activities, enhanced or reduced biological activity, or other characteristics, such as increased or decreased
30 half-life, as compared to the non-derivatized molecules.

CRP1 or B7RP1 polypeptides, fragments
variants, and derivatives, may be employed alone,
together, or in combination with other pharmaceutical
compositions. CRP1 or B7RP1 polypeptides, fragments,
35 variants, and derivatives may be used in combination
with cytokines, growth factors, antibiotics, anti-

inflammatories, and/or chemotherapeutic agents as is appropriate for the indication being treated.

5 The invention provides for selective binding
agents of CRP1 or B7RP1. A selective binding agent
refers to a molecule having specificity for CRP1 or
B7RP1 and may include a protein, peptide, nucleic acid,
carbohydrate, lipid or small molecular weight compound.
A selective binding agent interacts either with CRP1 or
10 B7RP1 and in turn regulates the binding of CRP1 to
B7RP1. In one embodiment, a selective binding agent
partially or completely blocks the binding of CRP1 to
B7RP1 and partially or completely inhibits at least one
biological activity of CRP1 or B7RP1, such as immune
15 costimulatory activity. In another embodiment, the
selective binding agent is an antibody. The antibody
may be immunoreactive with either CRP1 or B7RP1 and is
preferably immunoreactive with B7RP1. In yet another
embodiment of the invention, an antibody reactive with
20 B7RP1 binds to an epitope on B7RP1 such that binding to
CRP1 is partially or completely blocked and at least
one biological activity of B7RP1, such as immune
costimulatory activity, is partially or completely
inhibited. The term partially inhibited means that at
25 least a detectable level of inhibition has occurred.
The term completely inhibited means that no further
increase in inhibition has occurred.

CRP1 or B7RP1 polypeptides, fragments,
variants, and/or derivatives may be used to prepare
30 antibodies using methods known in the art. Thus,
antibodies that react with the CRP1 or B7RP1
polypeptides, as well as reactive fragments of such
antibodies, are also contemplated as within the scope
of the present invention. The antibodies may be
35 polyclonal, monoclonal, recombinant, chimeric, single-
chain and/or bispecific. Typically, the antibody or

fragment thereof will either be of human origin, or will be "humanized", i.e., prepared so as to prevent or minimize an immune reaction to the antibody when administered to a patient. The antibody fragment may
5 be any fragment that is reactive with CRP1 and B7RP1 polypeptides of the present invention, such as, Fab, Fab', etc. Also provided by this invention are the hybridomas generated by presenting any CRP1 or B7RP1 polypeptide or fragments thereof as an antigen to a
10 selected mammal, followed by fusing cells (e.g., spleen cells) of the mammal with certain cancer cells to create immortalized cell lines by known techniques. The methods employed to generate such cell lines and antibodies directed against all or portions of a human
15 CRP1 or B7RP1 polypeptide of the present invention are also encompassed by this invention.

Monoclonal antibodies of the invention include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or
20 homologous to corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chains(s) is identical with or homologous to corresponding sequence in antibodies
25 derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison, et al., Proc. Natl. Acad. Sci. 81, 6851-6855
30 (1985)).

In a preferred embodiment, the chimeric anti-CRP1 or B7RP1 antibody is a "humanized" antibody. Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has
35 one or more amino acid residues introduced into it from

a source which is non-human. Humanization can be performed following methods known in the art (Jones, et al., Nature 321, 522-525 (1986); Riechmann, et al., Nature, 332, 323-327 (1988); Verhoeyen, et al., Science 239, 1534-1536 (1988)), by substituting rodent complementarily-determining regions (CDRs) for the corresponding regions of a human antibody.

Also encompassed by the invention are fully human anti-CRP1 or anti-B7RP1 antibodies. Such antibodies may be produced by immunization with a CRP1 or B7RP1 antigen of transgenic animals (e.g., mice) that are capable of producing a repertoire of human antibodies in the absence of endogenous immunoglobulin production. See, for example, Jakobovits, et al., Proc. Natl. Acad. Sci. 90, 2551-2555 (1993); Jakobovits, et al., Nature 362, 255-258 (1993). Human antibodies can also be produced in phage-display libraries (Hoogenboom, et al., J. Mol. Biol. 227, 381 (1991); Marks, et al., J. Mol. Biol. 222, 581 (1991).

Selective binding agents of the invention may be used to regulate the binding of CRP1 to B7RP1 and regulate at least one biological activity mediated by CRP1 and B7RP1 such as immune co-stimulation. An example of such selective binding agents are antibodies immunoreactive with either CRP1 or B7RP1. The antibodies may be used therapeutically, such as to inhibit binding of the CRP1 and B7RP1 polypeptide to its binding partner. The antibodies may further be used for *in vivo* and *in vitro* diagnostic purposes, such as in labeled form to detect the presence of CRP1 and B7RP1 polypeptide in a body fluid or cell sample.

Pharmaceutical Compositions and Administration

Pharmaceutical compositions of CRP1 or B7RP1 polypeptides are within the scope of the present invention. Such compositions may comprise a

therapeutically effective amount of the polypeptide or fragments, variants, or derivatives in admixture with a pharmaceutically acceptable carrier. In preferred embodiments, pharmaceutical compositions comprise CRP1 or B7RP1 polypeptides as soluble forms which comprise part or all of a CRP1 or B7RP1 extracellular domain. Typically, a CRP1 and B7RP1 polypeptide therapeutic compound will be administered in the form of a composition comprising purified polypeptide, fragment, variant, or derivative in conjunction with one or more physiologically acceptable carriers, excipients, or diluents. The carrier material may be water for injection, preferably supplemented with other materials common in solutions for administration to mammals. Neutral buffered saline or saline mixed with serum albumin are exemplary appropriate carriers. Preferably, the product is formulated as a lyophilizate using appropriate excipients (e.g., sucrose). Other standard carriers, diluents, and excipients may be included as desired. Other exemplary compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which may further include sorbitol or a suitable substitute therefor.

CRP1 or B7RP1 pharmaceutical compositions can be administered parenterally. Alternatively, the compositions may be administered intravenously or subcutaneously. When systemically administered, the therapeutic compositions for use in this invention may be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such pharmaceutically acceptable protein solutions, with due regard to pH, isotonicity, stability and the like, is within the skill of the art.

Therapeutic formulations of CRP1 and B7RP1 polypeptide compositions useful for practicing the present invention may be prepared for storage by mixing

the selected composition having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (*Remington's Pharmaceutical Sciences*, 18th Edition, A.R. Gennaro, ed., Mack Publishing Company (1990)) in the form of a lyophilized cake or an aqueous solution. Acceptable carriers, excipients or stabilizers are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, pluronics or polyethylene glycol (PEG).

An effective amount of a CRP1 or B7RP1 polypeptide composition(s) to be employed therapeutically will depend, for example, upon the therapeutic objectives such as the indication for which the CRP1 and B7RP1 polypeptide is being used, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage may range from about 0.1 µg/kg to up to 100 mg/kg or more, depending on the factors mentioned above. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as two

or more doses (which may or may not contain the same amount of a CRP1 or B7RP1 polypeptide) over time, or as a continuous infusion via implantation device or catheter.

5 As further studies are conducted, information
will emerge regarding appropriate dosage levels for
treatment of various conditions in various patients,
and the ordinary skilled worker, considering the
therapeutic context, the type of disorder under
10 treatment, the age and general health of the recipient,
will be able to ascertain proper dosing.

The CRP1 or B7RP1 polypeptide composition to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using these methods may be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration ordinarily will be stored in lyophilized form or in solution.

Therapeutic compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

25 The route of administration of the
composition is in accord with known methods, e.g. oral,
injection or infusion by intravenous, intraperitoneal,
intracerebral (intraparenchymal),
intracerebroventricular, intramuscular, intraocular,
30 intraarterial, or intralesional routes, or by sustained
release systems or implantation device which may
optionally involve the use of a catheter. Where
desired, the compositions may be administered
continuously by infusion, bolus injection or by
35 implantation device.

Alternatively or additionally, the composition may be administered locally via implantation into the affected area of a membrane, sponge, or other appropriate material on to which CRP1
5 and B7RP1 polypeptide has been absorbed.

Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and delivery of a CRP1 or B7RP1 polypeptide may be directly through the device via bolus, or via
10 continuous administration, or via catheter using continuous infusion. A CRP1 or B7RP1 polypeptide may be administered in a sustained release formulation or preparation. Suitable examples of sustained-release preparations include semipermeable polymer matrices in
15 the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices include polyesters, hydrogels, polylactides (U.S. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al*, *Biopolymers*, 22: 547-556
20 (1983)), poly (2-hydroxyethyl-methacrylate) (Langer *et al.*, *J. Biomed. Mater. Res.*, 15: 167-277 (1981)) and Langer, *Chem. Tech.*, 12: 98-105 (1982)), ethylene vinyl acetate (Langer *et al.*, *supra*) or poly-D(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release
25 compositions also may include liposomes, which can be prepared by any of several methods known in the art (e.g., Eppstein *et al.*, *Proc. Natl. Acad. Sci. USA*, 82: 3688-3692 (1985); EP 36,676; EP 88,046; EP 143,949).

30 In some cases, it may be desirable to use CRP1 or B7RP1 polypeptide compositions in an *ex vivo* manner. Here, cells, tissues, or organs that have been removed from the patient are exposed to a CRP1 or B7RP1 polypeptide compositions after which the cells, tissues
35 and/or organs are subsequently implanted back into the patient.

003240.024260

In other cases, a CRP1 or B7RP1 polypeptide may be delivered through implanting into patients certain cells that have been genetically engineered, using methods such as those described herein, to

5 express and secrete the polypeptides, fragments, variants, or derivatives. Such cells may be animal or human cells, and may be derived from the patient's own tissue or from another source, either human or non-human. Optionally, the cells may be immortalized.

10 However, in order to decrease the chance of an immunological response, it is preferred that the cells be encapsulated to avoid infiltration of surrounding tissues. The encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or

15 membranes that allow release of the protein product(s) but prevent destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissues.

Methods used for membrane encapsulation of

20 cells are familiar to the skilled artisan, and preparation of encapsulated cells and their implantation in patients may be accomplished without undue experimentation. See, e.g., U.S Patent Nos. 4,892,538; 5,011,472; and 5,106,627. A system for

25 encapsulating living cells is described in PCT WO 91/10425 (Aebischer et al.). Techniques for formulating a variety of other sustained or controlled delivery means, such as liposome carriers, bio-erodible particles or beads, are also known to those in the art,

30 and are described, for example, in U.S. Patent No. 5,653,975. The cells, with or without encapsulation, may be implanted into suitable body tissues or organs of the patient.

As discussed above, it may be desirable to

35 treat cell preparations with one or more CRP1 or B7RP1 polypeptides, variants, derivatives and/or fragments.

This can be accomplished by exposing, for example, cells comprising T-cells, such as bone marrow cells, to the polypeptide, variant, derivative, or fragment directly, where it is in a form that is permeable to the cell membrane. For example, cells comprising T-cells may be exposed to a B7RP1 polypeptide in order to activate T-cell function and the cells so treated are implanted in the patient.

Alternatively, gene therapy can be employed. One manner in which gene therapy can be applied is to use a CRP1 or B7RP1 gene (either genomic DNA, cDNA, and/or synthetic DNA encoding a CRP1 or B7RP1 polypeptide, or a fragment, variant, or derivative thereof) which may be operably linked to a constitutive or inducible promoter to form a "gene therapy DNA construct". The promoter may be homologous or heterologous to the endogenous CRP1 or B7RP1 gene, provided that it is active in the cell or tissue type into which the construct will be inserted. Other components of the gene therapy DNA construct may optionally include, as required, DNA molecules designed for site-specific integration (e.g., endogenous flanking sequences useful for homologous recombination), tissue-specific promoter, enhancer(s) or silencer(s), DNA molecules capable of providing a selective advantage over the parent cell, DNA molecules useful as labels to identify transformed cells, negative selection systems, cell specific binding agents (as, for example, for cell targeting) cell-specific internalization factors, and transcription factors to enhance expression by a vector as well as factors to enable vector manufacture.

This gene therapy DNA construct can then be introduced into the patient's cells (either *ex vivo* or *in vivo*). One means for introducing the gene therapy DNA construct is via viral vectors. Suitable viral

5 retrovirus vectors. Some of these vectors, such as
retroviral vectors, will deliver the gene therapy DNA
construct to the chromosomal DNA of the patient's
cells, and the gene therapy DNA construct can integrate
into the chromosomal DNA; other vectors will function
10 as episomes and the gene therapy DNA construct will
remain in the cytoplasm. The use of gene therapy
vectors is described, for example, in U.S. Patent Nos.
5,672,344, 5,399,346.

15 constructs to a patient's cells without the use of
viral vectors include, without limitation, liposome-
mediated transfer, direct injection of naked DNA,
receptor-mediated transfer (ligand-DNA complex),
electroporation, calcium phosphate precipitation, and
20 microparticle bombardment (e.g., "gene gun"). See U.S.
Patent Nos. 4,970,154, WO 96/40958, 5,679,559,
5,676,954, and 5,593,875.

25 is to insert one or more enhancer elements into the CRP1 or B7RP1 polypeptide promoter, where the enhancer element(s) can serve to increase transcriptional activity of a CRP1 or B7RP1 polypeptide gene. The enhancer element(s) used will be selected based on the tissue in which one desires to activate the gene(s); enhancer elements known to confer promoter activation in that tissue will be selected. For example, if a CRP1 or B7RP1 polypeptide is to be "turned on" in T-cells, the *lck* promoter enhancer element may be used.

35 Here, the functional portion of the transcriptional element to be added may be inserted into a fragment of

i

5

10

15

20

25

30

35

via a viral vector as described above. Typically, integration of the construct into the genomic DNA of the cells will be via homologous recombination, where the 5' and 3' flanking DNA sequences in the promoter
5 construct can serve to help integrate the modified promoter region via hybridization to the endogenous chromosomal DNA.

Other gene therapy methods may also be employed where it is desirable to inhibit one or more
10 CRP1 or B7RP1 polypeptides. For example, antisense DNA or RNA molecules, which have a sequence that is complementary to at least a portion of a selected CRP1 or B7RP1 polypeptide gene(s) can be introduced into the cell. Typically, each such antisense molecule will be
15 complementary to the start site (5' end) of each selected CRP1 or B7RP1 gene. When the antisense molecule then hybridizes to the corresponding CRP1 or B7RP1 polypeptide mRNA, translation of this mRNA is prevented.

20 Alternatively, gene therapy may be employed to create a dominant-negative inhibitor of one or more CRP1 or B7RP1 polypeptides. In this situation, the DNA encoding a mutant full length or truncated polypeptide of each selected CRP1 or B7RP1 polypeptide can be
25 prepared and introduced into the cells of a patient using either viral or non-viral methods as described above. Each such mutant is typically designed to compete with endogenous polypeptide in its biological role.

30

Agonists and Antagonists

The invention also provides for agonists and antagonists of CRP1 or B7RP1 which regulate the activity of either or both molecules. A CRP1 or B7RP1
35 agonist will stimulate or enhance at least one activity of CRP1 or B7RP1. A CRP1 or B7RP1 antagonist will

partially or completely inhibit at least one activity of CRP1 or B7RP1. Agonists and antagonists may be identified from test molecules which alter the binding of B7RP1 to CRP1.

5 The term "test molecule(s)" refers to the molecule(s) that is/are under evaluation for the ability to bind a CRP1 or B7RP1 polypeptide and thereby alter the binding of B7RP1 to CRP1. Preferably, the test molecule will bind with an affinity constant of at
10 least about 10^6 M.

 A variety of assays may be used to measure binding of B7RP1 to CRP1. These assays may be used to screen test molecules for their ability to increase or decrease the rate or extent of binding of B7RP1 to
15 CRP1. In one type of assay, a CRP1 polypeptide, preferably a soluble form of CRP1 such as an extracellular domain, is immobilized by attachment to the bottom of the wells of a microtiter plate. Radiolabeled B7RP1 and the test molecule(s) can then be
20 added either one at a time (in either order) or simultaneously to the wells. After incubation, the wells can be washed and counted using a scintillation counter for radioactivity to determine the extent of binding to CRP1 protein by B7RP1. Typically, the
25 molecules will be tested over a range of concentrations, and a series of control wells lacking one or more elements of the test assays can be used for accuracy in evaluation of the results. An alternative to this method involves reversing the "positions" of
30 the proteins, *i.e.*, immobilizing B7RP1 to the microtiter plate wells, incubating with the test molecule and radiolabeled CRP1, and determining the extent of CRP1 binding (see, for example, chapter 18 of *Current Protocols in Molecular Biology*, Ausubel *et al.*,
35 eds., John Wiley & Sons, New York, NY [1995]).

002211 0248260

As an alternative to radiolabelling, CRP1 or B7RP1 may be conjugated to biotin and the presence of biotinylated protein can then be detected using streptavidin linked to an enzyme, such as horse radish peroxidase [HRP] or alkaline phosphatase [AP], that can be detected colorometrically, or by fluorescent tagging of streptavidin. An antibody directed to CRP1 or B7RP1 that is conjugated to biotin may also be used and can be detected after incubation with enzyme-linked streptavidin linked to AP or HRP

CRP1 and B7RP1 may also be immobilized by attachment to agarose beads, acrylic beads or other types of such inert substrates. The substrate-protein complex can be placed in a solution containing the complementary protein and the test compound; after incubation, the beads can be precipitated by centrifugation, and the amount of binding between CRP1 and B7RP1 can be assessed using the methods described above. Alternatively, the substrate-protein complex can be immobilized in a column and the test molecule and complementary protein passed over the column. Formation of a complex between CRP1 and B7RP1 can then be assessed using any of the techniques set forth above, i.e., radiolabelling, antibody binding, or the like.

Another type of in vitro assay that is useful for identifying a test molecule which increases or decreases formation of an CRP1/B7RP1 complex is a surface plasmon resonance detector system such as the Biacore assay system (Pharmacia, Piscataway, NJ). The Biacore system may be carried out using the manufacturer's protocol. This assay essentially involves covalent binding of either CRP1 or B7RP1 to a dextran-coated sensor chip which is located in a detector. The test compound and the other complementary protein can then be injected into the

chamber containing the sensor chip either simultaneously or sequentially and the amount of complementary protein that binds can be assessed based on the change in molecular mass which is physically associated with the dextran-coated side of the of the sensor chip; the change in molecular mass can be measured by the detector system.

In some cases, it may be desirable to evaluate two or more test compounds together for use in increasing or decreasing formation of a CRP1/B7RP1 complex. In these cases, the assays set forth above can be readily modified by adding such additional test compound(s) either simultaneously with, or subsequently to, the first test compound. The remainder of steps in the assay are as set forth above.

In vitro assays such as those described above may be used advantageously to screen rapidly large numbers of compounds for effects on complex formation by CRP1 and B7RP1. The assays may be automated to screen compounds generated in phage display, synthetic peptide and chemical synthesis libraries.

Compounds which increase or decrease complex formation of CRP1 and B7RP1 may also be screened in cell culture using cells and cell lines expressing either polypeptide. Cells and cell lines may be obtained from any mammal, but preferably will be from human or other primate, canine, or rodent sources. The binding of B7RP1 to cells expressing CRP1 on the surface is evaluated in the presence or absence of test molecules and the extent of binding may be determined by, for example, flow cytometry using a biotinylated antibody to B7RP1. Cell culture assays may be used advantageously to further evaluate compounds that score positive in protein binding assays described above.

Therapeutic Uses

Polypeptides of the invention, and agonists and antagonists thereof, may be used to regulate T-cell function. Agonists and antagonists include those molecules which regulate CRP1 and/or B7RP1 activity and either increase or decrease at least one activity of a CRP1 or B7RP1 protein such as one activity associated with T-cell functions, for example, T-cell activation. Agonists or antagonists may be co-factors, such as a protein, peptide, carbohydrate, lipid, or small molecular weight molecule, which interact with either CRP1 or B7RP1 and thereby regulate their activity. Potential polypeptide agonists or antagonists include antibodies that react with either soluble or membrane-bound forms of CRP1 or B7RP1 which comprise part or all of the extracellular domains of the said proteins. Molecules that regulate CRP1 or B7RP1 expression typically include nucleic acids encoding CRP1 or B7RP1 protein that can act as anti-sense regulators of expression.

CRP1 or B7RP1 polypeptides, and agonists and antagonists thereof, may be used in the treatment of autoimmune disease, graft survival, immune cell activation for inhibiting tumor cell growth, T-cell dependent B-cell mediated diseases, and cancer gene immunotherapy. In one embodiment, antagonists or inhibitors of CRP1 and/or B7RP1 function may be beneficial to alleviate symptoms in diseases with chronic immune cell dysfunction. Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, immune thrombocytopenic purpura (ITP), and psoriasis, may be treated with antagonists or inhibitors of CRP1/B7RP1. In addition, chronic inflammatory diseases, such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), Grave's disease, Hashimoto's thyroiditis, and diabetes mellitus, may also be treated with inhibitors to

CRP1/B7RP1. As described in Example 18, CRP1-Fc inhibits and B7RP1-Fc enhances, the onset of disease in a rodent rheumatoid arthritis disease model. These opposite effects in this model support an agonistic role for the B7RP1-Fc protein and an antagonistic role for the CRP1-Fc protein. The results also illustrate how T-cell responses can be regulated by manipulation of this pathway and the significance of this pathway in the progression of rheumatoid arthritis. In addition, as described in Example 19, expression of B7RP1-Fc *in vivo* stimulates an inflammatory bowel disease (IBD) phenotype in transgenic mice. This example supports the role for B7RP1/CRP1 in the development of inflammation in the intestine. Therefore, antagonists of the B7RP1/CRP1 pathway may be used to treat human IBD.

Antagonists of CRP1 or B7RP1 may be used as immunosuppressive agents for bone marrow and organ transplantation and may be used to prolong graft survival. Such antagonists may provide significant advantages over existing treatment. Bone marrow and organ transplantation therapy must contend with T-cell mediated rejection of the foreign cells or tissue by the host. Present therapeutic regimens for inhibiting T-cell mediated rejection involve treatment with the drugs cyclosporine or FK506. While drugs are effective, patients suffer from serious side effects, including hepatotoxicity, nephrotoxicity, and neurotoxicity. The target for the cyclosporin/FK506 class of therapeutics is calcineurin, a phosphatase with ubiquitous expression. Since CRP1 expression is restricted to T-cells, inhibitors of CRP1 or B7RP1 may lack the severe side effects observed with the use of the present immunotherapeutic agents.

Antagonists of CRP1 or B7RP1 may be used as immunosuppressive agents for autoimmune disorders, such

Variable	Mean	SD	Min	Max
Age	34.5	10.2	21	55
Gender	Male	Female	Male	Female
Marital status	Married	Single	Married	Single
Education	High school	College	High school	College
Occupation	Manager	Worker	Manager	Worker
Income	Low	High	Low	High
Health status	Good	Poor	Good	Poor
Stress level	Low	High	Low	High
Life satisfaction	Low	High	Low	High
Resilience	Low	High	Low	High
Optimism	Low	High	Low	High
Self-efficacy	Low	High	Low	High
Perceived stress	Low	High	Low	High
Perceived social support	Low	High	Low	High
Perceived family support	Low	High	Low	High
Perceived work support	Low	High	Low	High
Perceived community support	Low	High	Low	High
Perceived spiritual support	Low	High	Low	High
Perceived religious support	Low	High	Low	High
Perceived cultural support	Low	High	Low	High
Perceived ethnic support	Low	High	Low	High
Perceived national support	Low	High	Low	High
Perceived international support	Low	High	Low	High
Perceived global support	Low	High	Low	High
Perceived universal support	Low	High	Low	High
Perceived cosmic support	Low	High	Low	High
Perceived divine support	Low	High	Low	High
Perceived supernatural support	Low	High	Low	High
Perceived mystical support	Low	High	Low	High
Perceived magical support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support	Low	High	Low	High
Perceived paranormal support	Low	High	Low	High
Perceived occult support	Low	High	Low	High
Perceived esoteric support	Low	High	Low	High
Perceived occultic support	Low	High	Low	High
Perceived mystic support	Low	High	Low	High
Perceived magic support				

Antibodies, soluble proteins comprising for example extracellular domains, and other regulators of CRP1 or B7RP1 that result in prolonged or enhanced T-cell activation can be used to increased the immune response to tumors. Example 20 shows B7RP1-Fc can inhibit tumor cell growth in mice. Similarly, human B7RP1-Fc, or other activators of the B7RP1/CRP1 pathway, may be used to enhance immune responses against human tumors. Anti-tumor activity is generally considered to have a strong cytolytic T-lymphocyte component. In fact, the anti-tumor effects of B7-Fc fusion proteins (Sturmhoefel et al., Cancer Res. 59: 4964-4972, 1999) were mediated by cytolytic CD8+ T-cells. Since CRP1 is also expressed on cytolytic CD8+ T-cells (Example 9), it is probable that the anti-tumor effects demonstrated in Example 20 were due to B7RP1-Fc action on CD8+ cells. The B7RP1/CRP1 pathway can also be manipulated to regulate CTL response in a number of other clinical settings, including allograft transplantation, graft vs. host disease, and autoimmune diseases.

Gene therapy using B7RP1 genes of the invention may be used in cancer immunotherapy. B7RP1 genes introduced into cancer cells can transform them into antigen presenting cells that can be recognized by the T-cells of the immune system when introduced back into an animal. Recognition of the transfected tumor cells by the T-cells results in eradication of both

tumors cells expressing, or not expressing, the B7RP1 gene. This immunotherapy approach may be used for various leukemias, sarcomas, melanomas, adenocarcinomas, breast carcinomas, prostate tumors, lung carcinomas, colon carcinomas and other tumors. This invention encompasses using the B7RP1 gene in a similar manner to enhance T-cell activation in response to variety of tumors.

As described in Example 14, the phenotype of transgenic mice expressing B7RP1 indicates that B7RP1 is important in the control of antibody production. Agonists and antagonists of B7RP1 protein activity may be useful in therapeutic indications that call for the inhibition or enhancement of antibody production.

For instance, many vaccines act by eliciting an effective and specific antibody response. Some vaccines, especially those against intestinal micro-organisms (e.g. Hepatitis A virus, and Salmonellas), elicit a short-lived antibody response. It is desirable to potentiate and prolong this response in order to increase the effectiveness of the vaccine. Therefore, soluble B7RP1 or activating antibodies to CRP1 may serve as a vaccine adjuvant.

Anti-viral responses may also be enhanced by activators or agonists of the B7RP1/CRP1 pathway. The data in Example 20 indicate that cellular immunity is enhanced by B7RP1-Fc. The enhancement of cellular immune functions by B7RP1-Fc, or other activators of the B7RP1/CRP1 pathway, may also be beneficial in eliminating virus-infected cells. In a complementary fashion, B7RP1-Fc has effects on humoral immune functions that may enhance antibody mediated responses as observed in Example 13 that may function to help clear free-virus from the body.

Enhancement of cellular immune functions, would be desirable in treating cancer or viral

infection. Immune response may be enhanced by activation of the B7RP1/CRP1 pathway optionally in conjunction with activation of a separate immune stimulating pathway. A synergistic effect of B7RP1 and B7.2 in a mouse chronic hypersensitivity model is shown in Example 24. Thus, B7RP1 or an agonist of CRP1 may be administered with B7.1 or B7.2 to stimulate immune functions. In another embodiment, B7RP1 or an agonist of CRP1 may be administered with a CD28 agonist or a CTLA4 antagonist to stimulate immune functions. It is also contemplated that B7RP1 or a CRP1 agonist may be used with other immune stimulating molecules, such as T-cell stimulating molecules, in order to enhance cellular immune functions. In one embodiment, a CRP1 agonist is an antibody which binds CRP1 and stimulates or enhances CRP1 activity.

Conversely, there are a number of clinical conditions that would be ameliorated by the inhibition of antibody production. Hypersensitivity is a normally beneficial immune response that is exaggerated or inappropriate, and leads to inflammatory reactions and tissue damage. Hypersensitivity reactions which are antibody-mediated may be particularly susceptible to antagonism by inhibitors of B7RP1 activity. Allergies, hay fever, asthma, and acute edema cause type I hypersensitivity reactions, and these reactions may be suppressed by protein, antibody or small molecule inhibitors of B7RP1 activity.

Diseases that cause antibody-mediated hypersensitivity reactions, including systemic lupus erythematosus, arthritis (rheumatoid arthritis, reactive arthritis, psoriatic arthritis), nephropathies (glomerulo-nephritis, membranous, mesangiocapillary, focal segmental, focal necrotizing, crescentic, proliferative - tubulopathies), skin disorders (pemphigus and pemphigoid, erythema nodosum),

In addition, lymphoproliferative disorders, such as multiple myeloma, Waldenstrom's
10 macroglobulinemia, and crioglobulinemias, may be inhibited by protein, antibody, or small molecule antagonists of B7RP1.

The B7RP1/CRP1 pathway is involved in regulating IgE production. IgE is an immunoglobulin isotype specifically involved in mediating allergic responses such as asthma, food allergies, hay fever, type 1 hypersensitivity and sinus inflammation. Upon exposure to an allergen, a process involving T-cell and B cell collaboration results in B cell production of IgE specific for the allergen. Allergen-specific IgE released into the circulation by B cells bind to mast cells and basophils through the high affinity IgE receptor (Fc ϵ RI). Mast cells and basophils to which IgE is bound become sensitized and subsequent exposure to the allergen results in cross-linking of the surface receptors and release of histamines.

30 Example 22 shows that transgenic mice
expressing a B7RP1 fusion protein have increased levels
of IgE compared to normal mice. In addition, CRP1
"knockout" mice show complete inhibition of class
switching to IgE (see Example 23). These results

indicate that activation of the B7RP1/CRP1 pathway leads to IgE production.

The invention provides for use of modulators of B7RP1 or CRP1 to regulate IgE production and to prevent or treat IgE-mediated disorders. In one embodiment, antagonists of B7RP1 or CRP1 are used to partially or completely inhibiting IgE production. The antagonists may be used separately, or in combination, in a treatment regimen for decreasing IgE levels.

Examples of B7RP1 and CRP1 antagonists include nucleic acids, polypeptides, peptides, antibodies, carbohydrates, lipids, and small molecules. In one embodiment, the antagonist is an antibody which binds to B7RP1 and partially or completely inhibits IgE production. In another embodiment, the antagonist is an antibody which binds to CRP1 and partially or completely inhibits CRP1 activity. In another embodiment, a combination of a B7RP1 antagonist and a CRP1 antagonist may be used, for example, B7RP1 antagonist antibody and a CRP1 antagonist antibody. B7RP1 and CRP1 antagonists are administered in amounts effective to decrease IgE production.

The antagonists of the invention may be used to prevent and/or treat disorders characterized by excessive or inappropriate IgE production. By way of example, such disorders include allergic responses such as asthma, food allergies, hay fever, hypersensitivity, and sinus inflammation.

The invention also provides for the use of a B7RP1 antagonist or a CRP1 antagonist in combination with an IgE antagonist to partially or completely inhibit IgE production and to prevent and/or treat disorders characterized by excessive or inappropriate IgE production. As used herein the term "IgE antagonist" refers to a compound capable of disrupting or blocking the interaction of IgE with its high

affinity receptor $\text{Fc}_\epsilon\text{RI}$ on cells such that the response to allergen stimulus is attenuated or eliminated. Antagonists include an anti-IgE antibody and fragments thereof, soluble $\text{Fc}_\epsilon\text{RI}$ receptor and fragments thereof, 5 anti- $\text{Fc}_\epsilon\text{RI}$ antibody and fragments thereof, IgE variants and fragments thereof, IgE binding peptides, $\text{Fc}_\epsilon\text{RI}$ receptor binding peptides, and small molecules capable of binding to IgE or competing with IgE for binding to $\text{Fc}_\epsilon\text{RI}$ receptor. B7RP1 antagonists may also be used 10 with in combination with antihistamines, allergen desensitization, reduction in exposure to allergen and the like for treatment of allergic disorders.

In some instances, it may be useful to increase IgE production, such as to prevent and/or 15 treat immune-related disorders in an immune comprised host. In such cases, B7RP1 alone or in conjunction with a CRP1 agonist may be administered in amounts sufficient to increase IgE production.

The invention also provides for the 20 prevention and/or treatment of asthma comprising administering a B7RP1 antagonist or a CRP1 antagonist alone or in conjunction with one or more agents for treating asthma. Examples of such agents include bronchodilators (anti-cholinergic agents, β_2 adrenergic 25 receptor agonists, lenkotriene D_4 antagonists, neurokinin antagonists, potassium channel openers, substance P antagonists, thromboxane A_2 antagonists, and xanthines), anti-inflammatories (5-lipoxygenase inhibitors, 5-lipoxygenase activating protein 30 inhibitors, phosphodiesterase IV inhibitors, platelet activating factor antagonists, respiratory NSAIDS, steroids, and tyrosine kinase inhibitors), cytokine

inhibitors (CD4, IL-4 and IL-5 inhibitors) and IgE antagonists as set forth above.

The following examples are offered to more fully illustrate the invention, but are not construed as limiting the scope thereof.

Example 1

CRP1 cDNA and Amino Acid Sequence

Female C57/ Black 6 mice were sacrificed, and the small intestines were excised, and the Peyer's patches were removed. The small intestine tissue was sliced open and washed to remove mucus and other debris. The epithelial layer, which contains the intestinal intraepithelial cells (iIELs), was released by gentle agitation in RPMI-1640 supplemented with 1 mM dithiothreitol (DTT), for 20 minutes at 37°C. Disassociated cells were passed through a 100 μ filter, washed in 50 ml of RPMI-1640, mixed to further break up clumps of cells, and then passed through a 40 μ strainer to obtain single cell populations. These cells were then washed again in a 50 ml volume of RPMI-1640 to ensure the removal of the residual DTT. The tissue was then agitated and washed as before to gather the remaining iIELs. The iIELs were separated from the adipose cells and most epithelial cells on a 3-step Percol gradient, with the iIELs banding at the 40% to 80% interface. These cells were then washed twice with RPMI-1640 to remove traces of Percol, immunostained with CD103 (integrin alpha IEL) antibodies, and separated on a FACS Star cell sorter. These sorted cells were then either used to prepare total RNA directly using Trizol (Gibco BRL, Gaithersburg, MD), or activated overnight on plate-bound activating

antibodies, which crosslink the gamma/delta TCR, alpha/beta TCR, or CD3. The RNA was prepared as above and pooled for use in constructing EST cDNA libraries.

A cDNA clone, designated sm12-00082-a1, contained nucleotide sequence homology to CD28 (Figure 1B). Translation of the sequence and subsequent comparison to known proteins in a public database revealed 19% amino acid identity with murine CD28 (Figure 1B). This low homology was significant because murine CD28 shares only 26% amino acid identity with murine CTLA-4. All of the putative cysteines thought to be critical for intra- and inter-molecular cysteine bonding in the CD28/CTLA-4 family were found to be conserved (amino acid residues 83, 109, and 137; relative to the initiating methionine). In addition, the overall length of the putative open reading frame, and the relative position of the transmembrane domain, were similar to those of both CD28 and CTLA-4. We named the gene CRP1, for CD28-Related Protein-1.

Example 2

Cloning of Human CRP1 cDNA

The nucleic acid sequence encoding human CRP1 protein is identified by the following procedures. A human cDNA library was prepared from enriched lymphocytes from peripheral human blood from normal human volunteers. The lymphocytes were purified and red blood cells were removed by Lymphocyte Separation Media (ICN Pharmaceuticals, Inc., Costa Mesa, CA). The cells were then activated overnight in media containing 10 ng/ml PMA, 500 ng/ml ionomycin, and plate-bound activating antibodies to CD3. Total RNA was prepared from the activated cells by the Trizol method (Gibco/BRL) and poly A RNA was isolated by Dynal bead purification. cDNA was made from the isolated poly A

RNA and size selected for largest cDNA fragments. The size selected cDNA was then ligated into the plasmid pSPORT (Gibco/BRL). DNA encoding human CRP1 protein is obtained by screening the activated lymphocyte cDNA library by either recombinant bacteriophage plaque, or transformed bacteria colony hybridization protocols (Sambrook et al. *Supra*). The phage or plasmid cDNA library are screened using radioactively-labeled probes derived from the murine CRP1 gene clone as described in Example 1 and Figure 1. The probes are used to screen nylon filters lifted from the plated library. These filters are prehybridized for 4 hr at 42°C in 50% formamide, 5X SSPE, 2X Denhardt's solution, 0.5% SDS, and 100 µg/ml salmon sperm DNA and then hybridized for 24 hr at 42°C in 50% formamide, 5X SSPE, 2X Denhardt's solution, 0.5% SDS, 100 µg/ml salmon sperm DNA, and 5 ng/ml mB7RP1 probe. The blots are washed in 2X SSC, 0.1% SDS for 10 min at RT, 1X SSC, 0.1% SDS for 10 min at 50°C, 0.2X SSC, 0.1% SDS for 10 min at 50°C, then 0.2X SSC for 10 min at 50°C again. Inserts obtained from any human CRP1 clones are sequenced and analyzed as described in Example 1.

Example 3

25 B7RP1 DNA and Amino Acid Sequence

A cDNA clone, designated sm11-00003-g5, contained nucleotide sequence homology to B7.1 (CD80) and B7.2 (CD86). Translation of the sequence (Figure 2A) and subsequent comparison to known proteins in a public database revealed 20% amino acid identity with murine B7.1 (Figure 2B). This low homology was significant because murine B7.1 shares only 24% amino acid identity with murine B7.2. Despite this low homology, critical cysteine residues are conserved

between the open reading frame of this clone and murine B7.1 and B7.2 at residues 62, 138, 185, and 242 (relative to the initiating methionine, Figure 2B). The approximate mature protein length and the location of the transmembrane region relative to the carboxy terminus are also similar in the putative ORF of this clone, as compared to B7.1 and B7.2. We named the gene B7RP1, for B7-Related Protein-1.

10

Example 4

Cloning of Human B7RP1 cDNA

A Genbank blast homology search (GCG, University of Wisconsin) using murine B7RP1 sequence (see Figure 2) retrieved a clone (AB014553) containing a 4358 bp sequence with 1679 bp of ORF. PCR cloning primers were designed according to this sequence. A DNA fragment of 1313 bp was obtained by 5' and 3' RACE using Human Lymph Node Marathon-Ready™ cDNA (Clontech, Palo Alto, CA) according to the manufacturer's recommended procedures. Primers used for full length human B7RP1:

2083-75	ACC ATG CGG CTG GGC AGT CCT GGA
25	(SEQ ID NO: 25)
2083-76	TGG TGA CCT ACC ACA TCC CAC AG
	(SEQ ID NO: 26)
2083-77	TCC GAT GTC ATT TCC TGT CTG GC
	(SEQ ID NO: 27)
30 2083-78	GCT CTG TCT CCG GAC TCA CAG CCC
	(SEQ ID NO: 28)
2113-29	GTG GCA GCA AAC TTC AGC GTG CCC GTC G
	(SEQ ID NO: 29)
2113-30	CCC AAC GTG TAC TGG ATC AAT AAG ACG G
35	(SEQ ID NO: 30)
2113-31	GCG TGC TGA GGA TCG CAC GGA CCC CCA G

(SEQ ID NO: 31)

Primers 2083-75 and 2083-76 were used to amplify the 5' end of the gene using RACE protocols. Primers 2083-77, 2083-78, 2113-29, 2113-30, and 2113-31, were used to amplify the 3' end of the gene using RACE protocols.

The resulting nucleotide sequence contained an ORF of 288 amino acid residues beginning at the methionine. The predicted mature human B7RP1 amino acid sequence was then compared to the mature mouse B7RP1 amino acid sequence (Figure 3B) and found to share 48% amino acid identity. This homology is significant because the homology between species is low with the CD80 (B7.1) gene, in fact, the mouse and human CD80 share only 41% amino acid identity. Importantly, the human B7RP1 protein conserve critical cysteine residues necessary for Ig loop structures (amino acid residues 16, 92, 138, 194, and 195, relative to the mature protein, Figure 3B). In addition, the overall length and position of the transmembrane domain are consistent with a human B7RP1 homolog.

Example 5

Expression of B7RP1 RNA

RNA in situ hybridization using RNA probes to the B7RP1 gene. Adult mouse tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 5 μ m. Prior to in situ hybridization, tissues were permeabilized with 0.2M HCL, followed by digestion with Proteinase K, and acetylation with triethanolamine and acetic anhydride. Sections were hybridized overnight at 55°C with a 969 base ³³P-labeled riboprobe corresponding to nucleotides 1 to 969 of the mouse B7RP1 sequence. Excess probe was removed by RNase

digestion, followed by a series of washes in buffer with decreasing salt concentrations, and then a high stringency wash in 0.1X SSC at 55°C. Slides were dipped in Kodak NTB2 emulsion, exposed at 4°C for 2-3 weeks, developed, and counterstained with hematoxylin and eosin. Sections were examined with darkfield and transmitted light illumination to allow simultaneous evaluation of the tissue morphology and the hybridization signal.

The analysis of the B7RP1 RNA by in situ hybridization showed that the B7RP1 RNA was highly expressed in areas of lymphoid maturation and lymphocyte activation. B7RP1 RNA was expressed in the lymphoid tissues of the thymus, Peyer's patches of the intestine, spleen, and lymph nodes. Expression within these lymphoid tissues demonstrated that the B7RP1 RNA was generally expressed in the areas of B-cell and other APC involvement. These regions include the medulla area of the thymus, the primary follicles of the lymph nodes, and the follicular and dome regions of the Peyer's patches. The expression of B7RP1 RNA is highly specific to the regions of APC involvement in lymphoid tissues.

The analysis of several non-lymphoid tissues also revealed B7RP1 expression in regions of APC involvement. In the lung, B7RP1 expression was found in the submucosal regions, consistent with a function in antigen processing. In the small intestine, B7RP1 RNA was found in the lamina propria. Notably, we found a section of damaged liver, which showed lymphocyte infiltration that overlapped with the expression of B7RP1 RNA. This coincidence of B7RP1 expression with lymphocyte accumulation in response to tissue damage strongly indicates that B7RP1 is involved in lymphocyte activation.

Example 6

Expression of CRP1 RNA

RNA in situ hybridization using RNA probes to
5 the CRP1 gene. Mouse tissues were prepared as in
Example 5. Tissue permeabilization, probe
hybridization, slide treatment, and tissue staining
were as described in Example 5. Sections were
hybridized overnight at 55°C with a 603 base ³³P-
10 labeled riboprobe corresponding to nucleotides 1 to 603
of the mouse CRP1 sequence. Sections were examined
with darkfield and transmitted light illumination to
allow simultaneous evaluation of the tissue morphology
and the hybridization signal.

15 Lymph nodes from normal mice or a mouse
treated with oxazolone were sectioned and analyzed for
CRP1 RNA expression. The sensitized mouse lymph node
showed greater expression of CRP1 RNA than the normal
mouse lymph node. The expression of CRP1 was in the
20 paracortex, a region of T-cell activity. Therefore,
the expression of CRP1 RNA is consistent with that of
T-lymphocyte expression and is up-regulated upon T-cell
activation.

25

Example 7Expression and Purification of
CRP1-Fc and B7RP1-Fc Fusion Proteins

30 To construct the DNA expression vector for
the CRP1- Fc fusion protein, the coding sequence for
the first amino terminal 147 amino acids of the CRP1
was fused, inframe, to the coding sequence for the
carboxy terminal 235 amino acids of the human Fc gene
35 (isotype IgG1) and ligated within the polylinker

sequence of pcDNA3 (pcDNA3/CRP1-Fc). To construct the DNA expression vector for the B7RP1- Fc fusion protein, the coding sequence for the first amino terminal 269 amino acids of the B7RP1 was fused, inframe, to the coding sequence for the carboxy terminal 235 amino acids of the human Fc gene (isotype IgG1) and ligated within the polylinker sequence of pcDNA3 (pcDNA3/B7RP1-Fc). The coding sequences of both CRP1 and B7RP1 contained sequences from the N-terminus of each protein up to, but not including, the putative transmembrane region of each protein. 293T-cells were transfected with either pcDNA3/CRP1-Fc or pcDNA3/B7RP1-Fc using the FuGene 6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN). After four days, the conditioned media were collected and the Fc fusion proteins were purified by batch chromatography using Protein A Sepharose (Pharmacia). Fc fusion proteins bound to the column were eluted with three column volumes of Immunopure Gentle Elution Buffer (Pierce), and then were dialyzed against 150 volumes of 20 mM HEPES, 100 mM NaCl, pH 7.5. The dialyzed protein was concentrated using Macrosep centrifugal concentrates, 30 kD MWCO (Pall Filtron), and the protein concentrations were calculated using extinction coefficients derived from the amino acid sequence of each protein. Expression of CRP1-Fc fusion protein is shown in Figure 4A, expression of B7CPR1-Fc fusion protein is shown in Figure 4B.

Example 8

Identification of CRP1 and B7RP1 as a Receptor-ligand Pair

In order to determine whether the novel proteins were part of the same costimulatory pathway as

that containing CD28, CTLA-4, B7.1, and B7.2, we utilized a cell surface display assay. This assay uses ACAS (Adherent Cell Analysis and Sorting) analysis to analyze whether membrane-bound proteins expressed in
5 cells interact with various Fc fusion proteins. Cells expressing membrane-bound proteins, indicated on the left side of Figure 5, were incubated with Fc fusions proteins, indicated at the top of the figure.

Cos-7 cells, grown in DMEM media with 10%
10 FBS, were plated at 500,000 cells/well in a 24-well plate. Cells were transfected using the FuGene 6 reagent (Roche Molecular Biochemicals, Indianapolis, IN). For each transfection, 3 μ l of FuGene 6 reagent was added to 47 μ l of serum free DMEM media. After a
15 10 min incubation at room temperature, the mix was added to 0.25 μ g of plasmid dropwise and then was incubated for 15 minutes. The above mix was then added to the cells with 0.5 ml of DMEM with 10% FBS. The cells were incubated at 37°C in a 5% CO₂ atmosphere.
20 As a control, CHO D- cells, stably transfected with an expression plasmid containing the cDNA for human CD28, were also plated at 500,000 cells/well in a 24-well plate.

After 48 hr, the medium with transfection
25 reagent was removed and the cells were washed twice with RPMI plus 5% FBS. 10 to 20 ng of purified Fc fusion proteins in 1 ml of media were added to the cells, which were incubated for 30 min on ice. The cells were washed three times with RPMI plus 5% FBS and
30 then were incubated with 2 μ l of FITC-conjugated anti-human Fc antibody (1 mg/ml) for another 30 min on ice. After three successive washes with RPMI, the cells were covered with 250 μ l of RPMI media without phenol red for ACAS analysis.

ACAS analysis of the cells that bound the various Fc fusion proteins demonstrated that the B7RP1 protein bound CRP1, but not the proteins in the known costimulatory pathway, CD28 or CTLA-4. Conversely, CRP1 interacted with B7RP1, but not B7.2, a component in the known pathway. (See Figure 5). These results strongly indicate that CRP1 and B7RP1 represent a novel receptor-ligand pair, analogous to CD28 and B7.2. However, since CRP1 and B7RP1 do not interact with B7.2, CTLA-4, or CD28, they are separate and independent of the known costimulatory pathway.

Example 9

15 Identification of Cells Expressing B7RP1 Receptors

The B7RP1-Fc fusion protein was utilized to detect cells that expressed receptors to B7RP1, presumably including the CRP1 protein (see Example 6), by FACS analysis. Spleens were removed from female C57/Black 6 mice, ground on 100 micron mesh filters to release the lymphocytes, passed through 70 micron filters, and then washed in 50 ml of RPMI-1640. They were pelleted at 1500 rpm, resuspended in fresh RPMI, mixed to break up the clumping cells, and passed through a 40 micron filter. T-cells to be activated were seeded into 6 well plates in RPMI-1640, 5% FBS, 1XPSG, PMA, ionomycin, and incubated at 37°C, 5% CO₂ overnight. T-cell activation was checked by visual confirmation after 12 hr.

Activated spleen cells for immunostaining were washed in PBS, 0.5% BSA (Path-ocyte 4, ICN Pharmaceuticals) wash buffer, resuspended, and then aliquoted in 100 μ l volumes. 15 μ g/ml of either the CRP1-Fc fusion protein or the B7RP1-Fc fusion protein was added (1.5 μ g/sample) as appropriate, and then the

mixtures were incubated on ice for 30 min with occasional mixing. The cells were washed twice in 5.0 ml of wash buffer. Binding of the fusion proteins was visualized with 2 μ g of goat-anti-human (GaHuFc-FITC) conjugated secondary antibody in a 100 μ l volume for cell staining. Cell marker antibodies conjugated with PE were added with the GaHUFc-FITC, as well as control isotype-PE conjugated antibody controls where indicated (rat isotype). The samples were incubated on ice and washed as before. Visualization was done by FACScan analysis with gating on the lymphocyte populations. Double staining with CD4+ antibodies and the B7RP1-Fc fusion protein indicated that the cells expressed both the CD4 marker and the receptor to B7RP1, presumably CRP1 (Figure 6). Similarly, double staining with CD8+ antibodies and the B7RP1-Fc fusion protein demonstrated that cells expressed both CD8 and B7RP1 receptors (Figure 6). We could not reliably detect such double staining cells in inactivated splenocyte preparations. Since CD4 and CD8 are T-lymphocyte markers, we can postulate that CRP1 is expressed on activated CD4+ and CD8+ T-cells. These data are consistent with the increased expression of CRP1 RNA in the T-cell regions of lymph nodes from sensitized mice as compared to normal mice (Example 6).

Example 10

Identification of Cells Expressing CRP1 Ligands

The CRP1-Fc fusion protein was utilized to detect cells that expressed ligands to CRP1, presumably including the B7RP1 protein (see Example 8), by FACS analysis (Figure 7). Splenocytes were prepared as in Example 8, except the 12 hr T-cell activation step was omitted and the cells were directly analyzed. Splenocytes were double stained with CD45R (B220)

marker antibodies and the CRP1-Fc fusion protein. Cells were detected that expressed both the CD45R B-cell marker and the putative ligands for CRP1, presumably including B7RP1 (Example 8). Therefore, we
5 conclude that B7RP1 is expressed on B-cells, a type of antigen-presenting cell. These data are consistent with the expression of B7RP1 RNA in B-cell regions of various lymphoid tissues (Example 5).

FACS analysis of the expression of B7RP1 on
10 peritoneal macrophages (Figure 8). Peritoneal cells were collected by local lavage from a normal mouse and washed before being incubated with the CRP1-Fc fusion protein or the Fc protein as a control or with the F4/80 monoclonal antibody (which detects an antigen
15 specific for macrophages) or an irrelevant, isotype-matched control monoclonal antibody. Cells were then washed again and incubated with goat-anti-human Fc-FITC conjugated antibody. After further washing, cells were assessed in a FACS analyzer for their light scattering
20 and fluorescence staining properties. Peritoneal cells were first distinguished in subsets on the ground of their light scattering properties (Figure 8A). Macrophages were identified in region 5 (R5) because of their ability to strongly scatter light forward (FSC)
25 and sideways (SSC) and because of their positive staining for the F4/80 antigen, a marker for macrophages (Figure 8B). Macrophages in region 6 (R6) were singled out on the basis of their less intense staining for the F4/80 antigen and found to be stained
30 by the CRP1-Fc fusion protein (Figure 8C). These data indicate that ligands for CRP1, possibly including B7RP1, are expressed on macrophages, a professional antigen presenting cell. This is consistent with CRP1 and B7RP1 function in T-lymphocyte activation.

35

Example 11

In vitro Inhibitory Activity of the B7RP1-Fc Fusion
Protein on ConA-Stimulated T-Lymphocytes

Mouse splenocytes were prepared as in Example
5 8 and enriched for T-lymphocytes by negative selection
(R and D Systems, Inc., Minneapolis, MN)). 200,000
splenocytes were used in T-cell proliferation assays in
a 96-well round-bottom plate. Cells were incubated for
1 hr with media (no adds), CRP1-Fc, B7RP1-Fc, or B7.2-
10 Fc, fusion proteins as indicated Figure 9. Media (no
adds), or Con A at various concentrations were added as
indicated in at the bottom of Figure 9. The cells were
then incubated at 37°C and 5% CO₂. After 42 hr, cells
were pulsed with 3H-thymidine for 6 hr, harvested and
15 incorporated radioactivity determined. Average CPM and
standard deviation from triplicate samples are
represented in Figure 9.

The Fc fusion proteins did not demonstrate
significant T-cell stimulatory or inhibitory activity
20 by themselves, however, in the presence of 1 µg/ml and
3 µg/ml Con A, both the B7RP1-Fc and the known B7.2-Fc
fusion proteins showed significant inhibitory activity
(Figure 9). At high concentrations (10 µg/ml), Con A
stimulation results in cell death, presumably through
25 over-activation of the T-cells. Addition of either
B7RP1-Fc or B7.2-Fc, significantly protected the cells
from the detrimental effects of high concentrations of
Con A. In both inhibitory and protective functions,
the effect by B7RP1-Fc protein was greater than B7.2-Fc
30 protein on the Con A stimulated cells. These data
indicate that the B7RP1 protein functions to regulate
T-cell proliferation.

Example 12

35 Systemic delivery of B7RP1-Fc fusion protein in
transgenic mice

0923420 12300
The B7RP1-Fc fusion protein described in Example 7 was subcloned into an ApoE-liver specific expression vector (Simonet et al. J. Clin. Invest. 94, 1310-1319 (1994) and PCT Application No. US94/11675). The coding region was excised from pCEP4/B7RP1-Fc using the restriction enzymes, Spe I and Not I, and the fragment subcloned into the same sites in the previously mentioned ApoE-liver specific expression vector. The resultant plasmid, HE-B7RP1-Fc, was sequenced through it's protein coding region, and sequences flanking the coding region, to ensure it was mutation free.

The plasmid was amplified and purified through two rounds of CsCl density gradient centrifugation. The purified plasmid DNA was digested with the restriction enzymes, Cla I and Ase I, and the 1.5 kb transgene insert was purified by agarose gel electrophoresis. The purified fragment was diluted to a stock injection solution of 1 μ g/ml in 5 mM Tris, pH 7.4, and 0.2 mM EDTA. Single-cell embryos from BDF1 X BDF1-bred mice were injected essentially as described (Brinster et al., Proc. Natl. Acad. Sci. USA 82, 4338 (1985)), except that injection needles were beveled and siliconized before use. Embryos were cultured overnight in a CO2 incubator and 15 to 20 2-cell embryos were transferred to the oviducts of pseudopregnant CD1 female mice.

Following term pregnancy, 56 offspring were obtained from implantation on the microinjected embryos. The offspring were screened by PCR amplification of the integrated transgene in genomic DNA samples. The target region for amplification was a 369 bp region of the human Apo E intron which was included in the expression vector. The oligos used for PCR amplification were:

5'-GCC TCT AGA AAG AGC TGG GAC-3' (SEQ ID NO: 32)

5'-CGC CGT GTT CCA TTT ATG AGC-3' (SEQ ID NO: 33)

5 The conditions for the PCR were: 94°C for 2 min, 1 cycle; 94°C for 1 min, 63°C for 20 sec, and 72°C for 30 sec, 30 cycles. Of the 56 original offspring, 7 were identified as PCR positive transgenic founder mice.

10 At 12 weeks of age, nine transgenic founders (mouse #1, 2, 4, 6, 8, 30, 32, 33, 40) and five controls (mouse #5, 9, 10, 25, 28) were sacrificed for necropsy and pathological analysis. Total cellular RNA was isolated from the livers of the founder animals and
15 negative control littermates as described (McDonald et al. Meth. Enzymol. 152, 219 (1987)). Northern blot analysis was performed on these samples to assess the level of transgene expression. Approximately 10 µg of total RNA from each animal was resolved by agarose
20 electrophoresis denaturing gels (Ogden et al. Meth. Enzymol. 152, 61 (1987)), then transferred to HYBOND-N nylon membrane (Amersham), and probed with ³²P dCTP-labeled mB7RP1-Fc insert DNA. Hybridization was performed for 1 hr at 63°C in ExpressHyb Solution
25 (Clonetech) and 2-4 X 10⁶ CPM of labeled probe/ml hybridization buffer. Following hybridization, blots were washed twice in 2X SSC, 0.1% SDS at room temperature for 5 min each, and then twice in 0.1X SSC, 0.1% SDS at 55°C for 15-20 min each. Expression of the
30 transgene in founder and control littermates was determined following autoradiography.

 Northern blot analyses indicated that seven of the transgenic founders expressed detectable levels of the transgene RNA (mouse #1, 2, 6, 8, 32, 33, and
35 40). The negative control mice and three founders (#4,

008211 02482/60

30, and 31) did not express detectable levels of RNA. Since the B7RP1-Fc fusion protein was determined to be secreted from mammalian cells in culture (Figure 4B and Example 7), expression of the transgene mRNA should be indicative of the level of systemically delivered gene product.

Example 13

Biological activity of B7RP1-Fc fusion protein

10

Seven of the transgenic mice (mouse #1, 2, 6, 8, 32, 33, and 40) and five control littermates (#5, 9, 10, 25, and 28) were sacrificed for necropsy and pathological analysis using the following procedures:

15 Prior to euthanasia, all animals had their identification numbers verified, then were weighed, anesthetized and blood drawn. The blood was saved as both serum and whole blood for a complete serum chemistry and hematology panel. Radiography was

20 performed just after terminal anesthesia by lethal CO₂ inhalation, and prior to gross dissection. Tissues were then removed and fixed in 10% buffered Zn-formalin for histological examination. The tissues collected included the liver, spleen, pancreas, stomach,

25 duodenum, ileum, Peyer's patches, colon, kidney, reproductive organs, skin, mammary glands, bone, brain, heart, lung, thymus, trachea, esophagus, thyroid/parathyroid glands, jejunum, cecum, rectum, adrenal glands, white and brown fat, sciatic nerve,

30 bone marrow, urinary bladder, and skeletal muscle. Prior to fixation, the whole organ weights were determined for the liver, heart, stomach, kidney, adrenals, spleen, and thymus. After fixation, the tissues were processed into paraffin blocks, and 3 μ m

35 sections were obtained.

Immunohistochemistry for the B-lymphocyte marker, B220, and the T-lymphocyte marker, CD3, was performed. To detect B220 or CD3 expression, formalin fixed, paraffin embedded, 4 μ m sections were
5 deparaffinized and hydrated to deionized water. The sections were quenched with 3% hydrogen peroxide, blocked with Protein Block (Lipshaw, Pittsburgh, PA), and incubated in rat monoclonal antibody to B220 (Pharmingen, San Diego, CA) or rabbit polyclonal
10 antibody to CD3 (Dako, Carpinteria, CA). The antibodies were detected by biotinylated rabbit anti-rat or goat anti-rabbit immunoglobulins, peroxidase conjugated streptavidin, (BioGenex, San Ramon, CA) with DAB as chromagen (Biotek, Santa Barbara, CA). Sections
15 were counterstained with hemaoxylin.

In this study, normal clinical signs were reported during the in-life phase of the study. The whole body radiographs of the transgenic mice were comparable to those of the control mice. The overall
20 hematologic parameters of the transgenic mice were comparable to those of the negative control group, although sporadic changes in individual mice were present: transgenic #8 and #40 had increased serum globulin levels (hyperglobulinemia) and #32 and #33 had
25 globulin levels in the high normal range accompanied by albumin levels in the low normal range, which is a pattern commonly seen with chronic antigenic stimulation of the immune system. Organ weights of the other transgenic mice were not significantly different
30 from those of the control group.

The following histopathological changes were present in the transgenic mice: The mesenteric lymph nodes of the transgenic B7RP1-Fc mice were moderately to markedly enlarged when compared to the control mice
35 (Fig. 10A-10D; Fig. 11A-11E). The cortex had prominent

follicular hyperplasia seen as enlarged secondary follicles (Fig. 10B-11B) with large germinal centers containing mostly B220+ B cells (Fig. 11D) and a few scattered CD3+ T cells (Fig. 11F). The paracortical (CD3+ T-cell) area was also moderately enlarged (Fig. 11B-11F) and the medullary sinuses had slightly increased numbers of fleshy macrophages (sinus histiocytosis). The most conspicuous change in the nodes was present in the medullary cords, which were mildly to markedly expanded by large numbers of well-differentiated plasma cells in the B7RP1-Fc transgenic mice (Fig. 10D). In transgenic mouse #40, small numbers of scattered Russell bodies (i.e. plasma cells with prominent, large, round, intracytoplasmic vesicles containing immunoglobulins) were also found in the medullary cords (Fig. 10D). Interestingly, the other internal and peripheral lymph nodes (e.g. cervical, inguinal) had similar morphologic features of reactive lymphoid hyperplasia suggestive of a systemic response. These findings are consistent with a chronic, ongoing immune stimulation with enhancement of the humoral immune reaction, which leads to B cell proliferation and terminal differentiation into plasma cells.

The spleen of B7RP1-Fc transgenic mice had variably enlarged white pulp areas with moderate reactive lymphoid hyperplasia involving particularly the B-cell secondary follicles with prominent germinal centers and periarteriolar T-cell sheaths when compared to the control mice (Fig. 10E-10F). Another conspicuous finding in B7RP1-Fc transgenic mice was minimal to mild plasmacytosis in the marginal zone surrounding the white pulp areas and in the adjacent red pulp. Transgenic mouse #6 had a few scattered Russell bodies (Fig. 10F, inset). The red pulp had mild to moderate extramedullary hematopoiesis, which

was comparable to that seen in the control mice (Fig. 10E).

The small intestinal Peyer's patches were mildly to markedly enlarged in the B7RP1-Fc transgenic mice over those of the control mice (Fig. 10G) and had very large follicles with prominent germinal centers, particularly in transgenic mouse #40 and #32 (Fig. 10H). In addition, there was a minimal (in #32) to mild (in #8 and #33) increase in the numbers of lymphocytes and plasma cells (admixed with a mild eosinophil infiltrate in the ileum of mouse #32) in the thickened lamina propria layer of the mucosa, which was present in the small intestine, but more prominent in the colon of the transgenic mice. The large intestinal lymphoid aggregates (GALT) were also slightly more prominent in some B7RP1-Fc transgenic mice (particularly mouse #8 and #2) than in the control group.

Generally, the other tissues examined, including the thymus, bone marrow, liver, lung, heart, pancreas, kidneys, adrenal gland, thyroid, parathyroid, trachea, reproductive organs, urinary bladder, mammary gland, skin, skeletal muscle, peripheral nerve, brain, esophagus, stomach, small and large intestine, bone (femur/tibia), stifle joint, white and brown fat appeared normal and comparable to the background changes detected in the control mice.

The data from this study demonstrate that overexpression of the B7-related protein Fc chimera (B7RP1-Fc) in transgenic mice induces a phenotype characterized by prominent reactive lymphoid hyperplasia detected in the spleen, peripheral and internal lymph nodes, and gut-associated lymphoid tissue, as follicular hyperplasia, expansion of T-cell areas and conspicuous plasmacytosis accompanied by hyperglobulinemia in some animals. The plasmacytosis

is accompanied by higher levels of circulating IgG (mean \pm SD = 597 ± 298 mg/ml in transgenic mice vs. 209 ± 80 mg/ml in control littermates, $n = 7$, $P < 0.05$, t test), in particular IgG2a (217 ± 100 mg/ml vs. 75 ± 29 mg/ml, $n = 7$, $P < 0.01$, t test). The induction of IgG2a is normally associated with a Th1 cytokines such as IFN- γ . Thus, B7RP1 induces B- and T-cell proliferation and stimulates B-cells to differentiate into plasma cells and to produce immunoglobulin.

These changes are consistent with a persistent systemic immune response with hyperstimulation of the humoral arm of the immune system which results in B cell stimulation, proliferation, and differentiation to antibody-producing plasma cells throughout the lymphoid organs examined.

We conclude from the marked lymphoid hyperplasia demonstrated in the B7RP1-Fc transgenic mice that B7RP1 protein has significant *in vivo* biological activity, related to immune system stimulation.

Example 14

Cloning of human B7RP1

Normal human circulating peripheral lymphocytes were separated from red blood cells using Lymphocyte Separation Medium (ICN Pharmaceuticals). The T-cells were then activated with $10 \mu\text{g/ml}$ plate bound anti-CD3 antibody (Immunotech, Westbrook, ME), 10 ng/ml PMA, and 500 ng/ml ionomycin overnight (16 hours) at 37°C and $5\% \text{ CO}_2$. Total RNA was then prepared from the cells using TRIzol reagent (Gibco BRL). The cells were pelleted by centrifugation and the cell pellet was resuspended in 1 ml TRIzol reagent for each 5×10^6 cells and incubated at room temperature for 5 min. 0.2

5
10

15
20
25
30

35

Figure 1 consists of 12 bar charts, labeled (a) through (l), each representing a different variable. The y-axis for all charts is 'Percentage' ranging from 0 to 100. The x-axis for each chart has two categories: '1997' and '2000'. The data is as follows:

Variable	1997 (%)	2000 (%)
a) Age	18.0, 22.0, 25.0, 28.0, 32.0, 35.0, 38.0, 42.0, 45.0, 48.0, 52.0, 55.0, 58.0, 62.0, 65.0, 68.0, 72.0, 75.0, 78.0, 82.0, 85.0, 88.0, 92.0, 95.0, 98.0, 100.0	18.0, 22.0, 25.0, 28.0, 32.0, 35.0, 38.0, 42.0, 45.0, 48.0, 52.0, 55.0, 58.0, 62.0, 65.0, 68.0, 72.0, 75.0, 78.0, 82.0, 85.0, 88.0, 92.0, 95.0, 98.0, 100.0
b) Sex	50.0, 50.0	50.0, 50.0
c) Education	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
d) Income	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
e) Employment	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
f) Religion	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
g) Political affiliation	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
h) Party affiliation	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
i) Attitude towards the environment	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
j) Attitude towards the economy	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
k) Attitude towards the government	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0
l) Attitude towards the military	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0	10.0, 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0

5

15

35

[illegible]

position of the transmembrane domain, is consistent with other B7 family members. The human B7RP1 gene has 43% amino acid identity with the mouse clone. This degree of homology is significant since the mouse and human CD80 proteins are only 41% identical. Notably conserved between the mouse and human genes are the cysteine residues at amino acid positions 37, 113, 158, 215, and 216.

10

Example 15

Cloning of human CRP1

15

A Genbank blast homology search (GCG, University of Wisconsin) using murine B7RP1 sequence (see Figure 2) retrieved a genomic clone (Gen Bank Assession NO. AQ022676) containing a 104 bp sequence that showed high homology with the murine CRP1 gene. PCR cloning primers were designed to overlap this sequence.

20

5'-GCA TAT TTA TGA ATC CCA-3' (SEQ ID NO: 34)
5'-ACT ATT AGG GTC ATG CAC-3' (SEQ ID NO: 35)

25

Using the above primers, a 151 bp DNA fragment of the murine CRP1 was PCR amplified using the murine CRP1 plasmid described in Figure 1 and Example 1 as template. 125 ng of the DNA was labeled with 32P dCTP (Amersham) following the Redi-Prime 2 (Amersham) random prime labeling system protocol. The colony lift filters from human peripheral blood libraries described in Example 15 were then allowed to hybridize with the probe in the following hybridization buffer overnight (15 hr) at 41°C, 50% formamide, 5X SSPE, 2X Denhardt's solution, 0.5% SDS, 100 µg/ml ssDNA. The specific activity of the probe was 3.52×10^9 cpm/µg DNA, 1.5 ng labeled probe/ml hybridization buffer. The probe was

30

35

00821 043260

pulled off and saved for the next round of screening. The filters were then washed in 2X SSC, 0.1% SDS at RT for 10 min, followed by 1X SSC, 0.1% SDS at 37°C for 7 minutes, 40°C for 7 minutes, 44°C for 7 minutes, then
5 50°C for 7 minutes, continually monitoring the rate at which the filters were releasing the labeled probe. The filters were wrapped in plastic and exposed to film overnight at -80°C with 2 enhancing screens. This method revealed 9 possible independent positive clones.
10 Exposures were aligned to the bacterial plates and the positive clones scraped, deposited into 200 µl SOC, 2 serial dilutions of 1:10 were performed and 70 µl from the second dilution was replated on LB plates containing ampicillin at 100 µg/ml and grown overnight
15 as before. The colonies were lifted, prepared and probed as before. Eight independent clones were isolated and DNA prepared by the Qiagen miniprep method.

A cDNA clone containing an open reading frame
20 of 199 amino acids was obtained (Figure 13A). This cDNA clone contained nucleotide and amino acid homologies to the murine CRP1 clone described in Example 1 and Figure 1. The nucleotides corresponding to the open reading frame of this human clone was 77%
25 identical to the murine CRP1 gene. Translation of the human sequence and subsequent comparison with the murine CRP1 protein revealed 69% amino acid identity with the murine protein (Figure 13B). In addition, the motif between amino acids 114 to 119, "FDPPPF", was
30 conserved between the murine and human CRP1 genes. This motif corresponds to the "MYPPPY" motif in murine and human CD28 that is essential for B7 protein interaction. Furthermore, the cysteines at amino acid positions 42, 109, and 141 are also conserved. These
35 cysteines correspond to cysteines in CD28 and CTLA-4 at

are involved in Ig loop formation and intermolecular disulfide dimerization. The close similarity with murine CRP1, and structural similarities with the CD28 homology family, indicate that this is the human CRP1 homolog.

Example 16

CRP1 is expressed on resting memory T-lymphocytes

10

In order to study CRP1 expression on memory T-cells, splenic T-cells were collected from 6-7 month old mice. These cells were double-stained using B7RP1-Fc labeled by an FITC-conjugated anti-human Fc antibody and a PE-conjugated antibody to either CD44, CD45RB, or CD69. Staining with the B7RP1-Fc fusion protein detects expression of CRP1 protein on these T-cells. Older mice show more CRP1+ splenic T-cells than younger mice. Interestingly, a conspicuous number of these cells are CD44 high (Fig 14a) and CD45RB low (Fig 14b), a profile typical of memory T-cells. These CRP1+ memory T-cells are in a resting state, since they do not express the activation marker CD69 (Fig. 14c). The expression of CRP1 on memory T-cells indicates that CRP1 has costimulatory functions on memory T-cells.

15

20

25

Example 17

In vitro T-cell costimulation
inhibited by antibodies to B7RP1.

30

To determine if the B7RP1 protein has functional relevance to T-cells, we incubated CD3+ T-cells with the B7RP1-Fc fusion protein and an anti-CD3 antibody in an *in vitro* proliferation assay. Rabbit anti-mouse B7RP1 polyclonal antibodies or rat anti-mouse B7RP1 monoclonal antibodies were then used to

35

Table 1. Demographic characteristics of the study population	
Age (years)	65.5 ± 1.2
Gender (male/female)	10/10
Education (years)	12.5 ± 0.5
Occupation (white/blue)	10/0
Marital status (married/divorced/widowed)	10/0/0
Smoking status (smoker/nonsmoker)	10/0
Alcohol consumption (yes/no)	10/0
Comorbidities (hypertension/diabetes/cholesterol)	10/0/0
Medication (antihypertensive/antidiabetic/anticholesterol)	10/0/0
Family history (hypertension/diabetes/cholesterol)	10/0/0
Physical activity (yes/no)	10/0
Stress level (high/low)	10/0
Sleep quality (good/poor)	10/0
Depression (yes/no)	10/0
Anxiety (yes/no)	10/0
Quality of life (high/low)	10/0
Health status (good/poor)	10/0
Life expectancy (years)	12.5 ± 0.5
Healthcare utilization (yes/no)	10/0
Health insurance (yes/no)	10/0
Healthcare costs (high/low)	10/0
Healthcare satisfaction (yes/no)	10/0
Healthcare access (yes/no)	10/0
Healthcare quality (high/low)	10/0
Healthcare safety (yes/no)	10/0
Healthcare effectiveness (yes/no)	10/0
Healthcare efficiency (yes/no)	10/0
Healthcare equity (yes/no)	10/0
Healthcare transparency (yes/no)	10/0
Healthcare accountability (yes/no)	10/0
Healthcare responsibility (yes/no)	10/0
Healthcare integrity (yes/no)	10/0
Healthcare honesty (yes/no)	10/0
Healthcare justice (yes/no)	10/0
Healthcare fairness (yes/no)	10/0
Healthcare equality (yes/no)	10/0
Healthcare freedom (yes/no)	10/0
Healthcare security (yes/no)	10/0
Healthcare stability (yes/no)	10/0
Healthcare sustainability (yes/no)	10/0
Healthcare resilience (yes/no)	10/0
Healthcare adaptability (yes/no)	10/0
Healthcare innovation (yes/no)	10/0
Healthcare leadership (yes/no)	10/0
Healthcare vision (yes/no)	10/0
Healthcare mission (yes/no)	10/0
Healthcare values (yes/no)	10/0
Healthcare principles (yes/no)	10/0
Healthcare standards (yes/no)	10/0
Healthcare best practices (yes/no)	10/0
Healthcare evidence-based (yes/no)	10/0
Healthcare patient-centered (yes/no)	10/0
Healthcare family-centered (yes/no)	10/0
Healthcare community-centered (yes/no)	10/0
Healthcare society-centered (yes/no)	10/0
Healthcare global-centered (yes/no)	10/0
Healthcare universal-centered (yes/no)	10/0
Healthcare inclusive-centered (yes/no)	10/0
Healthcare equitable-centered (yes/no)	10/0
Healthcare just-centered (yes/no)	10/0
Healthcare fair-centered (yes/no)	10/0
Healthcare equal-centered (yes/no)	10/0
Healthcare free-centered (yes/no)	10/0
Healthcare secure-centered (yes/no)	10/0
Healthcare stable-centered (yes/no)	10/0
Healthcare sustainable-centered (yes/no)	10/0
Healthcare resilient-centered (yes/no)	10/0
Healthcare adaptable-centered (yes/no)	10/0
Healthcare innovative-centered (yes/no)	10/0
Healthcare leadership-centered (yes/no)	10/0
Healthcare vision-centered (yes/no)	10/0
Healthcare mission-centered (yes/no)	10/0
Healthcare values-centered (yes/no)	10/0
Healthcare principles-centered (yes/no)	10/0
Healthcare standards-centered (yes/no)	10/0
Healthcare best practices-centered (yes/no)	10/0
Healthcare evidence-based-centered (yes/no)	10/0
Healthcare patient-centered-centered (yes/no)	10/0
Healthcare family-centered-centered (yes/no)	10/0
Healthcare community-centered-centered (yes/no)	10/0
Healthcare society-centered-centered (yes/no)	10/0
Healthcare global-centered-centered (yes/no)	10/0
Healthcare universal-centered-centered (yes/no)	10/0
Healthcare inclusive-centered-centered (yes/no)	10/0
Healthcare equitable-centered-centered (yes/no)	10/0
Healthcare just-centered-centered (yes/no)	10/0
Healthcare fair-centered-centered (yes/no)	10/0
Healthcare equal-centered-centered (yes/no)	10/0
Healthcare free-centered-centered (yes/no)	10/0
Healthcare secure-centered-centered (yes/no)	10/0
Healthcare stable-centered-centered (yes/no)	10/0
Healthcare sustainable-centered-centered (yes/no)	10/0
Healthcare resilient-centered-centered (yes/no)	10/0
Healthcare adaptable-centered-centered (yes/no)	10/0
Healthcare innovative-centered-centered (yes/no)	10/0
Healthcare leadership-centered-centered (yes/no)	10/0
Healthcare vision-centered-centered (yes/no)	10/0
Healthcare mission-centered-centered (yes/no)	10/0
Healthcare values-centered-centered (yes/no)	10/0
Healthcare principles-centered-centered (yes/no)	10/0
Healthcare standards-centered-centered (yes/no)	10/0
Healthcare best practices-centered-centered (yes/no)	10/0
Healthcare evidence-based-centered-centered (yes/no)	10/0
Healthcare patient-centered-centered-centered (yes/no)	10/0
Healthcare family-centered-centered-centered (yes/no)	10/0
Healthcare community-centered-centered-centered (yes/no)	10/0
Healthcare society-centered-centered-centered (yes/no)	10/0
Healthcare global-centered-centered-centered (yes/no)	10/0
Healthcare universal-centered-centered-centered (yes/no)	10/0
Healthcare inclusive-centered-centered-centered (yes/no)	10/0
Healthcare equitable-centered-centered-centered (yes/no)	10/0
Healthcare just-centered-centered-centered (yes/no)	10/0
Healthcare fair-centered-centered-centered (yes/no)	10/0
Healthcare equal-centered-centered-centered (yes/no)	10/0
Healthcare free-centered-centered-centered (yes/no)	10/0
Healthcare secure-centered-centered-centered (yes/no)	10/0
Healthcare stable-centered-centered-centered (yes/no)	10/0
Healthcare sustainable-centered-centered-centered (yes/no)	10/0
Healthcare resilient-centered-centered-centered (yes/no)	10/0
Healthcare adaptable-centered-centered-centered (yes/no)	10/0
Healthcare innovative-centered-centered-centered (yes/no)	10/0
Healthcare leadership-centered-centered-centered (yes/no)	10/0
Healthcare vision-centered-centered-centered (yes/no)	10/0
Healthcare mission-centered-centered-centered (yes/no)	10/0
Healthcare values-centered-centered-centered (yes/no)	10/0
Healthcare principles-centered-centered-centered (yes/no)	10/0
Healthcare standards-centered-centered-centered (yes/no)	10/0
Healthcare best practices-centered-centered-centered (yes/no)	10/0
Healthcare evidence-based-centered-centered-centered (yes/no)	10/0
Healthcare patient-centered-centered-centered-centered (yes/no)	10/0
Healthcare family-centered-centered-centered-centered (yes/no)	10/0
Healthcare community-centered-centered-centered-centered (yes/no)	10/0

5 Three New Zealand white rabbits (5-8 lbs.
initial weight) were injected IM with murine B7RP1
protein. Each rabbit was immunized on day 1 with 150 µg
of murine B7RP1 protein emulsified in an equal volume
of Hunters Titer Max complete adjuvant. Further boosts
10 (days 14 and 28) were performed by the same procedure.
Antibody titers were monitored by EIA. After the
second boost, the antisera revealed moderate antibody
titers. A 30ml production bleed was then obtained from
each animal. This was repeated each week for 6 weeks.
15 Polyclonal antibodies were then purified by protein-A
agarose chromatography, followed by negative selection
Fc protein affinity chromatography and positive
selection by B7RP1-Fc affinity chromatography.

Rat anti-murine B7RP1 monoclonal antibodies were generated as described in Practical Immunology, second edition (1980; L. Hudson and F.C. Hay; Blackwell Scientific Publications; St. Louis, MO). Briefly, Lou
25 rats (Harlan; Indianapolis, IN) were injected intraperitoneally with muB7RP1-Fc fusion protein emulsified in Freund's Adjuvant at 4 week intervals. Three days prior to fusion, rats were boosted intravenously with soluble muB7RP1. On the day of
30 fusion, the animal was sacrificed under carbon dioxide and the spleen removed aseptically. Single cell suspension was generated using a tissue stomacher. Both splenocytes and Y3-Ag1.2.3 myeloma cells (American Type Culture Collection; Rockville, MD) were washed in
35 serum-free media then fused by the addition of

polyethylene glycol (PEG 1500; Boehringer Mannheim Biochemicals; Indianapolis, IN). The cells were rinsed once, resuspended in serum-containing media, and plated into 96-well tissue culture plates. Ten to 12 days later, media from each well was tested for specific antibody to B7RP1 via a direct Enzyme-linked Immunosorbent Assay (EIA). Cells from wells indicating potential binding were grown to 10 ml cultures and frozen in liquid nitrogen. Media from each culture was further tested in flow cytometry and in a functional T-cell proliferation assay. Those determined to be of interest by these methods were plated to single cell colonies, selected again by EIA, and final cell lines maintained for antibody generation. Antibodies were purified from the cell media by protein A agarose chromatography.

T-cell preparation and T-cell proliferation assay

T-cells from the spleens of C57Bl/6 mice (8-12 week-old females, Charles River Laboratories) were purified by negative selection through a murine T-cell enrichment column (R&D Systems). The T-cells were then either used directly or further purified by antibody and complement lysis as follows. Cells were resuspended (2.5×10^6 cells/ml) in RPMI medium containing antibodies (all at 10 μ g/ml and from Pharmingen) against murine CD11b (Clone M1/70), NK-1.1 (Clone PK136), CD8a (Clone 53-6.7), I-A^b (Clone M5/114.15.2), CD11c (Clone HL3), and the B220 antigen (Clone RA3-6B2). The cells were then incubated on ice for 30 min, pelleted at 1200 rpm, resuspended in 4:1 vol/vol of RPMI: rabbit complement (Sigma, #S-7764), and incubated for an additional 30 min at 37°C. The cells were pelleted again, and the complement treatment was repeated. Before plating, the cells were washed with RPMI containing 10% FCS. U-bottomed 96 well

plates were coated with an anti-CD3 antibody (Clone 145-2C11, Pharmingen) at concentrations ranging between 0 and 1.2 µg/ml), and anti-human IgG Fab₂ (Sigma, 12.5 µg/ml) overnight at 4°C, followed by a 6-9 hr incubation at 37°C. T-cells (1x 10⁵/well) were cultured in the absence or presence of various Fc fusion proteins for 48 hr and were pulsed during the last 18 hours with 1 µCi of ³H-thymidine. Control Fc proteins included a fusion protein of OPG and Fc and a nonfused Fc protein fragment. The cells were then harvested and the incorporated radioactivity was counted. B7RP1-Fc co-stimulates T-cells to proliferate in a dose-dependent fashion (Fig. 15a), and an anti-B7RP1-Fc antibody specifically inhibits this co-stimulation dose-dependently (Fig. 15b).

Example 18

Inhibitors of the CRP1/B7RP1 pathway decrease the onset of rheumatoid arthritis induced by collagen.

Collagen-induced arthritis (CIA) is an animal model of autoimmune polyarthritis in rodents and primates that has many similarities with rheumatoid arthritis in humans. Immunization with heterologous species of type II collagen (CII) induces an autoimmune response to CII that leads to the development of CIA in susceptible mouse strains. Congenic strains of mice with H-2^r and H-2^q are highly susceptible to CIA. CIA is mediated by the synergistic effects of both CII-reactive T-cells and antibodies. Porcine CII (Nabozny et al., Autoimmunity 20, 51-58 (1995)) was dissolved in 0.01N acetic acid at a concentration of 2mg/ml and then was emulsified at a 1:1 ratio with CFA (Difco). Arthritis susceptible B10.RIII (H-2^r) mice (Jackson

Laboratories, Bar Harbor, ME) were immunized with 100 μ l of emulsion intradermally at the base of the tail. Mice were monitored 2-3 times per week for the development of arthritis. Arthritis severity was determined using a grading system for each paw as follows: 0: no arthritis; 1: redness or swelling in 1-3 toes; 2: severe swelling of paw; 3: joint ankylosis. The score of each limb was summed to give a severity range from 0 to 12 for each animal.

Mice were injected with 100ug (in 200 μ L) of protein intraperitoneally twice per week. The treatment was begun 1 day after immunization with porcine CII and was stopped at day 52 post-immunization. The experiment was conducted in treatment groups of 10 mice, and animals with scores of 1 or above were scored as positive. The results are shown in Figure 16 and Table 1.

TABLE 1

Effect of CRP1, B7RP1, CTLA-4, and B7.2 Fc fusion proteins on the onset of arthritis

	<u>Treatment groups</u>	<u>Mean+/-s.d. day of onset</u>
25	CTLA4-Fc	60.0 \pm 0.0
	CRP1-Fc	48.9 \pm 13.2
30	B7.2-Fc	28.4 \pm 14.1
	B7RP1-Fc	33.9 \pm 16.6
	PBS	37.7 \pm 17.1

In mice treated with CRP1-Fc fusion protein, the onset of arthritic symptoms were delayed by approximately 10 days as compared to the PBS treated mice. This demonstrates that the inhibition of the

CRP1/B7RP1 pathway can alleviate disease symptoms in this mouse model of rheumatoid arthritis.

Mice treated with B7RP1-Fc or B7.2-Fc showed an earlier onset of disease (Table 1 and Figure 16a) with an increase in arthritic severity (Figure 16b) as compared to the PBS-treated controls. This indicates that the B7RP1-Fc fusion protein enhances the T-cell immune response. Such activity may be useful in generating anti-tumor immunity *in vivo*.

The opposite effects by CRP1-Fc and B7RP1-Fc in this mouse model of rheumatoid arthritis indicate that the pathway can be manipulated to either enhance or inhibit the disease progression. Targeting the CRP1 protein with soluble B7RP1-Fc enhances the disease, while the interaction of soluble CRP1-Fc with B7RP1 inhibits the disease symptoms.

Example 19

B7RP1-Fc induces an inflammatory bowel disease phenotype in transgenic mice.

Persistent overexpression of the B7-related protein (B7RP1-Fc) in 22-to-25-week-old transgenic mice (Example 12) induces a striking phenotype of inflammatory bowel disease (IBD) with marked thickening and chronic inflammation of the small and large bowels (enterocolitis) and weight loss in some animals. Histologically, the most severe inflammatory changes were found in the proximal and distal colon, with milder changes in the small intestine. The proximal colon was markedly thickened with fissuring ulceration, transmural inflammation, and hypertrophy of the colonic mucosa, while the distal colon had diffuse mucosal hypertrophy (or focal erosion and glandular atrophy)

without ulceration. The proximal small intestine had mild to marked mucosal hypertrophy with milder inflammatory changes, while the distal small intestine (ileum) had mild mucosal hypertrophy in some animals and atrophy in other mice. The intestinal changes were most severe and consistently found in the female B7RP1 transgenic mice, but were also observed in several of the male transgenic mice in this study.

It is interesting to note that the histologic features found in the proximal colon, including the fissuring ulceration and the transmural chronic granulomatous inflammation with multinucleated giant cells, more closely resemble those seen in Crohn's disease than ulcerative colitis in humans. Morphologically, this colitis also mimics the IBD described in mice deficient in interleukin-10, which develop wasting, anemia, and enterocolitis affecting their entire intestinal tract (Kuhn et al. 1993; Sartor 1995; Leach et al. 1999). As in the IL-10 knockout mice, the initial changes in the B7RP1-Fc transgenic mice consist of mild, focal infiltrates of inflammatory cells in the lamina propria without colonic epithelial hyperplasia (Example 13). In older mice, the affected colonic segments become thickened due to glandular hypertrophy/hyperplasia and chronic inflammation. The proximal and distal colons of the B7RP1-Fc mice had moderate to severe colitis with histologic features of inflammatory bowel disease (IBD). The affected segments of the proximal colon (Figure 17B-17D) were diffusely thickened, due to prominent glandular epithelial hypertrophy and hyperplasia with elongation and dilatation of the mucosal glands (Fig. 17B), which had increased numbers of mitotic figures and rare crypt abscesses, but retained goblet cells with mucin (Fig. 17D). The mucosa had diffuse chronic inflammation in the lamina propria, which in some animals extended

transmurally to involve the underlying layers of the gut wall, including the submucosa, muscularis, serosa, and the adjacent mesenteric fat tissue (Fig. 17B-17C). The inflammatory infiltrates consisted of lymphocytes (predominantly CD3+, CD44+ T-cells), plasma cells, and epithelioid macrophages (Fig. 17F) mixed with some neutrophils and occasional multinucleated giant cells (Fig. 17E), characteristic of chronic granulomatous inflammation. Lymphoid aggregates (mostly B220+ cells mixed with small numbers of CD3+ cells) were also present in the mucosa and around smaller blood vessels in the submucosa and deeper layers, including mesenteric fat (Fig. 17C). The lumen contained mucopurulent or mucous exudate (Fig. 17D). Severe evidence of colitis, with multifocal fissuring ulceration of the mucosa and transmural inflammation (Fig. 17B-17C), was found in these B7RP1-Fc transgenic mice.

The distal colon of the B7RP1-Fc transgenic mice was also diffusely thickened and hyperplastic with elongation, basophilia, and dilatation of the colonic glands (Fig. 18B-18G), some of which contained crypt abscesses (Fig. 18D and 18F) and mucus. The lamina propria had a mild diffuse inflammatory infiltrate of lymphocytes (predominantly CD3+, CD44+ cells, particularly in the superficial mucosa; Fig. 18E), as well as plasma cells and focal aggregates of epithelioid macrophages mixed with some neutrophils. Lymphoid aggregates (of predominantly B220+ cells; Fig. 18D and 18F) were also scattered throughout the mucosa. The small intestine of B7RP1-Fc transgenic mice had more variable changes, including mild to focally marked mucosal and crypt hypertrophy and hyperplasia (Fig. 19B and 19D with crypt/villus ratios ranging from 1:4 to 1.5:1, as compared to 1:10 in the control mice) accompanied by a predominantly lymphoplasmacytic

The B7RP1-Fc fusion protein acts to activate cells that are responsible for eliciting a phenotype very similar to that of human Crohn's disease. This indicates that the cells that may be responsible for the inflammation in Crohn's disease are activated by the B7RP1-Fc fusion protein. Soluble protein, antibody or small molecule inhibitors of B7RP1 may therefore be useful in inhibiting IBD.

25 The B7RP1-Fc fusion protein
 inhibits tumor growth in mice

Exponentially growing Meth A sarcoma cells were implanted by intradermal injection of 0.5 million cells in the abdomen of Balb/c mice on day 0. On day 7, when the tumors reached ~ 100 mm³, the mice were treated with either vehicle

(PBS) or B7RP1-Fc (8mg/kg), subcutaneously in the neck on days 7, 10, 14, and 17. The bidimensional diameters of the tumors were measured by calipers and the tumor volume (in mm³) was estimated using the formula: Tumor volume = [(width)² x length] / 2. The tumor growth was monitored up to day 28. Each group had eight mice.

The Meth A sarcoma growth pattern of the control tumor was bi-phasic: a slow initial phase was followed by a relatively rapid exponential phase. In B7RP1-Fc treated mice, the growth of the tumor was significantly slower in the rapid exponential phase. On day 28, the average volumes of the control and B7RP1-Fc treated mice were 1410 mm³ and 580 mm³, respectively (Figure 20). Therefore, B7RP1-Fc treatment inhibited tumor growth significantly in this model. The data strongly suggest the beneficial therapeutic utility of the soluble B7RP1-Fc protein, and other activators of the B7RP1/CRP1 pathway, in the treatment of immunogenic tumors.

Immunologic anti-tumor activity is closely associated with cytolytic T-lymphocyte (CTL) function. Consistently, the B7RP1-Fc protein is expressed on cytolytic CD8+ T-cells (Example 9, Figure 6). These data strongly support B7RP1 functions on cytolytic CD8+ T-cells. B7RP1-Fc, or other stimulators of the B7RP1/CRP1 pathway, may therefore be used to enhance cytolytic T-cell and cellular immune functions for a number of non-cancer-related indications.

Example 21

Inhibition of human B7RP1 activity in vitro

SECRET 0243260

To determine if human B7RP1 has positive co-stimulatory properties, we tested cells expressing human B7RP1 and human B7RP1-Fc fusion protein in T-cell proliferation assays. The human B7RP1-Fc fusion protein was constructed by fusing gene sequences corresponding to amino acids 1 to 247 to a partial human IgG1 gene sequence (Example 14). The human CRP1-Fc fusion protein was constructed by fusing gene sequences corresponding to amino acids 1 to 146 to a partial human IgG1 gene sequence (Example 2). The methods of construction, expression and purification of both fusion proteins were conducted as described in Example 7. B7RP1-Fc demonstrated co-stimulatory activities that are dependent on anti-CD3 stimulation (Figure 21a). In addition, this activity can be specifically inhibited with soluble CRP1-Fc protein (Figure 21b). Similar co-stimulatory effects were obtained using CHO cells that express membrane-bound, human B7RP1, containing the entire coding sequence (Figure 21c).

The production of cytokines by human T-cells under the above *in vitro* proliferation conditions was determined. Supernatants from T-cell cultures stimulated for 48 and 72 hours were analyzed for IL-2, IL-10, and IFN-gamma by ELISA according to the manufacturer's specifications (BioSource International). The IFN-gamma and IL-10 levels were significantly increased; however, unlike the case with CD28 co-stimulation, IL-2 was not notably induced (Figure 21d). The increased levels of IFN-gamma, a Th1 cytokine, correlate with the B7RP1 functions to increase IgG2a, as described in Example 13.

In vitro T-cell co-stimulation assays were conducted as follows. Highly purified human T-cells (>98% CD3+) were isolated by negative

selection of fresh or thawed, adherence depleted PBMC using mAb labeled magnetic beads (Miltenyi Biotec). T-cells (1×10^5 cells/well) were cultured in triplicate wells in 96 well plates in 200 μ l/well RPMI + 10% FCS. To evaluate B7RP1-Fc co-stimulation, various concentrations of anti-CD3 (Pharmingen) and 10 μ g/ml anti-human IgG Fc (Sigma) in 100 μ l 1X PBS were pre-coated onto U bottom plates by an incubation at 4°C overnight. The unbound anti-CD3 and anti-human IgG Fc were removed, and the cells were cultured in the presence or absence of various concentrations of B7RP1-Fc, OPG-Fc control or anti-CD28 (Pharmingen). For CRP1-Fc inhibition of B7RP1-Fc co-stimulation, T-cells were cultured in 0.33 μ g/ml anti-CD3 and 10 μ g/ml anti-human IgG Fc pre-coated wells with 0.5 μ g/ml B7RP1-Fc in the presence of serially diluted CRP1-Fc or OPG-Fc, starting at 10 μ g/ml. To evaluate co-stimulation by CHO cells expressing B7RP1, T-cells were cultured in flat bottom plates with various concentrations of soluble anti-CD3 in the presence or absence of various amounts of mitomycin-C treated CHO B7RP1 cells or CHO vector cells. To test for T-cell proliferation, cultures were pulsed with 1 uCi/well [3 H]TdR during the last 18 hrs of a 72 hr culture. T-cell proliferation was determined by [3 H]TdR incorporation. The results of one representative experiment from three random donors are expressed as mean CPM incorporated \pm SD. For analyses of cytokine production, cells were cultured for 48 and 72 hours and supernatants were collected for ELISA.

These experiments show that the extracellular portion of human B7RP1, as described

in Example 14, when fused to a human Fc fragment, can co-stimulate T-cells in vitro. This co-stimulation is inhibited by CRP1-Fc and thus demonstrates how a soluble inhibitor of human B7RP1 may function. In vitro assays, such as that described here using human B7RP1 and CRP1, could be used to screen for antibody, soluble protein, peptibody, or small molecule inhibitors of B7RP1/CRP1 activity.

Example 22

B7RP1 transgenic mice have increased IgE levels

Transgenic mice described in Example 12 were analyzed for serum IgE antibodies. Orbital sera from B7RP1-Fc transgenic mice and littermate controls were analyzed for IgE by an ELISA protocol. 96-well polystyrene EIA plates (Coster, Cambridge, MA) were coated with 50 μ l of a 5 μ g/ml solution of rat anti-mouse IgE antibody (BD Pharmingen, San Diego, CA) in 50 mM Na₂CO₃/NaHCO₃ buffer (pH 9.6 at room temperature for 2 hr then at 4°C overnight. The subsequent procedures were conducted at room temperature. After blocking with assay diluent (1% BSA, 1% normal goat serum, and 0.2% tween-20 in PBS) for 30 min, serum samples and mouse IgE standards (BD Pharmingen) were added into the wells, and the plates were incubated for 2 hr. The wells were washed 3 times with KPL wash buffer (KPL, Gaithersburg, MD). Biotin-conjugated goat anti-rat antibody (BD Pharmingen) was added and incubated for 1 hr. After washing 3 times with KPL wash buffer, horseradish peroxidase-conjugated streptavidin (BD Pharmingen) was added to the wells, and the plates were incubated for 30 min. After the wells were washed 5 times with KPL wash buffer, TMB-hydrogen peroxide substrate solution (KPL) was added, and the plates were

incubated for 10 min. The reaction was stopped by the addition of 1M phosphoric acid, and the absorbance was read at a wavelength of 450 nm. The IgE levels in the sera from the B7RP1-Fc transgenic mice were approximately three times higher than those in the littermate controls (Figure 22). This increase in the IgE serum levels indicates that B7RP1 regulates IgE expression.

10

Example 23

IgE-mediated response of CRP1 knockout mice

The CRP1 gene in mice was disrupted by deleting a genomic fragment corresponding to nucleotides 318-591 of the murine CRP1 cDNA sequence(see SEQ ID NO:___). The murine CRP1 gene was isolated from a 129J library using the full-length (800 bp) cDNA probe (Yoshinaga et al. Nature 402, 827-832 (1999). The targeting vector, which replaced a 2.8kb genomic fragment with a neomycin resistance (neo) cassette in sense orientation relative to CRP1 transcription, was electroporated into E14 embryonic stem (ES) cells (129/Ola, available from the American Type Culture Collection, Manassas, Va under accession no. CRL-1821). After G418 selection, homologous recombinants were identified by PCR using the primer pair GAG ACT CAT GCT GTG GTT TCA GG (SEQ ID NO:___) and TTC GCC AAT GAC AAG ACG CTG G (SEQ ID NO:___) and verified by Southern blotting. Chimeric mice generated from CRP1^{+/-} ES clones were crossed with C57BL6 females to produce CRP1^{+/-} mice. Germline transmission of the CRP1 mutation was assessed by PCR and Southern blot analysis of tail DNA. CRP1^{-/-} mice generated by the intercrossing of heterozygous offspring were born at the expected Mendelian frequency and were viable, fertile and of normal size. To verify that the CRP1

mutation had abolished CRP1 expression, activated T-cells from CRP1^{-/-} mice and control littermates were analyzed by flow cytometry. Upon in vitro T-cell activation, CRP1 was expressed on the surface of both
5 CD4⁺ and CD8⁺ wild type T-cells, but was undetectable on CRP1^{-/-} T-cells.

To investigate the role of CRP1 in T-cell mediated B cell antibody production and isotype class switching, CRP1^{-/-} mice and littermate controls were
10 immunized with 200 µg of nitrophenol conjugated ovalbumin (NP-OVA; Biosearch Technologies, Inc.) adsorbed to alum intraperitoneally. Blood was collected from mouse tails every week following immunization and the levels of nitrophenol (NP)-
15 specific IgM and IgG₁ as well as the levels of OVA-specific IgE were assessed in the serum.

Titers of NP-specific IgG₁ and IgM antibodies were assessed using sandwich ELISA (Southern Biotechnology Associates) in which ELISA plates were
20 coated with NP(23)-bovine serum albumin at 50 µg/ml in PBS or carbonate buffer pH 9.2 (Sigma). The arbitrary values obtained by using the SOFTmaxPRO (Molecular Devices) ELISA analysis program were based on the titration curve of the isotype standard used on each
25 plate. Levels of ovalbumin-specific IgE were detected using an antigen-capture (biotinylated ovalbumin) ELISA method as previously described (Stampfli et al. Am J. Respir. Cell Mol. Biol. 21, 317-326 (1999)). The ELISA was standardized using serum obtained from mice
30 sensitized to ovalbumin according to a conventional intraperitoneal sensitization model (Ohkawara et al. Am. J. Respir. Cell Mol. Biol. 16, 510 (1997)).

The levels of NP-specific IgM were normal (day 7); however, a significant reduction in the levels
35 of NP-specific IgG₁ at day 14 and 21 post-immunization,

indicating that T-cell-dependent antibody production was severely impaired in CRP1^{-/-} mice. Furthermore, we observed that OVA-specific IgE were completely undetectable in the serum of ICOS^{-/-} mice at day 21 and 28 post-immunization, whereas isotype switching occurred in both heterozygous and wild type control mice, as demonstrated by the presence of IgE in the serum of these animals. (see Table 3). These findings indicate that ICOS plays a role of primary importance in controlling T-B cell collaboration and switching of IgG₁ and IgE isotype classes.

Table 3
IgE isotype switching in CRP1^{-/-} mice

Days post-immunization	CRP1 ^{+/+}	CRP1 ^{+/-}	CRP1 ^{-/-}
Day 21	4/8	5/9	0/7
Day 28	4/6	8/9	0/8

Example 24
Effects of B7RP1 and B7.2
in a Contact Hypersensitivity Model

In order to induce contact hypersensitivity, female Balb/c mice (9 to 14 weeks old; Charles River Laboratories, Wilmington, MA) were first sensitized by applying a 1% solution of oxazolone (Sigma, St. Louis, MO) in acetone and olive oil onto the shaved skin of the abdomen. Seven days after sensitization, mice were challenged (day 0) by applying the oxazolone solution onto the right ear. The acetone and olive oil solvent was applied at the same time onto the left ear as a control. The thickness of the ears was measured daily

with a micrometer (Mitutoyo, Kawasaki, Japan) starting immediately before challenge. The difference in ear thickness (ΔET) between right and left ear was used to express the results (McHale et al. J. Immunol 162, 1648 (1999)).

It has been previously observed that administration of B7RP1-Fc fusion protein in this model exacerbates contact hypersensitivity both at the time of sensitization (induction of the primary immune response) or at the time of challenge (induction of the secondary immune response), although the effects are more pronounced when administration occurs at the time of challenge (Yoshinaga et al. Nature 402, 827-832 (1999)).

In order to study the combined effects of B7RP1-Fc and B7.2-Fc on contact hypersensitivity, B7RP1-Fc and B7.2-Fc were given at two different doses either alone or in combination around the time of challenge. At high dose (2 mg/Kg of B7RP1-Fc alone, 2 mg/Kg of B7.2-Fc alone, and 1 mg/Kg of each in combination), B7RP1-Fc, B7.2-Fc, and B7RP1-Fc+B7.2-Fc increased ΔET compared to Fc (2mg/Kg) from day 3 (Fig. 23A). At this dose B7RP1-Fc and B7RP1-Fc+B7.2-Fc increased ΔET more than B7.2-Fc from day 4 (Fig. 23A). B7RP1-Fc+B7.2-Fc also increased ΔET more than B7RP1-Fc from day 4 (Fig. 23A). At low dose (0.4 mg/Kg of B7RP1-Fc alone, 0.4 mg/Kg of B7.2-Fc alone, and 0.2 mg/Kg of each in combination), B7RP1-Fc and B7RP1-Fc+B7.2-Fc increased ΔET compared to Fc (0.4 mg/Kg) from day 4, while B7.2-Fc did not significantly change ΔET (Fig. 23B). Also at this dose B7RP1-Fc and B7RP1-Fc+B7.2-Fc increased ΔET more than B7.2-Fc, and B7RP1-Fc+B7.2-Fc more than B7RP1-Fc (Fig. 23B). Thus, half of full doses of B7RP1-Fc combined with half of full

doses of B7.2-Fc increased Δ ET on days 4 to 7 more than full doses of B7RP1-Fc alone or of B7.2 alone, indicating that B7RP1-Fc and B7.2-Fc synergistically interacted.

5

* * *

While the present invention has been
10 described in terms of the preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent
15 variations that come within the scope of the invention as claimed.

003217 "02432460

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- a) the nucleotide sequence as set forth in Figure 1A (SEQ ID NO: 1);
 - b) the nucleotide sequence encoding the polypeptide from residues 1-200 or from residues 21-200 as set forth in Figure 1A (SEQ ID NO: 1);
 - c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in Figure 1A (SEQ ID NO: 1);
 - d) a naturally occurring allelic variant or alternate splice variant of any of (a), (b) or (c);
 - e) a nucleotide sequence complementary to any of (a), (b) or (c);
 - f) a nucleotide sequence of (b), (c) or (d) encoding a polypeptide fragment of at least about 25, 50, 75, 100, or greater than 100 amino acid residues;
 - g) a nucleotide sequence of (a), (b) or (c) comprising a fragment of at least about 10, 15, 20, 25, 50, 75, 100, or greater than 100 nucleotides; and
 - h) a nucleotide sequence which hybridizes under stringent conditions to any of (a)-(g).

2. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- a) the nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 11) or Figure 3A (SEQ ID NO: 6) or Figure 12A (SEQ ID NO: 16);
- b) the nucleotide sequence encoding the polypeptide as set forth in Figure 2A (SEQ ID NO: 6) from residues 1-322 or from residues 47-322, or as set

forth in Figure 3A (SEQ ID NO: 11) from residues 1-288 or from residues 19-288, 20-288, 21-288, 22-288, 24-288, or 28-288 or as set forth in Figure 12A from residues 1-302, or from residues 19-302, 20-302, 21-302, 22-302, 24-302 or 28-302;

c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11) or Figure 12A (SEQ ID NO: 6);

d) a naturally occurring allelic variant or alternate splice variant of any of (a), (b) or (c);

e) a nucleotide sequence complementary to any of (a), (b) or (c);

f) a nucleotide sequence of (b), (c) or (d) encoding a polypeptide fragment of at least about 25, 50, 75, 100, or greater than 100 amino acid residues;

g) a nucleotide sequence of (a), (b) or (c) comprising a fragment of at least about 10, 15, 20, 25, 50, 75, 100, or greater than 100 nucleotides; and

h) a nucleotide sequence which hybridizes under stringent conditions to any of (a)-(g).

3. The nucleic acid molecule of Claims 1 or 2 wherein the nucleotide sequence is operably linked to an expression control sequence.

4. A host cell comprising the nucleic acid molecule of Claim 2.

5. The host cell of Claim 3 which is a eucaryotic cell.

6. The host cell of Claim 3 which is a procaryotic cell.

7. A process for producing a polypeptide comprising growing a culture of the host cell of Claim 3 in suitable culture medium and isolating the polypeptide from the culture.

5

8. A polypeptide produced by the process of Claim 7.

9. A polypeptide encoded by the nucleic acid molecule of Claim 1.

10

10. A polypeptide encoded by the nucleic acid molecule of Claim 2.

11. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:

15

a) the amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2);

b) the mature amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2) comprising a mature amino terminus at residue 21;

20

c) a fragment of the amino acid sequence set forth in Figure 1A (SEQ ID NO: 2) comprising at least about 25, 50, 75, 100, or greater than 100 amino acid residues;

25

d) an ortholog of (a), (b) or (c); and
e) an allelic variant or alternative splice variant of (a), (b), (c) or (d).

12. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:

30

a) the amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12) or Figure 12A (SEQ ID NO: 17);

35

b) the mature amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) comprising a mature

5

10

e) an allelic variant or alternative splice
f) (a), (b), (c) or (d).

15

20

15. The antibody of Claim 13 which is a human antibody.

25

17. The antibody or fragment of Claim 13 which binds B7RP1 or to a B7RP1 extracellular domain.

30

35

20. A polypeptide comprising a derivative of the polypeptide of Claims 9, 10, 11 or 12.

21. The polypeptide of Claim 20 which is covalently modified with a water-soluble polymer.

22. A fusion polypeptide comprising the polypeptide of Claims 9, 10, 11 or 12 fused to a
10 heterologous amino acid sequence.

23. The fusion polypeptide of Claim 22 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.

24. A method for treating, preventing or ameliorating a T-cell mediated disorder comprising administering to an animal the polypeptide of Claims 9, 10, 11 or 12.

25. A method of diagnosing a T-cell mediated disorder or a susceptibility to a T-cell mediated disorder in an animal comprising:

a) determining the presence or amount of
25 expression of the polypeptide of Claims 9, 10, 11 or
12; and

b) diagnosing a T-cell mediated disorder or a susceptibility to a T-cell mediated disorder based on the presence or amount of expression of the polypeptide.

26. A method of identifying a test molecule which binds to a polypeptide comprising:

a) contacting the polypeptide of Claims 9,
35 10, 11 or 12 with a test molecule; and

b) determining the extent of binding of the polypeptide to the test molecule.

27. The method of Claim 26 further comprising
5 determining the activity of the polypeptide when bound to the compound.

28. A method of regulating T-cell activation or proliferation in an animal comprising administering to
10 the animal the nucleic acid molecule of Claims 1, 2 or 3.

29. A transgenic non-human mammal comprising the nucleic acid molecule of Claim 3.
15

30. A method of suppressing an immune response in an animal comprising administering to the animal an antagonist of CRP1 or B7RP1.

20 31. The method of Claim 30 wherein the antagonist is an antibody which binds B7RP1.

32. A method of decreasing IgE production in an animal comprising administering a B7RP1 antagonist or a
25 CRP1 antagonist, or a combination thereof, in an amount effective to decrease IgE production.

33. A method of preventing or treating an IgE-mediated disorder comprising administering a
30 therapeutically effective amount of a B7RP1 antagonist, or a CRP1 antagonist, or a combination thereof.

34. The method of Claims 32 or 33 wherein the B7RP1 antagonist is an antibody which binds B7RP1 and
35 partially or completely inhibits IgE production.

00827 0248260

36. The method of Claim 33 wherein the IgE-mediated disorder is asthma or an allergic disorder.

10

15

20

25

FIGURE 1A

ATG AAG CCG TAC TTC TGC CGT GTC TTT GTC TTC TGC TTC CTA ATC	45
M K P Y F C R V F V F C F L I	
5 10 15	
AGA CTT TTA ACA GGA GAA ATC AAT GGC TCG GCC GAT CAT AGG ATG	90
R L L L G E I N G S A D H R M	
20 25 30	
TTT TCA TTT CAC AAT GGA GGT GTA CAG ATT TCT TGT AAA TAC CCT	135
F S F H N G G V Q I S C K Y P	
35 40 45	
GAG ACT GTC CAG CAG TTA AAA ATG CGA TTG TTC AGA GAG AGA GAA	180
E T V Q Q L K M R L F R E R E	
50 55 60	
GTC CTC TGC GAA CTC ACC AAG ACC AAG GGA AGC GGA AAT GCG GTG	225
V L C E L T K T K G S G N A V	
65 70 75	
TCC ATC AAG AAT CCA ATG CTC TGT CTA TAT CAT CTG TCA AAC AAC	270
S I K N P M L C L Y H L S N N	
80 85 90	
AGC GTC TCT TTT TTC CTA AAC AAC CCA GAC AGC TCC CAG GGA AGC	315
S V S F F L N N P D S S Q G S	
95 100 105	
TAT TAC TTC TGC AGC CTG TCC ATT TTT GAC CCA CCT CCT TTT CAA	360
Y Y F C S L S I F D P P P F Q	
110 115 120	
GAA AGG AAC CTT AGT GGA GGA TAT TTG CAT ATT TAT GAA TCC CAG	405
E R N L S G G Y L H I Y E S Q	
125 130 135	
CTC TGC TGC CAG CTG AAG CTC TGG CTA CCC GTA GGG TGT GCA GCT	450
L C C Q L K L W L P V G C A A	
140 145 150	
TTC GTT GTG GTA CTC CTT TTT GGA TGC ATA CTT ATC ATC TGG TTT	495
F V V V L L F G C L L L L W F	
155 160 165	
TCA AAA AAG AAA TAC GGA TCC AGT GTG CAT GAC CCT AAT AGT GAA	540
S K K K Y G S S V H D P N S E	
170 175 180	
TAC ATG TTC ATG GCG GCA GTC AAC ACA AAC AAA AAG TCT AGA CTT	585
Y M F M A A V N T N K K S R L	
185 190 195	
GCA GGT GTG ACC TCA	600
A G V T S	
200	

003211 02482250

[illegible]

765
310
855
900
945
966

FIGURE 2B

mB7RP1	MQLKCPCEFS	LGTRQPVWKK	LHVSSGFFSG	LGLFLLLS-	SLCAASAETE	49
mCD80	MA--CNC--Q	LMQDTPL---	LKFPCPRLI-	L-LFVLLIRL	SQVSSDVDEQ	41
Consensus	M...C.C...	L....P....	L.....	L.LF.LL...	S.....	
mB7RP1	VGAMVGSNNV	LSCIDPHRRH	FNLISGLYVYW	QIENPEVSVT	YYLPYKSPGI	99
mCD80	LSKSVKDKVL	LPC-RYNSPH	EDESEDRIYW	QKHKDVV---	--LSVIAGKL	85
Consensus	...V...V.	L.C.....H	...S....YW	Q...V...	..L.....	
mB7RP1	NVDSSYKNRG	HLSLDSMKQG	NFSLYLKNVT	PQDTQEFTCR	VFMNTATELV	149
mCD80	KVWPEYKNR-	--TL--YDNT	TYSLIILGLV	LSDRGTYSKV	VQKKERGTYE	130
Consensus	.V...YKNR.	...L.....	..SL.....	..D.....C.	V.....	
mB7RP1	KILEEVVRLR	VAANFSTPVI	STSDSSNPGQ	ERTYTCSMKN	GYPEPNLYWI	199
mCD80	VKHLALVKLS	IKADFSTPNI	TESGNPSADT	KRI-TCFASG	GFPKPRFSWL	179
ConsensusV.L.	...A.FSTP.I	..S.....	.R..TC...	G.P.P...W.	
mB7RP1	-NTTDSNLID	TALQNNTVYL	NKLGLYDVIS	TLRLPWTSRG	DVLCCVENVA	248
mCD80	ENGRELPGIN	TTISQDPESE	LYTISSQLDF	NTTRNHTIKC	LIKYGDAHVS	229
Consensus	.N.....I.	T.....T...V.	
mB7RP1	LHQNITSISQ	AESFTGNNTK	NPQETHNNEL	KVLVFLAVL	A-AAAFVSFI	297
mCD80	EDFTWEKPPE	DPPDSKNTLV	LFGAGFGAVI	TVVVIVVVIK	CFCKHRSCFR	279
ConsensusN...V.V.V....F.	
mB7RP1	IYRRT-R-PHR	SYT-GPKTVQ	LELTDHA			322
mCD80	RNEASRETNN	SLTFGPPEAL	AEQTVFL			306
Consensus	...R....	S.T.GP...	.E.T...			

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

ATG	CGG	CTG	GGC	CTC	GGA	CTG	CTC	TTC	CTG	CTC	TTC	AGC	AGC		45
M	R	L	G	S	P	G	L	L	F	L	L	F	S	S	
			5					10					15		
CTT	CGA	GCT	GAT	ACT	CAG	GAG	AAG	GAA	GTC	AGA	GCG	ATG	GTA	GGC	90
L	R	A	*D	*T	*Q	*E	K	*E	V	R	A	*M	V	G	
			20						25					30	
AGC	GAC	GTG	GAG	CTC	AGC	TGC	GCT	TGC	CCT	GAA	GGA	AGC	CGT	TTT	135
S	D	V	E	L	S	C	A	C	P	E	G	S	R	F	
			35						40					45	
GAT	TTA	AAT	GAT	GTT	TAC	GTA	TAT	TGG	CAA	ACC	AGT	GAG	TCG	AAA	180
D	L	N	D	V	Y	V	Y	W	Q	T	S	E	S	K	
			50						55					60	
ACC	GTG	GTG	ACC	TAC	CAC	ATC	CCA	CAG	AAC	AGC	TCC	TTG	GAA	AAC	225
T	V	V	T	Y	H	I	P	Q	N	S	S	L	E	N	
			65						70					75	
GTG	GAC	AGC	CGC	TAC	CGG	AAC	CGA	GCC	CTG	ATG	TCA	CCG	GCC	GGC	270
V	D	S	R	Y	R	N	R	A	L	M	S	P	A	G	
			80						85					90	
ATG	CTG	CGG	GGC	GAC	TTC	TCC	CTG	CGC	TTG	TTC	AAC	GTC	ACC	CCC	315
M	L	R	G	D	F	S	L	R	L	F	N	V	T	P	
			95						100					105	
CAG	GAC	GAG	CAG	AAG	TTT	CAC	TGC	CTG	GTG	TTG	AGC	CAA	TCC	CTG	360
Q	D	E	Q	K	F	H	C	L	V	L	S	Q	S	L	
			110						115					120	
GGA	TTC	CAG	GAG	GTT	TTG	AGC	GTT	GAG	GTT	ACA	CTG	CAT	GTG	GCA	405
G	F	Q	E	V	L	S	V	E	V	T	L	H	V	A	
			125						130					135	
GCA	AAC	TTC	AGC	GTG	CCC	GTC	GTC	AGC	GCC	CCC	CAC	AGC	CCC	TCC	450
A	N	F	S	V	P	V	V	S	A	P	H	S	P	S	
			140						145					150	
CAG	GAT	GAG	CTC	ACC	TTC	ACG	TGT	ACA	TCC	ATA	AAC	GGC	TAC	CCC	495
Q	D	E	L	T	F	T	C	T	S	I	N	G	Y	P	
			155						160					165	
AGG	CCC	AAC	GTG	TAC	TGG	ATC	AAT	AAG	ACG	GAC	AAC	AGC	CTG	CTG	540
R	P	N	V	Y	W	I	N	K	T	D	N	S	L	L	
			170						175					180	
GAC	CAG	GCT	CTG	CAG	AAT	GAC	ACC	GTC	TTC	TTG	AAC	ATG	CGG	GGC	585
D	Q	A	L	Q	N	D	T	V	F	L	N	M	R	G	
			185						190					195	
TTG	TAT	GAC	GTG	GTC	AGC	GTG	CTG	AGG	ATC	GCA	CGG	ACC	CCC	AGC	630
L	Y	D	V	V	S	V	L	R	I	A	R	T	P	S	
			200						205					210	
GTG	AAC	ATT	GGC	TGC	TGC	ATA	GAG	AAC	GTG	CTT	CTG	CAG	CAG	AAC	675
V	N	I	G	C	C	I	E	N	V	L	L	Q	Q	N	
			215						220					225	
CTG	ACT	GTC	GGC	AGC	CAG	ACA	GGA	AAT	GAC	ATC	GGA	GAG	AGA	GAC	720
L	T	V	G	S	Q	T	G	N	D	I	G	E	R	D	
			230						235					240	

Figure 1 consists of ten panels (a-j) showing the effect of the 1997-1998 El Niño on the growth of 10 tree species. The species are: *Alseodaphnophloeus*, *Alseodaphnophloeus*, *Alseodaphnophloeus*, *Alseodaphnophloeus*, *Alseodaphnophloeus*, *Alseodaphnophloeus*, *Alseodaphnophloeus*, *Alseodaphnophloeus*, *Alseodaphnophloeus*, and *Alseodaphnophloeus*. The panels show growth (cm) for each species in 1997 and 1998, and the difference in growth (cm) between 1997 and 1998. The growth in 1997 is generally higher than in 1998, and the difference in growth is generally negative, indicating a decrease in growth in 1998. The difference in growth is generally larger for the species *Alseodaphnophloeus* and *Alseodaphnophloeus*.

TAT GCA GGT
Y A G
288

[illegible]

hB7RP1	EKEVRAMVGS	DVELSCACPE	GSRFDLNDVY	VYWQTSESKT	VVTYHIPQNS	50
mB7RP1	ETEVGAMVGS	NVVLSCIDPH	RRHFNLSGLY	VYWQIENPEV	SVTYYLBYKS	50
Consensus	E.EV.AMVGS	.V.LSC..P.	..F.L...Y	VYWQ.....	.VTY..P..S	
hB7RP1	SLENVDSRYR	NRALMSPAGM	LRGDFSLRLF	NVTPODEQKF	HCLVLSQ-SL	99
mB7RP1	PGINVDSSYK	NRGHLSLDSM	KQGNFSLYLK	NVTPODTQEF	TCRVEMNTAT	100
Consensus	...NVDS.Y.	NR...S...M	..G.FSL.L.	NVTPOD.Q.F	.C.V.....	
hB7RP1	GFQEVLSVEV	TLHVAANFSV	PVVSAPHSPS	Q-DELTFTCT	SINGYPRPNV	148
mB7RP1	ELVKILEEVV	RLRVAANFST	PVISTSDSSN	PGQERTYTCM	SKNGYPEPNL	150
ConsensusL...V	.L.VAANFS.	PV.S...S..	...E.T.TC.	S.NGY.P.N.	
hB7RP1	YWINKTDNSL	LDQALQNDTV	FLNMRGLYDV	VSVLRIARTP	SVNIGCCIEH	198
mB7RP1	YWINTTDSNL	IDTALQNNTV	YLNKLGlyDV	ISTLRLPWTS	RGDVLCCVEN	200
Consensus	YWIN.TDNSL	.D.ALQN.TV	.LN..GLYDV	.S.LR...T.	A....CC.EN	
hB7RP1	VLLQQNLTVG	SQTGNDIGER	DKITENPVST	GEKNAATWSI	LAVLCLLVVV	248
mB7RP1	VALHQNITSI	SQAESFTGNN	TKNPQETHNN	ELKVLV--PV	LAVLAAAFV	248
Consensus	V.L.QN.T..	SQ...G...	.K....K...	..K...7...	LAVL.....V	
hB7RP1	AVAIGWVCRD	RCLQHSYAG				267
mB7RP1	SFIIYR--RT	R-PHRSYTGp	KTVQLELTDH	A		276
Consensus	...I...R.	R...SY.G.			

Figure 4A




Figure 4B




Figure 6




Figure 7




Figure 3




FIGURE 9

Con A stimulation of T-cells regulated
by B7RP1-Fc fusion protein




Figure 10




Figure 11




Figure 12A.

GCTGGTACGCCTGCAGGTACCGGTCCGGAATTCCCGGGTTCGACCCACGCGTCCGCCCACGCG	-138
TCCGCGGGAGCGCAGTTAGAGCCGATCTCCCGCGCCCCGAGGTTGCTCCTCTCCGAGGTCTC	-76
CCGCGGCCCAAGTTCTCCGCGCCCCGAGGTCTCCGCGCCCCGAGGTCTCCGCGGCCCGAGGT	-14
CTCCGCCCCGACC	-1
ATG CGG CTG GGC AGT CCT GGA CTG CTC TTC CTG CTC TTC AGC AGC	45
M R L G S P G L L F L L F S S	
5 10 15	
CTT CGA GCT GAT ACT CAG GAG AAG GAA GTC AGA GCG ATG GTA GGC	90
L R A *D *T *Q *E K *E V R A *M V G	
20 25 30	
AGC GAC GTG GAG CTC AGC TGC GCT TGC CCT GAA GGA AGC CGT TTT	135
S D V E L S C A C P E G S R F	
35 40 45	
GAT TTA AAT GAT GTT TAC GTA TAT TGG CAA ACC AGT GAG TCG AAA	180
D L N D V Y V Y W Q T S E S K	
50 55 60	
ACC GTG GTG ACC TAC CAC ATC CCA CAG AAC AGC TCC TTG GAA AAC	225
T V V T Y H I P Q N S S L E N	
65 70 75	
GTG GAC AGC CGC TAC CGG AAC CGA GCC CTG ATG TCA CCG GCC GGC	270
V D S R Y R N R A L M S P A G	
80 85 90	
ATG CTG CGG GGC GAC TTC TCC CTG CGC TTG TTC AAC GTC ACC CCC	315
M L R G D F S L R L F N V T P	
95 100 105	
CAG GAC GAG CAG AAG TTT CAC TGC CTG GTG TTG AGC CAA TCC CTG	360
Q D E Q K F H C L V L S Q S L	
110 115 120	
GGA TTC CAG GAG GTT TTG AGC GTT GAG GTT ACA CTG CAT GTG GCA	405
G F Q E V L S V E V T L H V A	
125 130 135	
GCA AAC TTC AGC GTG CCC GTC GTC AGC GCC CCC CAC AGC CCC TCC	450
A N F S V P V V S A P H S P S	
140 145 150	
CAG GAT GAG CTC ACC TTC ACG TGT ACA TCC ATA AAC GGC TAC CCC	495
Q D E L T F T C T S I N G Y P	
155 160 165	
AGG CCC AAC GTG TAC TGG ATC AAT AAG ACG GAC AAC AGC CTG CTG	540
R P N V Y W I N K T D N S L L	
170 175 180	
GAC CAG GCT CTG CAG AAT GAC ACC GTC TTC TTG AAC ATG CGG GGC	585
D Q A L Q N D T V F L N M R G	
185 190 195	
TTG TAT GAC GTG GTC AGC GTG CTG AGG ATC GCA CGG ACC CCC AGC	630
L Y D V V S V L R I A R T P S	
200 205 210	
GTG AAC ATT GGC TGC TGC ATA GAG AAC GTG CTT CTG CAG CAG AAC	675
V N I G C C I E N V L L Q Q N	
215 220 225	

002211 02482260

CTG ACT GTC GGC AGC CAG ACA GGA AAT GAC ATC GGA GAG AGA GAC 720
L T V G S Q T G N D I G E R D
230 235 240

AAG ATC ACA GAG AAT CCA GTC AGT ACC GGC GAG AAA AAC GCG GCC 765
K I T E N P V S T G E K N A A
245 250 255

ACG TGG AGC ATC CTG GCT GTC CTG TGC CTG CTT GTG GTC GTG GCG 810
T W S I L A V L C L L V V V A
260 265 270

GTG GCC ATA GGC TGG GTG TGC AGG GAC CGA TGC CTC CAA CAC AGC 855
V A I G W V C R D R C L Q H S
275 280 285

TAT GCA GGT GCC TGG GCT GTG AGT CCG GAG ACA GAG CTC ACT GGC 900
Y A G A W A V S P E T E L T G
300

CAC GTT TGA 909
H V STOP
302

CCGGAGCTCACCGCCCAGAGCGTGGACAGGGCTTCCGTGAGACGCCACCGTGAGAGGCCAGG 971
TGGCAGCTTGAGCATGGACTCCCAGACTGCAGGGGAGCACTTGGGGCAGCCCCAGAAGGAC 1033
CACTGCTGGATCCCAGGGAGAACCTGCTGGCGTTGGCTGTGATCCTGGAATGAGGCCCTTTC 1095

[illegible]

Variable	Mean	SD	Min	Max
Age	34.5	10.2	21	55
Gender	Male	Female		
Marital status	Married	Single		
Education	High school	College		
Occupation	Manager	Worker		
Income	Low	High		
Health status	Good	Poor		
Smoking status	Smoker	Non-smoker		
Alcohol consumption	Regular	Occasional		
Exercise frequency	High	Low		
Stress level	High	Low		
Sleep quality	Good	Poor		
Dietary habits	Healthy	Unhealthy		
Family size	Small	Large		
Religious beliefs	Religious	Secular		
Political views	Conservative	Liberal		
Travel frequency	High	Low		
Pet ownership	Yes	No		
Home ownership	Owner	Renter		
Car ownership	Yes	No		
Internet usage	High	Low		
Mobile phone usage	High	Low		
Video game usage	High	Low		
Reading frequency	High	Low		
Volunteering	Yes	No		
Charitable donations	High	Low		
Community involvement	High	Low		
Neighborhood safety	High	Low		
Local government satisfaction	High	Low		
Environmental awareness	High	Low		
Recycling participation	High	Low		
Energy conservation	High	Low		
Water conservation	High	Low		
Waste management	High	Low		
Public transportation usage	High	Low		
Walking or biking frequency	High	Low		
Use of public facilities	High	Low		
Participation in local events	High	Low		
Support for local businesses	High	Low		
Engagement in local politics	High	Low		
Trust in local government	High	Low		
Perception of local government effectiveness	High	Low		
Local government transparency	High	Low		
Local government accountability	High	Low		
Local government responsiveness	High	Low		
Local government communication	High	Low		
Local government participation	High	Low		
Local government involvement	High	Low		
Local government engagement	High	Low		
Local government support	High	Low		
Local government trust	High	Low		
Local government confidence	High	Low		
Local government respect	High	Low		
Local government recognition	High	Low		
Local government appreciation	High	Low		
Local government gratitude	High	Low		
Local government love	High	Low		
Local government affection	High	Low		
Local government fondness	High	Low		
Local government liking	High	Low		
Local government preference	High	Low		
Local government choice	High	Low		
Local government selection	High	Low		
Local government decision	High	Low		
Local government determination	High	Low		
Local government decision-making	High	Low		
Local government decision-making process	High	Low		
Local government decision-making system	High	Low		
Local government decision-making structure	High	Low		
Local government decision-making framework	High	Low		
Local government decision-making model	High	Low		
Local government decision-making approach	High	Low		
Local government decision-making method	High	Low		
Local government decision-making technique	High	Low		
Local government decision-making strategy	High	Low		
Local government decision-making plan	High	Low		
Local government decision-making policy	High	Low		
Local government decision-making procedure	High	Low		
Local government decision-making protocol	High	Low		
Local government decision-making process	High	Low		
Local government decision-making system	High	Low		
Local government decision-making structure	High	Low		
Local government decision-making framework	High	Low		
Local government decision-making model	High	Low		
Local government decision-making approach	High	Low		
Local government decision-making method	High	Low		
Local government decision-making technique	High	Low		
Local government decision-making strategy	High	Low		
Local government decision-making plan	High	Low		
Local government decision-making policy	High	Low		
Local government decision-making procedure	High	Low		
Local government decision-making protocol	High	Low		
Local government decision-making process	High	Low		
Local government decision-making system	High	Low		
Local government decision-making structure	High	Low		
Local government decision-making framework	High	Low		
Local government decision-making model	High	Low		
Local government decision-making approach	High	Low		
Local government decision-making method	High	Low		

human	MRLGSP----	-----	-----G	L-LF-LLFSS	LRADTQEKEV	25
mouse	MQLKPCPCFVS	LGTRQPVWKK	LHVSSGFFSG	LGLFLLLLSS	LCAASAEDEV	50
Consensus	M.L..P....G	L.LF.LL.SS	L.A...E.EV	50
human	RAMVGSDEL	SCACPEGSRF	DLNDVYVYQ	TSSEKTVVTY	HIPQNSSLN	75
mouse	GAMVGSNVVL	SCIDPHRRHF	NLSGLYVYQ	IENPEVSVTY	YLPYKSPGIN	100
Consensus	.AMVGS.V.L	SC...P...F	.L...YVYQVTY	..P..S...N	100
human	VDSRYNRAL	MSPAGMLRGD	FSLRLFNVTP	QDEQKFHCLV	LSQ-SLGFQE	124
mouse	VDSSYKNRGH	LSLDSMKQGN	FSLYLKNVTP	QDTQEFTCRV	FMNTATELVK	150
Consensus	VDS.Y.NR..	.S...M..G.	FSL.L.NVTP	QD.Q.F.C.V	150
human	VLSVEVTLHV	AANFSVPVVS	APHSPSQ-DE	LTFTCTSING	YPRPNVYWIN	173
mouse	ILEEVVRLRV	AANFSTPVIS	TSOSSNPGQE	RTYTCMSKNG	YPEPNLYWIN	200
Consensus	.L...V.L.V	AANFS.PV.S	...S.....E	.T.TC.S.NG	YP.PN.YWIN	200
human	KTDNSLLDQA	LQNDTVFLNM	RGLYDVVSVL	RIARTPSVNI	GCCIENVLLQ	223
mouse	TTDNSLIDTA	LQNNTVYLNK	LGLYDVISTL	RLPWTSRGDV	LCCVENVALH	250
Consensus	.TDNSL.D.A	LQN.TV.LN.	.GLYDV.S.L	R...T.....	.CC.ENV.L.	250
human	QNLTVGSQTG	NDIGERDKIT	ENPVSTGEKN	AATWSILAVL	CLLVVVAVAI	273
mouse	QNITSISQAE	SFTGNNTKNP	QETHNNELKV	LV--PVLAVL	AAAASFVSI	298
Consensus	QN.T..SQ..	...G...K..K.LAVLV...I	300
human	GWVCRDRCLQ	HSYAGAWAVS	PETELTGHV			302
mouse	YR--RTR-PH	RSYTGPKTVQ	LE--LTDHA			322
ConsensusR.R...	.SY.G...V.	.E..LT.H.			329

Figure 13A

AACAATTTACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAATACGA -111
 CTCACTATAGGGAAAGCTGGTACGCCTGCAGGTACCGGTCCGGAATCCCGGGTC -56
 GACCCACGCGTCCGTGAACACTGAACGCGAGGACTGTTAACTGTTTCTGGCAAAC -1

ATG AAG TCA GGC CTC TGG TAT TTC TTT CTC TTC TGC TTG CGC ATT 45
 M K S G L W Y F F L F C L R I 15
 5 10 15

AAA GTT TTA ACA GGA GAA ATC AAT GGT TCT GCC AAT TAT GAG ATG 90
 K V L T *G *E I N G S A N Y E M 30
 20 25 30

TTT ATA TTT CAC AAC GGA GGT GTA CAA ATT TTA TGC AAA TAT CCT 135
 F I F H N G G V Q I L C K Y P 45
 35 40 45

GAC ATT GTC CAG CAA TTT AAA ATG CAG TTG CTG AAA GGG GGG CAA 180
 D I V Q Q F K M Q L L K G G Q 60
 50 55 60

ATA CTC TGC GAT CTC ACT AAG ACA AAA GGA AGT GGA AAC ACA GTG 225
 I L C D L T K T K G S G N T V 75
 65 70 75

TCC ATT AAG AGT CTG AAA TTC TGC CAT TCT CAG TTA TCC AAC AAC 270
 S I K S L K F C H S Q L S N N 90
 80 85 90

AGT GTC TCT TTT TTT CTA TAC AAC TTG GAC CAT TCT CAT GCC AAC 315
 S V S F F L Y N L D H S H A N 105
 95 100 105

TAT TAC TTC TGC AAC CTA TCA ATT TTT GAT CCT CCT CCT TTT AAA 360
 Y Y F C N L S I F D P P P F K 120
 110 115 120

GTA ACT CTT ACA GGA GGA TAT TTG CAT ATT TAT GAA TCA CAA CTT 405
 V T L T G G Y L H I Y E S Q L 135
 125 130 135

TGT TGC CAG CTG AAG TTC TGG TTA CCC ATA GGA TGT GCA GCC TTT 450
 C C Q L K F W L P I G C A A F 150
 140 145 150

GTT GTA GTC TGC ATT TTG GGA TGC ATA CTT ATT TGT TGG CTT ACA 495
 V V V C L L G C I L I C W L T 165
 155 160 165

AAA AAG AAG TAT TCA TCC AGT GTG CAC GAC CCT AAC GGT GAA TAC 540
 K K K Y S S S V H D P N G E Y 180
 170 175 180

ATG TTC ATG AGA GCA GTG AAC ACA GCC AAA AAA TCT AGA CTC ACA 585
 M F M R A V N T A K K S R L T 195
 185 190 195

GAT GTG ACC CTA TAA 600
 D V T L STOP
 199

TATGGAAGTCTGGCACCCAGGCATGAAGCACGTTGGCCAGTTTTCTCAACTTGA 655
 AGTGCAAGATTCTCTTATTTCCGGGACCACGGAGAGTCTGACTTAACTACATACA 710

000217-0242260

Figure 13B

hCRP1	MKSGLWYFFLFCLRIKVLGTGEINGSANYEMFIFHNGGVQILCKYPDIVQQ	50
mCRP1	MKPYFCRVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPETVQQ	50
hCRP1	FKMQLLKGGQILCDLTCTKKGSGNTVSIKSLKFCHSQLSNNSVSFFLYNLD	100
mCRP1	LKMRLFREREVLCELTKTKGSGNAVSIKNPMLCLYHLSNNSVSFFLNND	100
hCRP1	HSHANYFFCNLSIFDPPPFKV.TLTGGYLHIYESQLCCQLKFWLPIGCAA	149
mCRP1	SSQGSYYFCSLSIFDPPPFQERNLSGGYLHIYESQLCCQLKLWLPVGCAA	150
hCRP1	FVVVCILGCILICWLTCKKYSSSVHDPNGEYMFMRVNTAKKSRLTDVTL	199
mCRP1	FVVVLLFGCILIIFWSKKKYGSSVHDPNSEYMFMAAVNTNKKSRLAGVTS	200





Figure 14

A.



B.





Figure 16



A. Control mouse#53F: Prox. colon 40X




B. Mouse#111F: Prox. colon 40X




C. Mouse#111F: Prox. colon 20X



D. Mouse#111F: closeup of mucosa 100X




E. Mouse#112F: Giant cell, submucosa




F. Mouse#112F: epithelioid macrophages


Figure 17



A. Control mouse#53F:Distal colon, 40X



B. mouse#111F:Distal colitis, 40X




C. mouse#55M:Distal colitis, 40X



D. mouse#112F:Distal colon, 40X



E. mouse#112:CD3+ T-cells, 40X



F. mouse#112:closeup, 100X

Figure 18



A. Control mouse#53F:duodenum, 40X




B. Mouse#51F:duodenum, 40X




C. Control mouse#53F:jejunum, 40X



D. Mouse#51F:jejunal hyperplasia, 40X



E. Control mouse#53F:ileum, 40X



F. Mouse#231M:ileal atrophy, 40X

Figure 19

Figure 20




Figure 21A/B.





Figure 21C.




Figure 21D




Figure 22





Figure 23



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first, and sole inventor (if only one name is listed below) or a joint inventor (if plural names are listed below) of the invention entitled

Novel Polypeptides Involved in Immune Response

which is described and claimed in the specification which:

- ☒ is attached hereto.
☐ was filed on _____
 as Application Serial No. _____
 and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)			
Country	Application Number	Filing Date (day, month, year)	Priority Claimed
PCT	PCT/US00/01871	27 January 2000	Yes

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the filing date of this application:

PRIOR U.S. APPLICATIONS		
APPLICATION SERIAL NO.	FILING DATE	STATUS
09/264,527	March 8, 1999	Pending
09/244,448	February 3, 1999	Pending

DECLARATION AND POWER OF ATTORNEY (cont'd)

Power of Attorney: As a named inventor I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Steven M. Odre (Reg. No. 29,094), Ron K. Levy (Reg. No. 31,539), Scott N. Bernstein (Reg. No. 38,827), Joseph W. Bullock (Reg. No. 37,103), Robert R. Cook (Reg. No. 31,602), Monique L. Cordray (Reg. No. 34,802), Craig A. Crandall (Reg. No. 38,416), Daniel R. Curry (Reg. No. 32,727), Joan D. Eggert (Reg. No. 32,980), Timothy J. Gaul (Reg. No. 33,111), Matthew W. Knight (Reg. No. 36,846), Richard J. Mazza (Reg. No. 27,657), Karen L. Nicastro (Reg. No. 35,968), Nancy A. Oleski (Reg. No. 34,688), Karol M. Pessin (Reg. No. 34,899), Frank S. Ungemach (Reg. No. 34,449), Stuart L. Watt (Reg. No. 32,511), Wendy A. Whiteford (Reg. No. 36,964), Robert B. Winter (Reg. No. 34,458), Thomas D. Zindrick (Reg. No. 32,185), said attorney(s)/agent(s) to have in addition full power of revocation, including the power to revoke any power herein granted.

Please send all future correspondence to:

U.S. Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Direct Telephone Calls To:

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447- 2425

DECLARATION AND POWER OF ATTORNEY (cont'd)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of Sole
or First Inventor:

Steven K. Yoshinaga

Inventor's Signature:

Date:

Residence and
Post Office Address:

1896 Calle Salto, Thousand Oaks, California, 91360, USA

(Address, City, State, Zip Code, Country)

Citizenship:

USA

Full Name of Second
Joint Inventor, if Any:

Tak W. Mak

Inventor's Signature:

Date:

Residence and
Post Office Address:

25 Elgin Avenue, Toronto, Ontario, M5R 1G5, Canada

(Address, City, State, Zip Code, Country)

Citizenship:

Canada

Full Name of Third
Joint Inventor, if Any:

Arda Shahinian

Inventor's Signature:

Date:

Residence and
Post Office Address:

85 Havelock Gate, Markham, Ontario, L3S 3P6, Canada

(Address, City, State, Zip Code, Country)

Citizenship:

Canada

Full Name of Fourth
Joint Inventor, if Any:

Anna Tafuri Bladt

Inventor's Signature:

Date:

Residence and
Post Office Address:

44 Gerrard Street West, Suite 1402, Toronto, Ontario, M5G 2K2, Canada

(Address, City, State, Zip Code, Country)

Citizenship:

Italy

Full Name of Fifth
Joint Inventor, if Any:

Inventor's Signature:

_____ Date: _____

Residence and
Post Office Address:

2846 White Ridge Place #24, Thousand Oaks, California, 91362, USA
(Address, City, State, Zip Code, Country)

Citizenship:

Italy

Figure 1 consists of 10 bar charts, labeled (a) through (j), each representing a different variable. The x-axis for all charts is divided into two sections: '1995' and '2000'. Within each section, there are two bars: a solid black bar and a white bar with a black outline. The y-axis for all charts represents the percentage of respondents, ranging from 0 to 100. The variables and their corresponding data are as follows:

Variable	1995 (Solid)	1995 (Outline)	2000 (Solid)	2000 (Outline)
a) Age	18-24: 15%, 25-34: 25%, 35-44: 30%, 45-54: 20%, 55-64: 10%	18-24: 10%, 25-34: 20%, 35-44: 35%, 45-54: 25%, 55-64: 10%	18-24: 15%, 25-34: 25%, 35-44: 30%, 45-54: 20%, 55-64: 10%	18-24: 10%, 25-34: 20%, 35-44: 35%, 45-54: 25%, 55-64: 10%
b) Sex	Male: 50%, Female: 50%	Male: 50%, Female: 50%	Male: 50%, Female: 50%	Male: 50%, Female: 50%
c) Education	High school or less: 40%, Some college: 30%, Bachelor's: 20%, Graduate: 10%	High school or less: 35%, Some college: 35%, Bachelor's: 20%, Graduate: 10%	High school or less: 40%, Some college: 30%, Bachelor's: 20%, Graduate: 10%	High school or less: 35%, Some college: 35%, Bachelor's: 20%, Graduate: 10%
d) Income	\$10,000 or less: 30%, \$10,000-\$19,999: 25%, \$20,000-\$29,999: 20%, \$30,000-\$39,999: 15%, \$40,000 or more: 10%	\$10,000 or less: 25%, \$10,000-\$19,999: 30%, \$20,000-\$29,999: 25%, \$30,000-\$39,999: 15%, \$40,000 or more: 5%	\$10,000 or less: 30%, \$10,000-\$19,999: 25%, \$20,000-\$29,999: 20%, \$30,000-\$39,999: 15%, \$40,000 or more: 10%	\$10,000 or less: 25%, \$10,000-\$19,999: 30%, \$20,000-\$29,999: 25%, \$30,000-\$39,999: 15%, \$40,000 or more: 5%
e) Employment	Employed: 60%, Unemployed: 40%	Employed: 65%, Unemployed: 35%	Employed: 60%, Unemployed: 40%	Employed: 65%, Unemployed: 35%
f) Religion	Protestant: 40%, Catholic: 35%, Jewish: 10%, Muslim: 5%, Other: 10%	Protestant: 35%, Catholic: 40%, Jewish: 10%, Muslim: 5%, Other: 10%	Protestant: 40%, Catholic: 35%, Jewish: 10%, Muslim: 5%, Other: 10%	Protestant: 35%, Catholic: 40%, Jewish: 10%, Muslim: 5%, Other: 10%
g) Political affiliation	Democrat: 60%, Republican: 30%, Independent: 10%	Democrat: 65%, Republican: 25%, Independent: 10%	Democrat: 60%, Republican: 30%, Independent: 10%	Democrat: 65%, Republican: 25%, Independent: 10%
h) Party affiliation	Democrat: 60%, Republican: 30%, Independent: 10%	Democrat: 65%, Republican: 25%, Independent: 10%	Democrat: 60%, Republican: 30%, Independent: 10%	Democrat: 65%, Republican: 25%, Independent: 10%
i) Attitude towards the environment	Very important: 40%, Important: 30%, Not important: 30%	Very important: 45%, Important: 35%, Not important: 20%	Very important: 40%, Important: 30%, Not important: 30%	Very important: 45%, Important: 35%, Not important: 20%
j) Attitude towards the government	Very satisfied: 10%, Satisfied: 30%, Dissatisfied: 40%, Very dissatisfied: 20%	Very satisfied: 15%, Satisfied: 35%, Dissatisfied: 35%, Very dissatisfied: 15%	Very satisfied: 10%, Satisfied: 30%, Dissatisfied: 40%, Very dissatisfied: 20%	Very satisfied: 15%, Satisfied: 35%, Dissatisfied: 35%, Very dissatisfied: 15%

<120> NOVEL POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE

<140> 09/264,527

<141> 1999-03-08

<160> 35

<170> PatentIn Ver. 2.1

 $\langle 210 \rangle$ 1

$\langle 211 \rangle$ 600

<212> DNA

<213> mouse

 $\langle 220 \rangle$

<221> CDS

```
<222> Complement((1)..(600))
```

<400> 1

atg aag ccg tac ttc tgc cgt gtc ttt gtc ttc tgc ttc cta atc aga 48
Met Lys Pro Tyr Phe Cys Arg Val Phe Val Phe Cys Phe Leu Ile Arg
1 5 10 15

ctt tta aca gga gaa atc aat ggc tcg gcc gat cat agg atg ttt tca 96
Leu Leu Thr Gly Glu Ile Asn Gly Ser Ala Asp His Arg Met Phe Ser
 20 25 30

ttt cac aat gga ggt gta cag att tct tgt aaa tac cct gag act gtc 144
Phe His Asn Gly Gly Val Gln Ile Ser Cys Lys Tyr Pro Glu Thr Val
35 40 45

cag cag tta aaa atg cga ttg ttc aga gag aga gaa gtc ctc tgc gaa 192
Gln Gln Leu Lys Met Arg Leu Phe Arg Glu Arg Glu Val Leu Cys Glu
50 55 60

ctc acc aag acc aag gga agc gga aat gcg gtg tcc atc aag aat cca 240
Leu Thr Lys Thr Lys Gly Ser Gly Asn Ala Val Ser Ile Lys Asn Pro
65 70 75 80

atg ctc tgt cta tat cat ctg tca aac aac agc gtc tct ttt ttc cta 288
Met Leu Cys Leu Tyr His Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
85 90 95

aac aac cca gac agc tcc cag gga agc tat tac ttc tgc agc ctg tcc 336
Asn Asn Pro Asp Ser Ser Gln Gly Ser Tyr Tyr Phe Cys Ser Leu Ser
100 105 110

att ttt gac cca cct cct ttt caa gaa agg aac ctt agt gga gga tat 384
Ile Phe Asp Pro Pro Pro Phe Gln Glu Arg Asn Leu Ser Gly Gly Tyr
115 120 125

ttg cat att tat gaa tcc cag ctc tgc tgc cag ctg aag ctc tgg cta 432
Leu His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Leu Trp Leu
130 135 140

ccc gta ggg tgt gca gct ttc gtt gtg gta ctc ctt ttt gga tgc ata 480
Pro Val Gly Cys Ala Ala Phe Val Val Val Leu Leu Phe Gly Cys Ile
145 150 155 160

ctt atc atc tgg ttt tca aaa aag aaa tac gga tcc agt gtg cat gac 528
Leu Ile Ile Trp Phe Ser Lys Lys Lys Tyr Gly Ser Ser Val His Asp
165 170 175

cct aat agt gaa tac atg ttc atg gcg gca gtc aac aca aac aaa aag 576
Pro Asn Ser Glu Tyr Met Phe Met Ala Ala Val Asn Thr Asn Lys Lys
180 185 190

tct aga ctt gca ggt gtg acc tca 600
Ser Arg Leu Ala Gly Val Thr Ser
195 200

<210> 2
<211> 200
<212> PRT
<213> mouse

<400> 2
Met Lys Pro Tyr Phe Cys Arg Val Phe Val Phe Cys Phe Leu Ile Arg
1 5 10 15
Leu Leu Thr Gly Glu Ile Asn Gly Ser Ala Asp His Arg Met Phe Ser
20 25 30
Phe His Asn Gly Gly Val Gln Ile Ser Cys Lys Tyr Pro Glu Thr Val
35 40 45
Gln Gln Leu Lys Met Arg Leu Phe Arg Glu Arg Glu Val Leu Cys Glu
50 55 60
Leu Thr Lys Thr Lys Gly Ser Gly Asn Ala Val Ser Ile Lys Asn Pro
65 70 75 80
Met Leu Cys Leu Tyr His Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
85 90 95
Asn Asn Pro Asp Ser Ser Gln Gly Ser Tyr Tyr Phe Cys Ser Leu Ser
100 105 110
Ile Phe Asp Pro Pro Pro Phe Gln Glu Arg Asn Leu Ser Gly Gly Tyr
115 120 125
Leu His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Leu Trp Leu
130 135 140
Pro Val Gly Cys Ala Ala Phe Val Val Val Leu Leu Phe Gly Cys Ile
145 150 155 160
Leu Ile Ile Trp Phe Ser Lys Lys Lys Tyr Gly Ser Ser Val His Asp
165 170 175
Pro Asn Ser Glu Tyr Met Phe Met Ala Ala Val Asn Thr Asn Lys Lys
180 185 190
Ser Arg Leu Ala Gly Val Thr Ser
195 200

<210> 3
<211> 200
<212> PRT

00221002483460

<400> 3

$\langle 210 \rangle$ 4

<211> 218

<212> PRT

<213> mouse

 $\langle 400 \rangle$ 4

Met 1	Thr	Leu	Arg	Leu 5	Leu	Phe	Leu	Ala	Leu 10	Asn	Phe	Phe	Ser	Val 15	Gln
Val	Thr	Glu	Asn 20	Lys	Ile	Leu	Val	Lys 25	Gln	Ser	Pro	Leu	Leu 30	Val	Val
Asp	Ser	Asn 35	Glu	Val	Ser	Leu	Ser 40	Cys	Arg	Tyr	Ser	Tyr 45	Asn	Leu	Leu
Ala	Lys 50	Glu	Phe	Arg	Ala	Ser 55	Leu	Tyr	Lys	Gly	Val 60	Asn	Ser	Asp	Val
Glu 65	Val	Cys	Val	Gly 70	Asn	Gly	Asn	Phe	Thr	Tyr 75	Gln	Pro	Gln	Phe	Arg 80

```
<210> 5
<211> 234
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
        Oglionucleotide

<400> 5
Met Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg
  1                               5                      10           15

Leu Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      20                        25                30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
    35                          40                  45

Val Xaa Xaa Ser Cys Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
   50                            55                      60

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Xaa Xaa Cys Xaa
   65                                70                    75          80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
       85                              90                     95

Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Val Xaa Phe Xaa Leu
     100                             105                   110

Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Phe Cys Xaa Xaa Xaa
     115                             120                   125

Xaa Xaa Xaa Pro Pro Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Gly Xaa
     130                             135                   140
```



```
<210> 6
<211> 966
<212> DNA
<213> mouse

<220>
<221> CDS
<222> Complement((1)..(966))
```

[illegible]

```

<400> 7
Met Gln Leu Lys Cys Pro Cys Phe Val Ser Leu Gly Thr Arg Gln Pro
  1          5          10          15
Val Trp Lys Lys Leu His Val Ser Ser Gly Phe Phe Ser Gly Leu Gly
          20          25          30
Leu Phe Leu Leu Leu Leu Ser Ser Leu Cys Ala Ala Ser Ala Glu Thr
          35          40          45

```

Glu Val Gly Ala Met Val Gly Ser Asn Val Val Leu Ser Cys Ile Asp
 50 55 60
 Pro His Arg Arg His Phe Asn Leu Ser Gly Leu Tyr Val Tyr Trp Gln
 65 70 75 80
 Ile Glu Asn Pro Glu Val Ser Val Thr Tyr Tyr Leu Pro Tyr Lys Ser
 85 90 95
 Pro Gly Ile Asn Val Asp Ser Ser Tyr Lys Asn Arg Gly His Leu Ser
 100 105 110
 Leu Asp Ser Met Lys Gln Gly Asn Phe Ser Leu Tyr Leu Lys Asn Val
 115 120 125
 Thr Pro Gln Asp Thr Gln Glu Phe Thr Cys Arg Val Phe Met Asn Thr
 130 135 140
 Ala Thr Glu Leu Val Lys Ile Leu Glu Glu Val Val Arg Leu Arg Val
 145 150 155 160
 Ala Ala Asn Phe Ser Thr Pro Val Ile Ser Thr Ser Asp Ser Ser Asn
 165 170 175
 Pro Gly Gln Glu Arg Thr Tyr Thr Cys Met Ser Lys Asn Gly Tyr Pro
 180 185 190
 Glu Pro Asn Leu Tyr Trp Ile Asn Thr Thr Asp Asn Ser Leu Ile Asp
 195 200 205
 Thr Ala Leu Gln Asn Asn Thr Val Tyr Leu Asn Lys Leu Gly Leu Tyr
 210 215 220
 Asp Val Ile Ser Thr Leu Arg Leu Pro Trp Thr Ser Arg Gly Asp Val
 225 230 235 240
 Leu Cys Cys Val Glu Asn Val Ala Leu His Gln Asn Ile Thr Ser Ile
 245 250 255
 Ser Gln Ala Glu Ser Phe Thr Gly Asn Asn Thr Lys Asn Pro Gln Glu
 260 265 270
 Thr His Asn Asn Glu Leu Lys Val Leu Val Pro Val Leu Ala Val Leu
 275 280 285
 Ala Ala Ala Ala Phe Val Ser Phe Ile Ile Tyr Arg Arg Thr Arg Pro
 290 295 300
 His Arg Ser Tyr Thr Gly Pro Lys Thr Val Gln Leu Glu Leu Thr Asp
 305 310 315 320
 His Ala

<210> 8
 <211> 322
 <212> PRT
 <213> mouse
 <400> 8

Met Gln Leu Lys Cys Pro Cys Phe Val Ser Leu Gly Thr Arg Gln Pro
1 5 10 15
Val Trp Lys Lys Leu His Val Ser Ser Gly Phe Phe Ser Gly Leu Gly
20 25 30
Leu Phe Leu Leu Leu Ser Ser Leu Cys Ala Ala Ser Ala Glu Thr
35 40 45
Glu Val Gly Ala Met Val Gly Ser Asn Val Val Leu Ser Cys Ile Asp
50 55 60
Pro His Arg Arg His Phe Asn Leu Ser Gly Leu Tyr Val Tyr Trp Gln
65 70 75 80
Ile Glu Asn Pro Glu Val Ser Val Thr Tyr Tyr Leu Pro Tyr Lys Ser
85 90 95
Pro Gly Ile Asn Val Asp Ser Ser Tyr Lys Asn Arg Gly His Leu Ser
100 105 110
Leu Asp Ser Met Lys Gln Gly Asn Phe Ser Leu Tyr Leu Lys Asn Val
115 120 125
Thr Pro Gln Asp Thr Gln Glu Phe Thr Cys Arg Val Phe Met Asn Thr
130 135 140
Ala Thr Glu Leu Val Lys Ile Leu Glu Glu Val Val Arg Leu Arg Val
145 150 155 160
Ala Ala Asn Phe Ser Thr Pro Val Ile Ser Thr Ser Asp Ser Ser Asn
165 170 175
Pro Gly Gln Glu Arg Thr Tyr Thr Cys Met Ser Lys Asn Gly Tyr Pro
180 185 190
Glu Pro Asn Leu Tyr Trp Ile Asn Thr Thr Asp Asn Ser Leu Ile Asp
195 200 205
Thr Ala Leu Gln Asn Asn Thr Val Tyr Leu Asn Lys Leu Gly Leu Tyr
210 215 220
Asp Val Ile Ser Thr Leu Arg Leu Pro Trp Thr Ser Arg Gly Asp Val
225 230 235 240
Leu Cys Cys Val Glu Asn Val Ala Leu His Gln Asn Ile Thr Ser Ile
245 250 255
Ser Gln Ala Glu Ser Phe Thr Gly Asn Asn Thr Lys Asn Pro Gln Glu
260 265 270
Thr His Asn Asn Glu Leu Lys Val Leu Val Pro Val Leu Ala Val Leu
275 280 285
Ala Ala Ala Ala Phe Val Ser Phe Ile Ile Tyr Arg Arg Thr Arg Pro
290 295 300
His Arg Ser Tyr Thr Gly Pro Lys Thr Val Gln Leu Glu Leu Thr Asp
305 310 315 320
His Ala

003476.04432460

<400> 9

Pro Cys Pro Arg Leu Ile Leu Leu Phe Val Leu Leu Ile Arg Leu Ser
20 25 30

Gln Val Ser Ser Asp Val Asp Glu Gln Leu Ser Lys Ser Val Lys Asp
35 40 45

Lys Val Leu Leu Pro Cys Arg Tyr Asn Ser Pro His Glu Asp Glu Ser
50 55 60

Glu Asp Arg Ile Tyr Trp Gln Lys His Asp Lys Val Val Leu Ser Val
65 70 75 80

Ile Ala Gly Lys Leu Lys Val Trp Pro Glu Tyr Lys Asn Arg Thr Leu
85 90 95

Tyr Asp Asn Thr Thr Tyr Ser Leu Ile Ile Leu Gly Leu Val Leu Ser
100 105 110

Asp Arg Gly Thr Tyr Ser Cys Val Val Gln Lys Lys Glu Arg Gly Thr
115 120 125

Tyr Glu Val Lys His Leu Ala Leu Val Lys Leu Ser Ile Lys Ala Asp
130 135 140

Phe Ser Thr Pro Asn Ile Thr Glu Ser Gly Asn Pro Ser Ala Asp Thr
145 150 155 160

Lys Arg Ile Thr Cys Phe Ala Ser Gly Gly Phe Pro Lys Pro Arg Phe
165 170 175

Ser Trp Leu Glu Asn Gly Arg Glu Leu Pro Gly Ile Asn Thr Thr Ile
180 185 190

Ser Gln Asp Pro Glu Ser Glu Leu Tyr Thr Ile Ser Ser Gln Leu Asp
195 200 205

Phe Asn Thr Thr Arg Asn His Thr Ile Lys Cys Leu Ile Lys Tyr Gly
210 215 220

Asp Ala His Val Ser Glu Asp Phe Thr Trp Glu Lys Pro Pro Glu Asp
225 230 235 240

Pro Pro Asp Ser Lys Asn Thr Leu Val Leu Phe Gly Ala Gly Phe Glu
245 250 255

Ala Val Ile Thr Val Val Val Ile Val Val Ile Ile Lys Cys Phe Cy
260 265 270

Lys His Arg Ser Cys Phe Arg Arg Asn Glu Ala Ser Arg Glu Thr Asn
275 280 285

Asn Ser Leu Thr Phe Gly Pro Glu Glu Ala Leu Ala Glu Gln Thr Va
290 295 300

Phe Leu

```
<210> 10
<211> 327
<212> PRT
<213> Artificial Sequence
```

<400> Met 1	10										Xaa	Xaa	Xaa	Xaa	Cys 5	Xaa	Cys	Xaa	Xaa	Xaa 10	Leu	Xaa	Xaa	Xaa	Xaa 15	Pro
Xaa	Xaa	Xaa	Xaa 20	Leu	Xaa	Xaa	Xaa	Xaa 25	Xaa	Xaa	Xaa	Xaa	Xaa 30	Leu	Xaa											
Leu	Phe	Xaa 35	Leu	Leu	Xaa	Xaa	Xaa 40	Ser	Xaa	Xaa	Xaa	Xaa 45	Xaa	Xaa	Xaa											
Xaa	Xaa 50	Xaa	Xaa	Xaa	Xaa	Val 55	Xaa	Xaa	Xaa	Val	Xaa 60	Leu	Xaa	Cys	Xaa											
Xaa 65	Xaa	Xaa	Xaa	Xaa	His 70	Xaa	Xaa	Xaa	Ser	Xaa 75	Xaa	Xaa	Xaa	Tyr	Trp 80											
Gln	Xaa	Xaa	Xaa 85	Xaa	Xaa	Val	Xaa	Xaa	Xaa 90	Xaa	Xaa	Leu	Xaa	Xaa 95	Xaa											
Xaa	Xaa	Xaa 100	Xaa	Xaa	Val	Xaa	Xaa 105	Tyr	Lys	Asn	Arg	Xaa 110	Xaa	Xaa	Xaa											
Xaa	Leu	Xaa 115	Xaa	Xaa	Xaa	Xaa	Xaa 120	Xaa	Xaa	Ser	Leu	Xaa 125	Xaa	Xaa	Xaa											
Xaa	Xaa 130	Xaa	Xaa	Asp	Xaa	Xaa 135	Xaa	Xaa	Xaa	Cys	Xaa 140	Val	Xaa	Xaa	Xaa											
Xaa 145	Xaa	Xaa	Xaa	Xaa	Xaa 150	Xaa	Xaa	Xaa	Xaa	Xaa 155	Xaa	Val	Xaa	Leu	Xaa 160											
Xaa	Xaa	Ala	Xaa	Phe 165	Ser	Thr	Pro	Xaa	Ile 170	Xaa	Xaa	Ser	Xaa	Xaa 175	Xaa											
Xaa	Xaa	Xaa	Xaa 180	Xaa	Arg	Xaa	Xaa	Thr 185	Cys	Xaa	Xaa	Xaa	Xaa 190	Gly	Xaa											
Pro	Xaa	Pro 195	Xaa	Xaa	Xaa	Trp	Xaa 200	Xaa	Asn	Xaa	Xaa	Xaa 205	Xaa	Xaa	Xaa											
Ile	Xaa 210	Thr	Xaa	Xaa	Xaa	Xaa 215	Xaa	Xaa	Xaa	Xaa	Xaa 220	Xaa	Xaa	Xaa	Xaa											
Xaa 225	Xaa	Xaa	Xaa	Xaa	Xaa 230	Xaa	Xaa	Xaa	Xaa	Xaa 235	Xaa	Thr	Xaa	Xaa	Xaa 240											
Xaa	Xaa	Xaa	Xaa	Xaa 245	Xaa	Xaa	Xaa	Val	Xaa 250	Xaa	Xaa	Xaa	Xaa	Xaa 255	Xaa											
Xaa	Xaa	Xaa	Xaa 260	Xaa	Xaa	Xaa	Xaa	Xaa 265	Xaa	Asn	Xaa	Xaa	Xaa 270	Xaa	Xaa											

<210>	11
<211>	864
<212>	DNA
<213>	mouse

<400>	11																48
atg	cgg	ctg	ggc	agt	cct	gga	ctg	ctc	ttc	ctg	ctc	ttc	agc	agc	ctt		
Met	Arg	Leu	Gly	Ser	Pro	Gly	Leu	Leu	Phe	Leu	Leu	Phe	Ser	Ser	Leu		
1				5					10					15			
cga	gct	gat	act	cag	gag	aag	gaa	gtc	aga	gcg	atg	gta	ggc	agc	gac	96	
Arg	Ala	Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp		
			20					25					30				
gtg	gag	ctc	agc	tgc	gct	tgc	cct	gaa	gga	agc	cgt	ttt	gat	tta	aat	144	
Val	Glu	Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn		
			35				40					45					
gat	gtt	tac	gta	tat	tgg	caa	acc	agt	gag	tcg	aaa	acc	gtg	gtg	acc	192	
Asp	Val	Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr		
	50					55					60						
tac	cac	atc	cca	cag	aac	agc	tcc	ttg	gaa	aac	gtg	gac	agc	cgc	tac	240	
Tyr	His	Ile	Pro	Gln	Asn	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr		
65					70					75					80		
cgg	aac	cga	gcc	ctg	atg	tca	ccg	gcc	ggc	atg	ctg	cgg	ggc	gac	ttc	288	
Arg	Asn	Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe		
				85					90					95			
tcc	ctg	cgc	ttg	ttc	aac	gtc	acc	ccc	cag	gac	gag	cag	aag	ttt	cac	336	
Ser	Leu	Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His		
			100					105					110				
tgc	ctg	gtg	ttg	agc	caa	tcc	ctg	gga	ttc	cag	gag	gtt	ttg	agc	gtt	384	
Cys	Leu	Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val		
		115					120					125					
gag	gtt	aca	ctg	cat	gtg	gca	gca	aac	ttc	agc	gtg	ccc	gtc	gtc	agc	432	
Glu	Val	Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser		
	130					135					140						
gcc	ccc	cac	agc	ccc	tcc	cag	gat	gag	ctc	acc	ttc	acg	tgt	aca	tcc	480	
Ala	Pro	His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser		
145					150					155					160		
ata	aac	ggc	tac	ccc	agg	ccc	aac	gtg	tac	tgg	atc	aat	aag	acg	gac	528	

Ile	Asn	Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp		
				165					170					175			
aac	agc	ctg	ctg	gac	cag	gct	ctg	cag	aat	gac	acc	gtc	ttc	ttg	aac	576	
Asn	Ser	Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn		
				180					185					190			
atg	cgg	ggc	ttg	tat	gac	gtg	gtc	agc	gtg	ctg	agg	atc	gca	cgg	acc	624	
Met	Arg	Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr		
				195					200					205			
ccc	agc	gtg	aac	att	ggc	tgc	tgc	ata	gag	aac	gtg	ctt	ctg	cag	cag	672	
Pro	Ser	Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln		
				210					215					220			
aac	ctg	act	gtc	ggc	agc	cag	aca	gga	aat	gac	atc	gga	gag	aga	gac	720	
Asn	Leu	Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp		
				225					230					235			
aag	atc	aca	gag	aat	cca	gtc	agt	acc	ggc	gag	aaa	aac	gcg	gcc	acg	768	
Lys	Ile	Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
				245					250					255			
tgg	agc	atc	ctg	gct	gtc	ctg	tgc	ctg	ctt	gtg	gtc	gtg	gcg	gtg	gcc	816	
Trp	Ser	Ile	Leu	Ala	Val	Leu	Cys	Leu	Leu	Val	Val	Val	Ala	Val	Ala		
				260					265					270			
ata	ggc	tgg	gtg	tgc	agg	gac	cga	tgc	ctc	caa	cac	agc	tat	gca	ggc	864	
Ile	Gly	Trp	Val	Cys	Arg	Asp	Arg	Cys	Leu	Gln	His	Ser	Tyr	Ala	Gly		
				275					280					285			
<210> 12																	
<211> 288																	
<212> PRT																	
<213> mouse																	
<400> 12																	
Met	Arg	Leu	Gly	Ser	Pro	Gly	Leu	Leu	Phe	Leu	Leu	Phe	Ser	Ser	Leu		
1				5					10					15			
Arg	Ala	Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp		
				20					25					30			
Val	Glu	Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn		
				35					40					45			
Asp	Val	Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr		
				50					55					60			
Tyr	His	Ile	Pro	Gln	Asn	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr		
				65					70					75			80
Arg	Asn	Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe		
				85					90					95			
Ser	Leu	Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His		
				100					105					110			
Cys	Leu	Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val		
				115					120					125			
Glu	Val	Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser		
				130					135					140			

Ala	Pro	His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser
145					150					155					160
Ile	Asn	Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp
				165					170					175	
Asn	Ser	Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn
			180					185					190		
Met	Arg	Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr
		195					200					205			
Pro	Ser	Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln
	210					215					220				
Asn	Leu	Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp
225					230					235					240
Lys	Ile	Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr
				245					250					255	
Trp	Ser	Ile	Leu	Ala	Val	Leu	Cys	Leu	Leu	Val	Val	Val	Ala	Val	Ala
			260					265					270		
Ile	Gly	Trp	Val	Cys	Arg	Asp	Arg	Cys	Leu	Gln	His	Ser	Tyr	Ala	Gly
		275					280					285			
<210> 13															
<211> 267															
<212> PRT															
<213> Human															
<400> 13															
Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu	Leu	Ser	Cys
1				5					10					15	
Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val	Tyr	Val	Tyr
			20					25					30		
Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His	Ile	Pro	Gln
		35					40					45			
Asn	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn	Arg	Ala	Leu
	50					55					60				
Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu	Arg	Leu	Phe
65					70					75					80
Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu	Val	Leu	Ser
				85					90					95	
Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val	Thr	Leu	His
			100					105					110		
Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro	His	Ser	Pro
		115					120					125			
Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr</						

```
<210> 14
<211> 276
<212> PRT
<213> mouse
```

<400>	14															
Glu	Thr	Glu	Val	Gly	Ala	Met	Val	Gly	Ser	Asn	Val	Val	Leu	Ser	Cys	
1				5					10					15		
Ile	Asp	Pro	His	Arg	Arg	His	Phe	Asn	Leu	Ser	Gly	Leu	Tyr	Val	Tyr	
			20					25					30			
Trp	Gln	Ile	Glu	Asn	Pro	Glu	Val	Ser	Val	Thr	Tyr	Tyr	Leu	Pro	Tyr	
		35					40					45				
Lys	Ser	Pro	Gly	Ile	Asn	Val	Asp	Ser	Ser	Tyr	Lys	Asn	Arg	Gly	His	
	50					55					60					
Leu	Ser	Leu	Asp	Ser	Met	Lys	Gln	Gly	Asn	Phe	Ser	Leu	Tyr	Leu	Lys	
65					70					75					80	
Asn	Val	Thr	Pro	Gln	Asp	Thr	Gln	Glu	Phe	Thr	Cys	Arg	Val	Phe	Met	
				85					90					95		
Asn	Thr	Ala	Thr	Glu	Leu	Val	Lys	Ile	Leu	Glu	Glu	Val	Val	Arg	Leu	
			100					105					110			
Arg	Val	Ala	Ala	Asn	Phe	Ser	Thr	Pro	Val	Ile	Ser	Thr	Ser	Asp	Ser	
		115					120					125				
Ser	Asn	Pro	Gly	Gln	Glu	Arg	Thr	Tyr	Thr	Cys	Met	Ser	Lys	Asn	Gly	
	130					135					140					
Tyr	Pro	Glu	Pro	Asn	Leu	Tyr	Trp	Ile	Asn	Thr	Thr	Asp	Asn	Ser	Leu	
145					150					155					160	
Ile	Asp	Thr	Ala	Leu	Gln	Asn	Asn	Thr	Val	Tyr	Leu	Asn	Lys	Leu	Gly	
				165					170					175		
Leu	Tyr	Asp	Val	Ile	Ser	Thr	Leu	Arg	Leu	Pro	Trp	Thr	Ser	Arg	Gly	

```
<210> 15
<211> 280
<212> PRT
<213> Artificial Sequence
```

<400>	15															
Glu	Xaa	Glu	Val	Xaa	Ala	Met	Gly	Val	Ser	Xaa	Val	Xaa	Leu	Ser	Cys	
1				5					10					15		
Xaa	Xaa	Pro	Xaa	Xaa	Xaa	Xaa	Phe	Xaa	Leu	Xaa	Xaa	Xaa	Tyr	Val	Tyr	
			20					25					30			
Trp	Gln	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Val	Thr	Tyr	Xaa	Xaa	Pro	Xaa	
		35					40					45				
Xaa	Ser	Xaa	Xaa	Xaa	Asn	Val	Asp	Ser	Xaa	Tyr	Xaa	Asn	Arg	Xaa	Xaa	
	50					55					60					
Xaa	Ser	Xaa	Xaa	Xaa	Met	Xaa	Xaa	Gly	Xaa	Phe	Ser	Leu	Xaa	Leu	Xaa	
65					70					75					80	
Asn	Val	Thr	Pro	Gln	Asp	Xaa	Gln	Xaa	Phe	Xaa	Cys	Xaa	Val	Xaa	Xaa	
				85					90					95		
Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Leu	Xaa	Xaa	Xaa	Val	Xaa	Leu	
			100					105					110			
Xaa	Val	Ala	Ala	Asn	Phe	Ser	Xaa	Pro	Val	Xaa	Ser	Xaa	Xaa	Xaa	Ser	
		115					120				125					
Xaa	Xaa	Xaa	Xaa	Xaa	Glu	Xaa	Thr	Xaa	Thr	Cys	Xaa	Ser	Xaa	Asn	Gly	
		130				135					140					
Tyr	Pro	Xaa	Pro	Asn	Xaa	Tyr	Trp	Ile	Asn	Xaa	Thr	Asp	Asn	Ser	Leu	
145					150					155					160	
Xaa	Asp	Xaa	Ala	Leu	Gln	Asn	Xaa	Thr	Val	Xaa	Leu	Asn	Xaa	Xaa	Gly	
				165					170					175		

Leu Tyr Asp Val Xaa Ser Xaa Leu Arg Xaa Xaa Xaa Thr Xaa Xaa Xaa
180 185 190
Xaa Xaa Xaa Cys Cys Xaa Glu Asn Val Xaa Leu Xaa Gln Asn Xaa Thr
195 200 205
Xaa Xaa Ser Gln Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Lys Xaa Xaa Xaa
210 215 220
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Xaa Xaa Xaa Xaa Xaa Leu
225 230 235 240
Ala Val Leu Xaa Xaa Xaa Xaa Xaa Val Xaa Xaa Xaa Ile Xaa Xaa Xaa
245 250 255
Xaa Arg Xaa Arg Xaa Xaa Xaa Xaa Ser Tyr Xaa Gly Xaa Xaa Xaa Xaa
260 265 270
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
275 280

<210> 16
<211> 1294
<212> DNA
<213> Human

<220>
<221> 5'UTR
<222> (1)..(199)

<220>
<221> CDS
<222> (200)..(1105)

<400> 16
gctggtacgc ctgcaggtac cgggtccggaa ttcccggggtc gaccacgcgc tccgcccacg 60
cgctccgcggg agegcagtta gagccgatct cccgcgcccc gaggttgctc ctctccgagg 120
tctcccgcgcg cccaagttct ccgcgccccg aggtctccgc gccccgaggt ctccgcggcc 180
cgaggtctcc gccgcacc atg cgg ctg ggc agt cct gga ctg ctc ttc ctg 232
Met Arg Leu Gly Ser Pro Gly Leu Leu Phe Leu
1 5 10
ctc ttc agc agc ctt cga gct gat act cag gag aag gaa gtc aga gcg 280
Leu Phe Ser Ser Leu Arg Ala Asp Thr Gln Glu Lys Glu Val Arg Ala
15 20 25
atg gta ggc agc gac gtg gag ctc agc tgc gct tgc cct gaa gga agc 328
Met Val Gly Ser Asp Val Glu Leu Ser Cys Ala Cys Pro Glu Gly Ser
30 35 40
cgt ttt gat tta aat gat gtt tac gta tat tgg caa acc agt gag tcg 376
Arg Phe Asp Leu Asn Asp Val Tyr Val Tyr Trp Gln Thr Ser Glu Ser
45 50 55
aaa acc gtg gtg acc tac cac atc cca cag aac agc tcc ttg gaa aac 424
Lys Thr Val Val Thr Tyr His Ile Pro Gln Asn Ser Ser Leu Glu Asn
60 65 70 75
gtg gac agc cgc tac cgg aac cga gcc ctg atg tca ccg gcc ggc atg 472
Val Asp Ser Arg Tyr Arg Asn Arg Ala Leu Met Ser Pro Ala Gly Met

002217 0243460

80								85					90					
ctg	cgg	ggc	gac	ttc	tcc	ctg	cgc	ttg	ttc	aac	gtc	acc	ccc	cag	gac	520		
Leu	Arg	Gly	Asp	Phe	Ser	Leu	Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp			
			95					100					105					
gag	cag	aag	ttt	cac	tgc	ctg	gtg	ttg	agc	caa	tcc	ctg	gga	ttc	cag	568		
Glu	Gln	Lys	Phe	His	Cys	Leu	Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln			
		110					115					120						
gag	gtt	ttg	agc	gtt	gag	gtt	aca	ctg	cat	gtg	gca	gca	aac	ttc	agc	616		
Glu	Val	Leu	Ser	Val	Glu	Val	Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser			
	125					130					135							
gtg	ccc	gtc	gtc	agc	gcc	ccc	cac	agc	ccc	tcc	cag	gat	gag	ctc	acc	664		
Val	Pro	Val	Val	Ser	Ala	Pro	His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr			
140					145					150					155			
ttc	acg	tgt	aca	tcc	ata	aac	ggc	tac	ccc	agg	ccc	aac	gtg	tac	tgg	712		
Phe	Thr	Cys	Thr	Ser	Ile	Asn	Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp			
				160					165					170				
atc	aat	aag	acg	gac	aac	agc	ctg	ctg	gac	cag	gct	ctg	cag	aat	gac	760		
Ile	Asn	Lys	Thr	Asp	Asn	Ser	Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp			
			175					180					185					
acc	gtc	ttc	ttg	aac	atg	cgg	ggc	ttg	tat	gac	gtg	gtc	agc	gtg	ctg	808		
Thr	Val	Phe	Leu	Asn	Met	Arg	Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu			
		190					195					200						
agg	atc	gca	cgg	acc	ccc	agc	gtg	aac	att	ggc	tgc	tgc	ata	gag	aac	856		
Arg	Ile	Ala	Arg	Thr	Pro	Ser	Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn			
	205					210					215							
gtg	ctt	ctg	cag	cag	aac	ctg	act	gtc	ggc	agc	cag	aca	gga	aat	gac	904		
Val	Leu	Leu	Gln	Gln	Asn	Leu	Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp			
220					225					230					235			
atc	gga	gag	aga	gac	aag	atc	aca	gag	aat	cca	gtc	agt	acc	ggc	gag	952		
Ile	Gly	Glu	Arg	Asp	Lys	Ile	Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu			
				240					245					250				
aaa	aac	gcg	gcc	acg	tgg	agc	atc	ctg	gct	gtc	ctg	tgc	ctg	ctt	gtg	1000		
Lys	Asn	Ala	Ala	Thr	Trp	Ser	Ile	Leu	Ala	Val	Leu	Cys	Leu	Leu	Val			
			255					260					265					
gtc	gtg	gcg	gtg	gcc	ata	ggc	tgg	gtg	tgc	agg	gac	cga	tgc	ctc	caa	1048		
Val	Val	Ala	Val	Ala	Ile	Gly	Trp	Val	Cys	Arg	Asp	Arg	Cys	Leu	Gln			
		270					275					280						
cac	agc	tat	gca	ggc	gcc	tgg	gct	gtg	agt	ccg	gag	aca	gag	ctc	act	1096		
His	Ser	Tyr	Ala	Gly	Ala	Trp	Ala											

[illegible]

<400> 18	Met	Arg	Leu	Gly	Ser	Pro	Gly	Leu	Leu	Phe	Leu	Leu	Phe	Ser	Ser	Leu
1					5					10					15	
Arg	Ala	Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	
			20					25						30		
Val	Glu	Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	
		35					40					45				
Asp	Val	Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	
	50					55					60					
Tyr	His	Ile	Pro	Gln	Asn	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	
65					70					75					80	
Arg	Asn	Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	
				85					90					95		
Ser	Leu	Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	
			100					105					110			
Cys	Leu	Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	
		115					120					125				
Glu	Val	Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	
	130					135					140					
Ala	Pro	His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	
145					150					155					160	
Ile	Asn	Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	
				165					170					175		
Asn	Ser	Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	
			180					185					190			
Met	Arg	Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	
		195					200					205				
Pro	Ser	Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	
	210					215					220					
Asn	Leu	Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	
225					230					235					240	
Lys	Ile	Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr	
				245					250					255		
Trp	Ser	Ile	Leu	Ala	Val	Leu	Cys	Leu	Leu	Val	Val	Val	Ala	Val	Ala	
			260					265					270			
Ile	Gly	Trp	Val	Cys	Arg	Asp	Arg	Cys	Leu	Gln	His	Ser	Tyr	Ala	Gly	
		275					280					285				
Ala	Trp	Ala	Val	Ser	Pro	Glu	Thr	Glu	Leu	Thr	Gly	His	Val			
	290					295					300					

<400>	19																
Met	Gln	Leu	Lys	Cys	Pro	Cys	Phe	Val	Ser	Leu	Gly	Thr	Arg	Gln	Pro		
1				5					10					15			
Val	Trp	Lys	Lys	Leu	His	Val	Ser	Ser	Gly	Phe	Phe	Ser	Gly	Leu	Gly		
			20					25					30				
Leu	Phe	Leu	Leu	Leu	Leu	Ser	Ser	Leu	Cys	Ala	Ala	Ser	Ala	Glu	Thr		
		35					40					45					
Glu	Val	Gly	Ala	Met	Val	Gly	Ser	Asn	Val	Val	Leu	Ser	Cys	Ile	Asp		
	50					55					60						
Pro	His	Arg	Arg	His	Phe	Asn	Leu	Ser	Gly	Leu	Tyr	Val	Tyr	Trp	Gln		
65					70					75					80		
Ile	Glu	Asn	Pro	Glu	Val	Ser	Val	Thr	Tyr	Tyr	Leu	Pro	Tyr	Lys	Ser		
				85					90					95			
Pro	Gly	Ile	Asn	Val	Asp	Ser	Ser	Tyr	Lys	Asn	Arg	Gly	His	Leu	Ser		
			100					105					110				
Leu	Asp	Ser	Met	Lys	Gln	Gly	Asn	Phe	Ser	Leu	Tyr	Leu	Lys	Asn	Val		
		115					120					125					
Thr	Pro	Gln	Asp	Thr	Gln	Glu	Phe	Thr	Cys	Arg	Val	Phe	Met	Asn	Thr		
	130					135					140						
Ala	Thr	Glu	Leu	Val	Lys	Ile	Leu	Glu	Glu	Val	Val	Arg	Leu	Arg	Val		
145					150					155					160		
Ala	Ala	Asn	Phe	Ser	Thr	Pro	Val	Ile	Ser	Thr	Ser	Asp	Ser	Ser	Asn		
				165					170					175			
Pro	Gly	Gln	Glu	Arg	Thr	Tyr	Thr	Cys	Met	Ser	Lys	Asn	Gly	Tyr	Pro		
			180					185					190				
Glu	Pro	Asn	Leu	Tyr	Trp	Ile	Asn	Thr	Thr	Asp	Asn	Ser	Leu	Ile	Asp		
		195					200					205					
Thr	Ala	Leu	Gln	Asn	Asn	Thr	Val	Tyr	Leu	Asn	Lys	Leu	Gly	Leu	Tyr		
	210					215					220						
Asp	Val	Ile	Ser	Thr	Leu	Arg	Leu	Pro	Trp	Thr	Ser	Arg	Gly	Asp	Val		
225					230					235					240		
Leu	Cys	Cys	Val	Glu	Asn	Val	Ala	Leu	His	Gln	Asn	Ile	Thr	Ser	Ile		
				245					250					255			
Ser	Gln	Ala	Glu	Ser	Phe	Thr	Gly	Asn	Asn	Thr	Lys	Asn	Pro	Gln	Glu		
			260					265					270				
Thr	His	Asn	Asn	Glu	Leu	Lys	Val	Leu	Val	Pro	Val	Leu	Ala	Val	Leu		
		275					280					285					
Ala	Ala	Ala	Ala	Phe	Val	Ser	Phe	Ile	Ile	Tyr	Arg	Arg	Thr	Arg	Pro		
						295					300						

[illegible]

<210>	22
<211>	199
<212>	PRT
<213>	Human

```

<400> 22
Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
 1          5          10          15
Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile
          20          25          30
Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
          35          40          45
Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp

```

```

<210> 23
<211> 199
<212> PRT
<213> Human

<400> 23
Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
  1          5          10
Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile
          20          25          30
Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
          35          40
Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp
  50          55          60
Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu
  65          70          75          80
Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
          85          90          95
Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser
          100          105          110
Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu
          115          120          125
His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro
          130          135          140

```

Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu
145 150 155 160
Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro
165 170 175
Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser
180 185 190
Arg Leu Thr Asp Val Thr Leu
195

<210> 24
<211> 200
<212> PRT
<213> mouse

<400> 24
Met Lys Pro Tyr Phe Cys Arg Val Phe Val Phe Cys Phe Leu Ile Arg
1 5 10 15
Leu Leu Thr Gly Glu Ile Asn Gly Ser Ala Asp His Arg Met Phe Ser
20 25 30
Phe His Asn Gly Gly Val Gln Ile Ser Cys Lys Tyr Pro Glu Thr Val
35 40 45
Gln Gln Leu Lys Met Arg Leu Phe Arg Glu Arg Glu Val Leu Cys Glu
50 55 60
Leu Thr Lys Thr Lys Gly Ser Gly Asn Ala Val Ser Ile Lys Asn Pro
65 70 75 80
Met Leu Cys Leu Tyr His Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
85 90 95
Asn Asn Pro Asp Ser Ser Gln Gly Ser Tyr Tyr Phe Cys Ser Leu Ser
100 105 110
Ile Phe Asp Pro Pro Pro Phe Gln Glu Arg Asn Leu Ser Gly Gly Tyr
115 120 125
Leu His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Leu Trp Leu
130 135 140
Pro Val Gly Cys Ala Ala Phe Val Val Val Leu Leu Phe Gly Cys Ile
145 150 155 160
Leu Ile Ile Trp Phe Ser Lys Lys Lys Tyr Gly Ser Ser Val His Asp
165 170 175
Pro Asn Ser Glu Tyr Met Phe Met Ala Ala Val Asn Thr Asn Lys Lys
180 185 190
Ser Arg Leu Ala Gly Val Thr Ser
195 200

<210> 25
<211> 24
<212> DNA
<213> Artificial Sequence

002211 02482260

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 25
accatgcggc tgggcagtcc tgga 24

<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 26
tggtgaccta ccacatccca cag 23

<210> 27
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 27
tccgatgtca tttcctgtct ggc 23

<210> 28
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 28
gctctgtctc cggactcaca gccc 24

<210> 29
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 29
gtggcagcaa acttcagcgt gcccgtcg 28

<210> 30
<211> 28
<212> DNA
<213> Artificial Sequence

00361 0043460

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 30
cccaacgtgt actggatcaa taagacgg 28

<210> 31
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 31
gcgtgctgag gatcgacgg acccccag 28

<210> 32
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 32
gcctctagaa agagctggga c 21

<210> 33
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 33
cgccgtgttc catttatgag c 21

<210> 34
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic
Oglionucleotide

<400> 34
gcatatttat gaatccca 18

<210> 35
<211> 18
<212> DNA

00321 0243460

